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Abstract 
In this thesis, metabolic profiling (MP) platforms were utilised to interrogate the manifestation of 
cardiovascular disease and provide candidate biomarkers. A number of LC-MS and NMR 
methodologies were employed. Data processing was followed by assessment using multivariate 
(MVDA) and univariate (UV) statistics. MP is applied under three cardiovascular disease themes: 
1) plaque rupture, 2) plaque formation, and 3) arterial ectopic calcification. Statistically significant 
features were structurally assigned. Identified metabolites were mapped to their corresponding 
biochemical pathways. 
For MP of ruptured plaque, tissue from symptomatic and asymptomatic patients for stroke was 
used. After detection of statistically significant features and structural assignment, two biochemical 
pathways showed dysregulations: the arachidonic acid pathway, indicating increased levels of 
inflammation, and the β-oxidation pathway with increased levels of three acyl-carnitines. 
Tissue extracts were used to investigate plaque formation. Arterial intima tissue, incorporating 
plaque lesions (carotid and femoral), was compared to intimal thickening tissue. Intima thickening 
demonstrated distinct MP compared to plaques. Plaques from different anatomical locations also 
demonstrated altered MP. After metabolite assignment, pathway mapping revealed dysregulations 
common to both anatomical locations. These were cholesterol, ceramide, purine, pyrimidine and β-
oxidation pathways. These pathways are related to inflammation and apoptosis. A metabolite 
previously unassociated to atherogenesis was detected with strong statistical significance (t-test; 
p≥9.8x10-12), namely phosphatidylethanolamine-ceramide. It also demonstrated high correlations to 
cholesterol, a well-established risk-factor of atherosclerosis. 
The third theme of the project explores ectopic cardiovascular calcification. Experiments were 
conducted on blood serum. Patients with coronary artery and aortic valve calcification were 
compared with non-calcified controls. Phosphatidylcholine moieties and sphingomyelins were the 
major discriminating metabolites between cases and controls. These are involved in inflammation 
and apoptosis. The two diseases manifested different profiles with only three commonly 
dysregulated metabolites. 
A number of experiments using additional samples and bottom-up approaches will follow to 
provide validation of results.  
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Chapter 1  Introduction 
1.1  Metabolic Profiling 
Metabolic profiling (MP), also referred to as Metabonomics, is defined as ―the quantitative 
measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification‖1. MP aims, by employing analytical chemical 
techniques, towards covering, ideally, the full ‗spectrum‘ of metabolites (metabolome) in a living 
system. Metabolites ―serve as direct signatures of biochemical activity‖2 and this activity provides 
current and historical information of the biological processes taking place in a cell or organism. 
Other –omic approaches are interrogating the parts of genetic information flow which can be 
subjected to further processes and modifications, such as genes, transcripts and proteins (genomics, 
transcriptomics and proteomics). However, the metabolome represents the real end-points of 
(patho-)biological reactions (Figure 1. 1) and can report on exogenous factors introduced by diet or 
gut microbiota in addition to the mammalian metabolism
3
. For these reasons metabolites can 
correlate closely to phenotype and deliver disease related information. 
 
Figure 1. 1: The central biological dogma indicating metabolites as the final products of genetic information flow. 
Metabolites excel compared to the information provided by proteins as being closer to the phenotype, since they are not 
subjected to further modifications. They practically represent an updated snapshot of the current status of a biological 
system. Adapted from Patti el al
2
. 
MP can define this ―multiparametric (metabolic) response‖ using multivariate data analysis 
(MVDA) methods. However, for this, metabolite measurements should be able to provide at least 
relative quantification. Therefore, techniques used should be responsive to differential metabolite 
concentrations, and have a good dynamic range in order to capture, as far as it can be possible, the 
dynamic range of living systems. MP, with the help of technological advances, has evolved into a 
powerful tool for discovering novel biomarkers for disease diagnosis
4
 and prognosis
5
. It can also be 
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implemented for pharmaceutical target discovery, and elucidation of disease pathways
6, 7
, paving 
the way for more individualised diagnostics and treatment schedules
5, 8
. 
Metabolome coverage has become extremely broad, due to advances in the analytical platforms 
employed e.g. the introduction of cryoprobes in NMR, high resolution mass spectrometers 
providing superior sensitivity, and Ultra Performance Liquid Chromatography (UPLC)
9
. Further, 
recent statistical developments, allowing data integration of different analytical matrices, have 
provided new insights in gene
10
 and enzyme function
11, 12
 studies and could potentially lead to cost 
reduction in the drug development pipeline 
8
, for example, by improving mechanistic understanding 
of drug toxicity
5, 8
.  
It has been shown that metabolic profiling of tissue, and/or of the biofluids that interact closely with 
the tissue of interest, delivers clinically and biologically significant results
13
. Consequently, 
metabolic profiling techniques are now being applied to homogenised or even intact tissues, cells, 
as well as biofluids
14-17
. Screening of biological samples, cells or tissues can nowadays be 
performed in order to obtain biomarker/metabolic pathway information relating to disease. Various 
spectroscopic techniques are employed
8, 18, 19
, such as Nuclear Magnetic Resonance (NMR) 
spectroscopy
14, 15
, Mass Spectrometry coupled to Liquid Chromatography (LC-MS)
16, 20
, Gas 
Chromatography (GC)-MS
21
, and less frequently Capillary Electrophoresis
22
. It is of supreme 
importance, when applying MP, to employ more than a single method or platform in order to 
maximise the range of the metabolites detected. Findings can then be mapped to reference pathways 
in online available databases
23, 24
 and literature. In cases where traditional biochemistry cannot 
deliver, data processing methods such as correlation networks can be employed to aid biochemical 
interpretation of results. This is generally the issue when it comes to metabolite classes such as 
lipids
25
. 
When approaches implementing homogenised tissue are employed, the significant parameter of 
spatial distribution of the biomolecules through the tissue is disregarded. Therefore, new screening 
techniques for untargeted determination of biomolecules, in a manner that incorporates the spatial 
distribution, have been considered
26, 27
. Applications of imaging techniques that can deliver 
chemical profiles related to organ or tissue topography have recently been demonstrated for MP
28-32
 
(Figure 1. 2). Mass Spectrometry Imaging (MSI) techniques appear to hold what is needed for 
metabolite in situ screening. Magnetic resonance imaging (MRI), able to analyse intact tissue 
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samples along with providing spatial information of the collected spectra, is the alternative in NMR 
spectroscopy. 
 
 
Figure 1. 2: A calcified human valve section after A) H&E staining and B), C) and D) after representation of three 
selected ions acquired after MALDI-MSI of the tissue section. 
Nonetheless, MP is now well-recognised
6, 8, 10, 33
, and in combination with other –omic 
technologies
2, 19, 34
, usually transcriptomics, or metagenomics
34
, can provide good coverage of 
metabolic and signalling pathways. It should be generally followed by appropriate validation, 
according to the function of the biomarker discovered. Biomarkers for diagnosis are generally 
validated to an independent cohort of samples, while novel pathways are validated by bottom-up 
approaches
35, 36
 (Note: A bottom-up approach is defined as the process when prior knowledge of a 
biological system exists, and the analyst explores the behaviour of this known network and tests 
hypotheses
37
. Bottom-up approach is also used to describe cell-based approaches, as opposed to 
top-down approaches used to describe whole organism, multicellular system applications
33
. Top-
down can also be used to describe the process where no prior knowledge of a system is used, and by 
the use of statistics and bioinformatics, modelling of a biological system is obtained). Still, in every 
case the biological basis of molecule serving as biomarkers, should be determined.  
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1.1.1 Lipid Profiling 
Lipid profiling approaches specifically target the lipidome, which can be considered a sub-category 
of the metabolome. The lipid moieties comprising the lipidome are calculated to several hundreds 
of thousands
38-40
.  Enzymes known for their participation in lipid synthesis do not reflect the 
―enormous diversity of the lipidome‖39, 41. Factors affecting lipidome variation could be 
environmental, such as the diet, and symbiotic microbiota
39
, which can obviously be to an extend 
independent to the genetic information of an individual. Nonetheless, the lipidome appears to play a 
very important role in biological systems and disease
42, 43
. There are currently two widespread 
approaches for perform lipid profiling: LC-MS, and direct MS infusion (shotgun lipidomics)
44
. 
However, the disadvantage of obtaining lipids as biomarkers lays to the difficulty of 
comprehensively place them in biological pathways. In order to assist mapping of the detected lipid 
moieties, correlation analysis can be used
25
, as well as combining analyses from polar metabolites 
and other levels of integration, such as the proteome and/or genome. At the same time this 
―disadvantage‖ of the lipidome depicts the importance for elucidating its biological potential in 
elucidating human disease.  
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1.2 Cardiovascular Disease 
The term cardiovascular disease (CVD) refers to all diseases affecting the heart or blood vessels 
(arteries, veins, or capillaries). CVD is the leading cause of death in the UK and the USA according 
to the World Health Organisation (WHO) report 
45
. The two most frequent causes of death of CVD 
are mainly related to atherosclerosis and hypertension. The theme of the current thesis is to 
elucidate the metabolic perturbations causing atherosclerosis-related diseases; such as plaque 
formation, rupture and arterial ectopic calcification. 
1.2.1 Atherosclerosis 
Atherosclerosis comprises of the formation of a lipid-rich lesion in the inner wall of the arteries. 
These lesions are generally referred to as (atherosclerotic) plaques. Firstly, this can cause limited 
flow to important organs such as the heart (angina or infarction), brain (transient ischemic attack, 
stroke, or microvascular disease) and kidneys (renal failure). In some cases the plaque can rupture 
and develop a blood clot on its surface. This clot can dislodge itself from the plaque and travel in 
the circulatory system blocking the blood supply to the brain or heart (thromboembolism), causing 
health and life-threatening events (e.g. stroke and heart attack). The important fact about 
atherosclerosis is that despite modern achievements, biologically as well as clinically, it still 
remains the leading cause of mortality and morbidity, in the western world
46
. 
1.2.1.1 Low and High- Density Lipoproteins (LDL and HDL) 
LDL and HDL are the lipoproteins responsible for transferring lipophilic molecules throughout the 
body, using the bloodstream. Most abundant lipophilic molecules in lipoproteins are cholesterol, 
cholesterol esters, triglycerides and phospholipids. Due to their lipophilic nature, these molecules 
cannot be dissolved in the blood. Therefore, proteins with appropriate structure (apolipoproteins) 
function as carriers of these molecules, by incorporating them in their core. LDL is considered to be 
the ―bad‖ lipoprotein for human health. LDL provides the cells with cholesterol by attaching to 
appropriate LDL-receptors. On the other hand, HDL, the smallest and densest of the lipoprotein 
particles, is considered the ―good‖ lipoprotein. For reasons that will be explained in the following 
paragraph, these two lipoproteins are routinely assessed as risk factors for atherosclerosis. As it 
would be expected by their pseudonyms, high circulating LDL and low HDL are considered to be 
highly correlated to the risk of atherosclerosis. 
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1.2.1.2 The process of atherosclerosis 
The whole process of plaque formation begins with the retention of LDL in the endothelial cells of 
the arterial wall
47
 and it occurs prior to monocyte recruitment in the area of plaque formation
48,49
. 
The trapped LDL soon starts to become oxidised. At this point, inflammatory
48
 and adhesion 
molecules such as chemokines
50
 are produced by the endothelial cells and stimulate the recruitment 
of leukocytes, primarily monocyte, into the endothelium. After recruitment to the lesion, monocytes 
are converted into macrophages. There macrophages will engulf the LDL particles forming foam 
cells (named after the foamy appearance of their cytoplasm) and initiating the atheroma.  
Macrophages further contribute to LDL oxidation. The protein part of LDL is also oxidatively 
modified, an event that diminishes the affinity to the LDL-receptors. This eventually leads to 
bypassing of the feedback loop, causing the cell to create more LDL-receptors in order to capture 
and retain more LDL in the cell. This can cause cholesterol overload in the endothelium and 
macrophages, known to be a characteristic of plaques. Other evidence also suggests that oxidised-
LDL can be recognised with higher affinity by appropriate acetyl-LDL receptors from the 
macrophages, leading them to form more foam cell populations
47, 51
.  
The HDL lipoprotein can help reduce the concentration of cholesterol by a mechanism called 
―reverse cholesterol transport‖46. With this mechanism, excess cholesterol is transferred to the liver 
where it will be secreted in the gastrointestinal track. HDL may also mitigate plaque formation due 
to anti-oxidative properties of two HDL associated enzymes
47
. The whole procedure described 
herein is schematically represented in Figure 1. 3. 
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Figure 1. 3: A schematic representation of atherogenesis. 1) LDL-receptors are produced by endothelial cells and capture LDL, 2) LDL is oxidised, 3) LDL and ox-LDL induce 
production of chemokines, adhesion and inflammatory molecules, 4) leukocytes and primarily monocytes are recruited, 5) monocytes are transformed to macrophages which engulf 
LDL and ox-LDL becoming 6) foam cells and forming the 7) atheroma (plaque). 8) HDL has anti-oxidative abilities and can reduce the oxidation of LDL. 9) HDL has the ability of 
incorporating plaque cholesterol and transports it to the liver.  
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Atherosclerotic lesions presenting evidence of lipid accumulation are preceded by a stage known as 
intimal thickening. During this stage, production of proteoglycans is observed
52
. Intimal thickening 
is generally found at points of bifurcation, providing evidence indicating that it is a consequence of 
hemodynamic stress. Points of bifurcation are known areas of application of low wall shear stress
53
. 
Shear stress is also known to play a role in monocyte adhesion
53
. However, atherosclerotic lesions 
can also be observed in areas without bifurcations or areas exposed to low hemodynamic stress
48
.  
Inflammatory mediators in the presence of loss of smooth muscle cells support can lead to 
weakening of the fibrous cap of the atheroma
54
. This can lead to the rupture of the atheroma and 
initiation of the coagulation cascade with platelet adhesion. Eventually a thrombus is formed which 
(Figure 1. 4) can migrate and cause thromboembolism to parts of the subsequent arterial tree. 
According to the location of the plaque, this could cause a stroke (usually carotid plaque), or heart 
attack (coronary plaque). Thrombi can also occur from an external erosion of the atheroma
54
 
(Figure 1. 4).  
 
Figure 1. 4: The basic stages of plaque formation, from normal artery (1), to plaque formation (4) and rupture (5). 
Adapted from Libby et al 
54
. 
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The basic stages of plaque formation could be synopsised to: 
1. Normal artery54.  
2. Lesion initiation54: First evidence of tissue injury and intimal thickening. 
3. Fibro-fatty stage54: Monocytes conversion into macrophages which engulf modified-LDL 
becoming foam cells. Intima layer becomes thicker. 
4. Progression to the atheroma stage54.  
5. Rupture of fibrous cap54. 
6. Thrombus resorption54. Evolution towards advance fibrous and calcified plaque. 
7. Thrombus from superficial erosion54. 
1.2.2 Cardiovascular Calcification 
Cardiovascular calcification is the process where vessels become ossified. It is believed that the 
calcification process is an active biological process rather than passive deposition with similarities 
to bone formation
55
. It does not occur in normal vessels. On the contrary, there are evidence that 
calcification occurs after vessel wall injury
48, 56
. Calcification is generally considered a progression 
from atherosclerosis and if present, it will classify a lesion as ―advanced‖48. However, some 
evidence of independent mechanisms also exist
57
. 
Calcification is an advanced degenerative process. It is generally present, and increases in 
magnitude with age. However, it should not be considered an age-related degenerative process, as it 
can occur at any age and can progress with time
58
. Figure 1. 5 demonstrates an X-ray of the post-
mortem examination of a young adult, where multicentric and advance calcification is obvious in 
the coronary artery
48
.  
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Figure 1. 5: A post-mortem X-ray film of the heart of a young adult with extensive ectopic calcification on coronary 
arteries. Adapted from Frink et al 
48
. 
Within Chapter 5, results from experiments on vascular but also valvural calcification will be 
presented and discussed. The elucidation of the pathophysiology of vascular calcification is 
important due to contradictory reports of prognostic significance of calcification in cardiovascular 
events
57, 59, 60
. On the other hand, aortic valve calcification (Figure 1. 6) is the second most common 
indication for cardiac surgery
61
, and the leading cause for valve replacement in the United States
62
. 
Calcific aortic valve disease is also associated with atherosclerosis
62
 and hemodynamic stress
63
. It is 
also important to state that there is evidence of the reversibility of the disease, e.g. in malignancies
56
 
and after statin treatment
64
, making the quest of an appropriate pharmaceutical target more 
essential. 
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Figure 1. 6: An image of two conjugated aortic heart valves. Valves show evidence of fibrous and calcium formation. 
 
1.3 Metabolic profiling studies on cardiovascular disease 
In this section, a review of the current literature relating to metabolic profiling applications on 
cardiovascular disease is performed. The PubMed search engine 
(http://www.ncbi.nlm.nih.gov/pubmed) was used for identifying relevant papers. The search quote 
used was: (metabolomics OR metabonomics OR "metabolic profiling") AND (atherosclerosis OR 
"cardiovascular disease"). Searching with this quote retrieved 141 results. However, only original 
research articles are reviewed and discussed. Review, editorials, commentaries or perspective 
articles were excluded. 
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Figure 1. 7: Number of published research articles relevant to metabolic profiling applications on cardiovascular 
disease, per calendar year. 
Metabolic profiling studies have been applied for cardiovascular disease and atherosclerosis-related 
research since 2005. Although until 2009 not many original research articles were published, there 
were a large number of reviews and perspective articles. This demonstrated very well the unmet 
need of the scientific community for new technologies able to provide novel candidate biomarkers, 
as well as aid the effort for elucidation of the dysregulated biological pathways. 
Application of metabolic profiling was initiated on pilot/feasibility studies
65
, and using recognised 
animal models
66-72
. Intervention studies conducted using metabolic profiling tools and relating to 
atherosclerosis, are also present in literature
69, 73-77
. Inevitably, - and due to the widespread interest 
for cardiovascular disease and importance for acquisition of relevant risk-factors – multi-centre, 
large population studies were conducted as soon as the technology could sustain the analysis and 
processing of the required sample numbers. The INTERMAP (INTERnational collaborative study 
of MAcronutrients, micronutrients and blood Pressure)
78
, ARIC (Atherosclerosis RIsk in 
Communities)
79, 80
 and LIPGENE
81
 studies are some of the noticeable examples in literature. 
Lastly, only five articles in published literature apply metabolic profiling using tissue as the 
biological matrix
65, 70, 82-84
. Moreover, only one is utilising the technology on human tissue
84
 rather 
than tissue from animal models. This depicts the need for further applications that can provide 
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important biological information that can only be obtained on tissue level rather than biofluids. 
Furthermore, the need for developing appropriate methodologies, in order to cover for the need of 
tissue applications, is evident. 
Overall, the great need for studies applying metabolic profiling on cardiovascular disease is 
obvious. These studies should work on elaborating on a global, systemic level, maximising the 
information obtained. Finally, more studies should be applied on tissue samples, a matrix that can 
provide invaluable information about the pathophysiology of the disease and dysregulation of 
biological pathways. 
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Chapter 2  Analytical Strategies 
2.1 Introduction 
As discussed in the preceding chapter, metabolic profiling uses a pallet of techniques and methods 
in order to maximise metabolome coverage. The most frequently used techniques are NMR 
spectroscopy and LC-MS. In both platforms several methodologies are used to cover a different 
range of compounds. For NMR it could be a range of sequences, such as CPMG and diffusion, and 
resonance of different nucleus such as proton, 
31
P and 
13
C. On the other hand for LC-MS a range in 
chromatographic columns such as reversed-phase and HILIC columns to cover for the different 
lipophilicity of metabolites, or even different sources for the ionisation of the compounds prior to 
detection, such electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI). In 
the following sections the two platforms, NMR and UPLC-MS, are discussed since they are the two 
techniques applied for obtaining results for studies relevant to this thesis. Statistical tools applied to 
deal with these holistic analytical approaches are also discussed. 
2.2 Ultra Performance Liquid Chromatography coupled to 
Mass Spectrometry (UPLC-MS) 
To address the complexity of the metabolome, platforms are needed that can provide enhanced 
resolution in order to detect and (semi-)quantify the wide range of compounds in a biological 
sample (such as urine, blood, tissues). In such cases coupled methodologies can provide the wide 
range of coverage required by holistic analytical approaches. This section describes the platform 
utilising the advantages of liquid chromatography coupled to mass spectrometry, which is becoming 
more ubiquitous as an analytical tool in metabolic profiling studies. 
Ultra Performance Liquid Chromatography – Mass Spectrometry (UPLC-MS) describes the 
coupling of these two very powerful and widely used techniques: liquid chromatography and mass 
spectrometry
85, 86
 (Figure 2. 1). Using liquid chromatography compounds are subjected to 
separation to be further ionised on elution and detected by the mass spectrometer. On one hand, 
liquid chromatography has become an invaluable separation tool in analysis, with numerous 
applications in bio-, as well as food
87, 88
 and drug analysis
89-92
. On the other hand, mass 
spectrometers, as compared to other detectors coupled with liquid chromatography, offer the 
additional specificity that liquid chromatographic separation need, especially when it comes to 
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complex matrices. Currently, mass spectrometry constitutes the heavyweight tool in the ‗arsenal‘ of 
untargeted metabolic profiling technologies, offering additional sensitivity in a wide range of 
analytes. 
 
Figure 2. 1: A diagram of an LC-MS format. The heart of the LC is the pump. The pump is supplying the mobile phase 
to the system at a specific flow. The mobile phase will pass through the column and reach the detector, an MS in this 
case, which is followed by a recorder. Between the pump and the column, there is the sample injector which is where 
the sample is loaded and injected into the flow to be separated. 
2.2.1 Ultra Performance Liquid Chromatography (UPLC) 
2.2.1.1 Liquid Chromatography 
Liquid chromatography is based on the chemical interactions of the analyte to: 1) the solid material 
that a chromatographic column is packed with, called the stationary phase, where the analyte is 
essentially partitioned, and 2) the mobile phase, which is constituted by the solvents that flow 
through the column. A correctly set up chromatographic method should firstly allow for the analyte 
to be retained in the column due to the interactions and physicochemical forces to the stationary 
phase, that are greater than to the mobile phase. This will allow for ‗non-specific‘ molecules and 
salts to flow through the column. By adjustments to the composition of the mobile phase, the 
physicochemical forces of the stationary phase to the analyte will be surpassed by the ones between 
the analyte and mobile phase. Therefore the analyte will elute from the column. When the 
composition of the mobile phase is adjusted through the analysis then this is called a gradient 
elution. However, there is ability for the system, after proper adjustments in solvent composition, to 
retain the analyte and elute without changing the composition of the mobile phase through the run. 
This is called isocratic elution. There are both advantages and disadvantages in both types of 
elution. The gradient elution is generally used when the analytes in a sample have a wide range of 
physicochemical properties. This is the case in metabolic profiling, when untargeted methodologies 
are used. The immediate issue from this is the long re-equilibration of the system to the initial 
conditions, i.e. initial mobile phase compositions. 
 48 
 
The efficiency of the chromatographic separation of a method/technique is measured by the 
resolution (R) of the system. This would be the measurement of separation of two peaks, 
proportional to their difference in retention time, and inversely proportional to the average width of 
the two peaks (Equation 2. 1)
93
.Figure 2. 2, and Equation 2. 1 describe the concept of 
chromatographic resolution. Another measure of chromatographic efficiency is the number of 
chromatographic plates which is inversely proportional to peak width. 
 
  
     
 
           
 
Equation 2. 1: The equation describing the calculation of chromatographic resolution: t1 and t2 represent the time of 
each peak at the apex, tw1 and tw2 represent the width of each peak. 
 
 
Figure 2. 2: A schematic representation of two chromatographic peaks, along with their characteristics important for 
calculation chromatographic resolution. 
The invention and coining of the term chromatography, in attributed to Mikhail Tsvet (1903). Since 
then, multiple contributions to chromatography are reported and recognised. However, the 
 49 
 
introduction of the first commercial HPLC (High Performance Liquid Chromatography) is credited 
to Waters in 1969, with the ALC100 HPLC. The HPLC came with advance resolution capabilities. 
This was due to the ability to support a stationary phase consisting of particles typically in a 
diameter of 5μm or larger93. This increased the surface of interaction, and provided tighter packing 
of the column. However, tighter packing came with increased backpressure. Thus, HPLC columns 
came with the advanced ability to tolerate such pressures, and at the same time providing constant 
and reproducible flowrate. 
The heart of the liquid chromatography instrumentation is the pumps. They are constructed with 
proviso to resist corrosion from salts and strong organic solvents which usually comprise the mobile 
phase. They are also designed to provide a pulse-free output. Reciprocating pumps are the ones 
generally used. According to the pump format single-, dual-, or triple- head pumps maybe used to 
reduce flow pulsation. Also pulse damping is sometimes used to compensate for the small 
fluctuations in flow and pressure
93
. 
2.2.1.2 Ultra Performance Liquid Chromatography 
HPLC was the separation technique of choice for over 30 years. Ten years ago the new concept of 
Ultra Performance Liquid Chromatography, UPLC, was introduced
94, 95
. It was introduced by Water 
Corporation and now the copyrights for the name UPLC belong to this company. Other companies 
use different names to describe UPLC, such as RRLC, for rapid resolution liquid chromatography 
(Agilent).  Therefore, the scientific community is currently using the term ultra high performance 
liquid chromatography (UHPLC). For the purposes of this thesis the term UPLC is used.  
The advancement that made UPLC a higher efficiency chromatographic technique was the 
reduction of particle size of the stationary phase and tighter packing. The theoretical background is 
that particles of less than 2.5μm in diameter can increase theoretical chromatographic plates and 
keep this high efficiency even at high flowrates. UPLC is using sub-2μm particles in diameter, 
generally 1.7 - 1.8μm. 
However, with smaller particle size and tighter packing, along came the increase in backpressure. 
This was another challenge that was resolved by the UPLC systems. A UPLC system and columns, 
can typically tolerate up to 15,000psi of system pressure. Additional provisions are in place to avoid 
any cause of high pressure. Such protective module is the pulse-free sample injection. 
In general, the UPLC can provide improved separation compared to its predecessor, HPLC. 
Additionally, the minimal dispersion of analytes provides higher sensitivity. Lastly, as discussed, 
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the analyst has the ability to go for faster analyses without significantly compromising 
chromatographic resolution. These are the advantages that make UPLC the separation platform of 
choice in today‘s bio- (or other) analysis applications. 
 
 
Figure 2. 3. Three-Dimensional Maps of (A) HPLC-MS and (B) UPLC-MS, showing retention time, m/z and intensity. 
The superiority of UPLC, especially in terms of sensitivity is obvious. The figure is adapted from Wilson ID et al
96
 and 
is obtained from the analysis of mouse urine.
96
 
2.2.1.3 UPLC Column chemistries 
In order to optimise the analyte-stationary phase chemical interactions, different column chemistries 
are used. This means that the material of the stationary phase will vary according to the 
physicochemical properties of the analyte, such as their structural groups and lipophilicity. An 
optimal interaction would mean that the analyte would elute without major interferences or 
background, in a rather pure form, and with a minimal diffusion within the system, translated to a 
sharp peak when detected.  
Two are the major concepts applied in column chemistries today in UPLC-MS untargeted metabolic 
profiling, reversed-phase and HILIC: 
2.2.1.3.1 Reversed-phase Chromatography 
Reversed-phase (RP) chromatography got its name due to the inverse principles applied compared 
to the classical mode that was initially used for chromatographic applications. This initial form was 
coined normal phase and it used to describe chromatographic systems where the mobile phase is 
less polar than the stationary phase. Typically for normal phase, the stationary phase is silica. 
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Consequently, RP describes the exact opposite. The mobile phase is more polar than the stationary 
phase. This is generally achieved by irreversible binding of aliphatic chains to the silica. The most 
common chains used are C8 (saturated aliphatic chain of 8 carbons) and C18 (saturated aliphatic 
chain of 18 carbons). 
For the current study two RP columns were used. The first was a C18 HSS (High Strength Silica) T3 
column (Figure 2. 4A). The high strength silica material is made in order to provide high 
mechanical stability to the silica. This allows for its application in high pressure methods. In high 
pressures the silica material can be crushed, thus restricting the flow and altering the profile of the 
analysis. This kind of stability is needed in metabolic profiling especially due to the long runs with 
large sample sets, in order to provide the required reproducibility
97
. 
 
Figure 2. 4: The chemical structures of an HSS T3 column and a BEH HILIC. 
The second column used is a C18 CSH (Charge Surface Hybrid) column. This column uses 
chemically stable silica material in an ethylene bridged hybrid (BEH) structure (Figure 2. 5). It 
provides the high chemical stability that silica was missing and in a wide range of pH, as well as 
increased mechanical stability. On top of the BEH silica particles a low-level charge is applied on 
the particle surface. Then the C18 chain is bonded to the silica. Apart from improved 
chromatographic efficiency, the CSH format provides increased loading capacity, tolerance to high 
pH and fast equilibration time
98
.  
B 
A 
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Figure 2. 5: The chemical structure of BEH column indicating the ethylene bridge in the silica structure for added 
stability. In the bottom is the reaction to produce this bridged polymer. Adapted from Waters Corp
99
. 
2.2.1.3.2 Hydrophilic Interaction (Liquid) Chromatography (HILIC) 
Hydrophilic Interaction (Liquid) Chromatography (HILIC) can be considered a variant of normal 
phase chromatography. HILIC uses silica as a stationary phase. For our experiments BEH HILIC 
columns were used. The ethylene bridge links of BEH, as discussed in Section 2.2.1.3.1 , provide 
extra chemical stability to the stationary phase. As expected, HILIC can manage very well with 
polar compounds (a property lacking in RP), and provide the retention needed. However, for the 
format of this approach, in contrast to normal phase, some water is required in the mobile phase. 
HILIC functions by ―partitioning of the analyte between a water-enriched layer of stagnant eluent 
on a hydrophilic stationary phase and a relatively hydrophobic bulk eluent‖100. This is demonstrated 
in Figure 2. 6. On top of the advantage of superior retention and separation of polar compounds
101, 
102
, HILIC also provides better ionisation when coupled to MS, than normal phase. This is due to 
the eluents used, which are not totally organic and non-polar
100
. Additionally, preparation on mobile 
phase is less laborious as water does not need to be totally omitted
100
. Lastly, the solvents used, 
water and acetonitrile, are more compatible to methods already applied (e.g. RP methods) which 
minimises the need of extensive priming of the UPLC system. 
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Figure 2. 6: The partitioning of an analyte (cytosine) between the water-enriched layer, formed by the interaction to 
silica, and the mobile phase. Adapted from Neue et al 
103
. 
2.2.2 Mass Spectrometry 
UPLC provides the improved separation needed for bioanalysis applications and especially for 
holistic analytical methods applied in metabolic profiling
96
. However, the short width of the UPLC 
peak profile (usually in the range of 3-10 s) demands detectors with high-speed scanning abilities, 
while at the same time, holistic, untargeted approaches, demand a detector that can provide 
specificity, sensitivity in a wide range of molecules and adequate structural information on the 
separated compounds. 
Mass Spectrometry (MS) is a physical analytical technique. It can function as a detector for UPLC, 
as it can accurately measure analyte mass, and with multiple scans per second. MS can provide 
identification of compounds, according to their mass-to-charge ratio (m/z), and fragmentation 
pattern (MS/MS). This makes MS an attractive tool for applications in the field of metabolic 
profiling, and has actually become the method of choice compared to other platforms
104
, especially 
when coupled to UPLC.  Nowadays, MS instruments come with enhanced sensitivity and 
specificity. Their universal format is summarised in Figure 2. 7, and it includes the source, analyser, 
detector and recorder. The detectors are usually using multichannel plates (MCP), which use the 
principle of secondary emission, to amplify the signal from each ion colliding on their surface. 
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Figure 2. 7: A diagram indicating the basic parts constituting an MS instrument. 
The high resolution abilities of modern MS instruments are a major contributor to the increased 
specificity. MS resolution (R) is a measure of separation between two m/z peaks. In most MS 
instruments this is considered a separation at 50% of two m/z peaks. It is therefore calculated as the 
m/z of the peak (m) divided by the difference between two resolved peaks (Δm) (Equation 2. 2). 
Resolution can be calculated for an isolated m/z peak by using as Δm the full width at half 
maximum (FWHM) of the peak.  
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Equation 2. 2: The equation for calculation of MS resolution: m is the m/z of the ion used for resolution calculation and 
Δm is the m/z difference between two separated ions. 
Mass accuracy is the measure of accuracy of the detected m/z of a specific ion. It is describing the 
error compared to the theoretical m/z, and it is important to be as low as possible for untargeted 
studies as it can make the structural assignment easier and the methodology more specific. It is 
expressed as parts per million (ppm) and calculated as the difference of the experimental m/z from 
the theoretical, divided by the theoretical and multiplied by 10
6
 (Equation 2. 3). The mass accuracy 
of an instrument is closely related to the resolution. Only high resolution instruments can provide a 
high mass accuracy
105
 such as Fourier transform ion cyclotron resonance (FTICR) mass 
spectrometers. 
 
              
                 
        
     
Equation 2. 3: Calculation of mass accuracy of a detected ion. 
 
2.2.2.1 Types of mass spectrometers for determination of m/z 
Several types of mass spectrometers exist, each relying on different principles and instrumental 
setup, in order to determine the m/z of an analyte. Some of the most widely used mass 
spectrometers for targeted and untargeted metabolic profiling (utilized for applications for this 
thesis) are described in the following paragraphs.  
2.2.2.1.1 Time of flight (TOF) mass spectrometers 
The most widely used in metabolic profiling are the time-of-flight (TOF) mass spectrometers. For 
the TOF-MS instrument to calculate the m/z of a charged molecule, an electric pulse (voltage) is 
applied to the molecule while guided in a field-free region. All molecules have the same initial 
energy according to the voltage applied (Ev=zV). The molecules travel in the TOF tube while under 
a vacuum, but have different velocities due to their differences in mass. This is due to the kinetic 
energy which is proportional to mass and velocity (Ek=½mv
2
). Provided the initial energy Ev is 
equal to the kinetic Ek, the time for the molecule to flight in the tube is analogous to the root of m/z. 
 56 
 
Thus, smaller ions will reach the detector faster than larger ions when introduced in the TOF, 
provided that they have the same charge. The advantage of the TOF-MS is that charged molecules 
reach the detector within nanoseconds, and therefore a full, wide-range, m/z scan can be obtained in 
high-speed. Typically, 5 scans are required per second when MS is coupled with UPLC, and TOF 
analysers can deliver this scan frequency, and in theory even as fast as 30 scans per second.  
Modern TOFs can also provide high resolution, especially since the introduction of reflectrons and 
orthogonal TOFs, and improved mass accuracy, enhanced by the use of lock-mass correction 
(Figure 2. 9). Reflectrons, also referred to as ion mirrors, are a set of parallel opposite charged metal 
rods, where ions can be reflected. This way the TOF separation is increased by elongating the ion 
path without physically making the TOF tube longer. This means that less space is needed for the 
analyser but also less power to pump down. Orthogonal TOFs (oTOF) were introduced to solve the 
issue with TOF-separation affecting ions prior to entering the TOF tube. This separation can cause 
widening of the ion peaks and reduce resolution. The oTOFs can increase resolution by 
orthogonally introducing ions into the TOF tube since they apply a voltage perpendicular to their 
current velocity.  These advantages, and the relative low cost of instrumentation and maintenance, 
are what make TOFs preferred for untargeted metabolic profiling. 
2.2.2.1.2 Quadrupole mass spectrometers 
On the other hand, quadrupoles use a different principle for calculating m/z. Quadrupole analysers 
use oscillating electric fields to isolate charged molecules according to m/z. This is done by usually 
two pairs of parallel cylindrical rods with opposite charge (Figure 2. 8). Trajectories followed by 
the charged molecules will differ according to their m/z and oscillation frequencies. Ions with m/z 
not focused to pass through the quadrupole, will eventually collide with the charged rods and 
neutralise. This apart from the obvious specificity, it can provide higher sensitivity when targeted 
approaches are applied. Additionally, the cost of instrument can be low. However, when a wide m/z 
range is required, a full scan can take up to a second
106
. Quadrupoles can also suffer in mass 
accuracy. These disadvantages restrain the application of quadrupoles for untargeted approaches, 
though they are preferred for targeted. 
 57 
 
 
Figure 2. 8: A schematic representation of a quadrupole. The two pairs of parallel cylindrical rods bear opposite 
charge and are under constant electric field oscillation, according to the desired ion. According to the oscillation, ions 
with different m/z will differ in their trajectories. Non-specific ions will eventually collide to the charged rods and 
neutralise. 
2.2.2.1.3 Quadrupole-TOF 
A hybrid of the two MS instrumentations that combines the best features from both is the 
instrument of choice for several laboratories working on metabolic profiling. This instrument is the 
quadrupole-TOF (qTOF) and has the quadrupole followed by a collision cell (where fragmentation 
of molecules occurs), and ending with a TOF for m/z determination and recording (Figure 2. 9). 
This provides the flexibility for TOF analyzer to be used with untargeted applications. The 
quadrupole can be used in order to select a specific m/z to be subjected to fragmentation, and the 
full m/z spectrum can be recorded again after TOF separation. 
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Figure 2. 9: A diagram of a Xevo G2. The sample is sprayed into the source by the sample sprayer. The ions are the 
guided through a z-shape course and by passing through ion optics, a quadrupole and a collision cell are entering the 
TOF tube to be subjected to separation and detection according to their m/z. 
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2.2.2.2 Ionisation Sources – Electrospray ionisation (ESI) 
The ionisation source is the part of an MS instrument that converts molecules to a charged state. It 
also transfers charged molecules into the gas-phase, appropriate for detection by MS analysers. The 
mostly used ionisation technique coupled to UPLC is ESI. ESI, introduced by Fenn et al
108
, is the 
preferred ionisation technique for UPLC-MS metabolic profiling studies, due to the ‗soft‘ ionisation 
it can provide
109
. It can interface very well UPLC and MS, as it can cope with transferring separated 
molecules, coming from the UPLC, into the gas-phase. 
ESI occurs in essentially ambient atmospheric pressure, and after application of strong electric field 
to a liquid. The liquid gets to the source through a capillary. The high voltage is applied between the 
capillary and the counter-electrode, in close proximity. Generally voltages range between 1-3kV 
and vary in polarity according to the charge of the molecules detected. The droplets created at the 
end of the capillary are subjected to high charge accumulation due to the electric field. A gas flow 
usually nitrogen is applied coaxially to the sample flow, with the intension of restraining the 
droplets axially and assisting to the production of fine aerosols. On top of that, the desolvation gas 
is applied (N2), usually at high temperature and flow, which causes solvents to evaporate (Figure 2. 
10). The droplet will experience greater opposite forces on the surface as the solvent evaporates and 
it gets smaller. This will cause a further explosion of the droplets into smaller ones, and will keep 
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occurring until no solvent is left and the analyte is in the gas-phase (Figure 2. 11). This way the 
accumulated charge on the surface of the droplet is passed to the molecules. The exact mechanism 
of transfer of the charge from the droplet to the molecules is not clear, but its principle is that the 
charge of the droplet remains unchanged as solvent evaporates
110
. The ions enter the MS analyser 
guided by the forces from the application of opposite charge voltage. This comes on top of the 
suction forces applied as the analyser constantly functions under a vacuum. Usually, the flow of the 
source and the entrance of the analyser (sample cone) are orthogonally located (Figure 2. 9 and 
Figure 2. 10). This avoids the direct infusion of neutral molecules into the analyser. In Figure 2. 9 it 
can be seen that the ions are guided through another orthogonal route. This works as additional 
improvement in ion-charge specificity, and eventually increases the sensitivity of the instrument by 
reducing the non-specific ions reaching the detector. At the same time it protects the instrument 
from unnecessary accumulation of debris. Perhaps the greater disadvantage of ESI and MS in 
general, is that molecules are competing for the same amount of charge. This causes a phenomenon 
called ion suppression and is the major restriction of sensitivity in MS technologies. 
 
Figure 2. 10: The design of an ESI source. On the left is the probe where the sample is injected. On the right is the lock-
spray, where the lock-mass is injected for constant adjustments to the recorded mass. The rotor is constantly switching 
between blocking either the sample entering the analyser or the lock-mass. 
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Figure 2. 11: A representation of the mechanism of electrospray ionisation in the source of an MS analyser. Adapted 
from  Waters Corp
110
. 
2.2.2.3 Tandem MS 
Tandem MS or MS/MS can provide structural information of a molecule according to the fragments 
produced, or by matching of the fragmentation pattern to a standard compound. As previously 
mentioned one of the most common instruments used for MS/MS acquisition is the QTOF, and it is 
the instrument used in this study as well. In order to obtain an MS/MS spectrum of an ion using a 
QTOF, this ion, called the parent ion, needs to be isolated first. This is done by a quadrupole, but in 
this case the analyser is not followed by a detector. Instead, the ion will pass through a collision cell 
where it will be fragmented by a neutral gas (such as nitrogen or helium) and application of voltage. 
The fragments will then pass into the TOF analyser and detected, providing only ions originated 
only from the precursor ion. An example of how MS/MS can provide structural information and be 
matched to a compound can be found in Figure 2. 12.  
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Figure 2. 12: Example of how tandem mass spectrometry (MS/MS) by using a QTOF mass analyser, can assist in 
structural assignment of a compound. Data from studies described in Chapter 4 are used, illustrating the identification 
of sphingosine from ms/ms data. (A) The MS function of a fraction eluted from a column at a given retention time shows 
multiple ions. (B) A specific m/z (282; black arrow) is chosen for MS/MS, and ion-specific fragments (orange arrows) 
after collision-induced dissociation are detected (Insert: Expansion of 50-300m/z). (C) Ion-specific fragments can be 
matched to online MS databases (in this case Metlin
111
). 
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The introduction of tandem MS acquisition modes such as data depended acquisition (DDA) has 
assisted to a great extent the assignment of statistically significant molecules in metabolic profiling. 
DDA can be set to automatically acquire MS/MS spectra from ions, usually according to an 
intensity threshold. 
Another mode which can be characterised as a variation of tandem MS is the MS
E
. It is different to 
MS
n
 as there is no initial parent ion isolation. All molecules will be fragmented as they pass from 
the collision cell, usually after ramping of the collision energy. It is generally used after UPLC 
separation and data are generally collected along with an MS
1
 acquisition scan
85
. The MS
E
 function 
is specific to Waters instruments. 
These approaches allow the scientist to collect, during the initial untargeted run, enough 
fragmentation information to assign a great number of molecules prior to knowing the outcome of 
the analysis. This saves time and the frustration of matching different retention times to the same 
analyte, as minor shifting may occur. Such fluctuations in retention time, observed between runs, 
are usually small, and are mostly due to small differences in the preparation of mobile phase or 
column degradation. Sometimes they can be quite large differences due to variations in tubing 
length. 
2.2.3 UPLC-MS data processing in metabolic profiling studies 
In untargeted UPLC-MS metabolic profiling methods, a vast amount of information is collected. In 
the case of UPLC-MS this information comes in the form of detected chromatographic peaks, 
attributed to a specific m/z. In order to handle this wealth of information, appropriate automation is 
required to transform the data into a concise and representative format, enabling the application of 
subsequent statistical analysis tools. Generally, the scientist requires a matrix consisting of all the 
samples as columns, and as rows all the detected peaks. The peaks are represented as features 
describing the intensity of a specific retention time and m/z. Generally peaks are characterised by 
the area under the peak, or height, and there are some basic steps to be applied in order to get to that 
point. 
Two are the major algorithms that need to be applied in order to obtain the information needed for 
statistical analysis. The first is peak-picking, which is comprised of an algorithm that identifies 
chromatographic peaks, and results in a number of identified peaks, with their own individual 
characteristics (retention time, m/z, area) per sample. This is followed by grouping, which involves 
the identification of peaks that describe the same feature. An example of the matrix generated by 
such algorithms in UPLC-MS can be seen in Figure 2. 13. 
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Figure 2. 13: A matrix (partial) generated from UPLC-MS data after data processing with peak-picking and grouping 
algorithms. Columns represent features describing m/z and retention time, and rows represent samples. 
There are a number of packages applying algorithms that generate these matrices of processed data. 
Some of them offer more flexibility and have more abilities than others. Two packages that are used 
in this study for data processing are the XCMS package
112
 and MarkerLynx. 
XCMS is an open-source package
112
, written in the R programming language. Apart from the peak-
picking and grouping, it can provide abilities such as retention time correction and filling of missing 
peak data. It also provides the flexibility of choosing from different algorithms for different 
processes. Disadvantages could be considered the low user friendliness, and necessity of 
transformation from the initial format (related to the software of the instrument company) to a 
compatible format to the package (e.g. NetCDF) 
MarkerLynx is a package from Waters Corporation that is built-in their central software MassLynx, 
used primarily to interface the instrument and for data visualisation. It makes processing easier as 
the scientist can move directly towards applying data processing algorithms. The disadvantage is 
the limited flexibility, and reduced abilities which don‘t include processes such as retention time 
correction and missing peak filling. 
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The last part of data processing is normalisation. Normalisation is a per sample adjustment of 
features in order to remove systematic variation occurring from biologically irrelevant factors. Such 
variations may include reduction in instrumental sensitivity through a run, inconsistencies in 
pipetting, and different sample dilutions (e.g. in urine). This way samples become comparable to 
each other, and variation is more likely to be biologically related. There are different approaches on 
how to properly normalise a dataset but which one is more appropriate is debated
113
. For this study, 
total area normalisation is applied for UPLC-MS studies. Total area normalisation accounts very 
well for reduction in analyser sensitivity (due to accumulation of debris and other sources of 
contamination, generally in the instrument source) which is a common issue in long runs
114
. 
2.2.4 UPLC-MS metabolite identification 
Structural assignment of metabolites can be a very tedious task, when untargeted approaches are 
applied. It is sometimes referred to as ―the bottleneck of metabolic profiling‖. The success of 
metabolite identification is, to a great extend, laying on the skills of the analyst and requires a wide 
range on knowledge. For this thesis, descriptions of modules used to identify compounds are 
described in each chapter. In this section, guidelines for: accomplishing structural assignment and 
appropriate reporting for the level of assignment are described. 
Metabolite assignment is essential no matter what the ultimate target of the analysis is; elucidation 
of a biological pathway, or diagnostic biomarker discovery. For revealing pathway dysregulations, 
pathway mapping can aid biological interpretation and placing differential metabolites into context 
with the studied disease. Altered biological processes contributing towards the pathological 
phenotype can be identified and targeted for further clarification of their dysfunctionality. On the 
other hand, although there is an impression that diagnostic biomarkers or profiling may not 
necessitate relating to pathways of disease, it is actually of supreme importance and is a part of 
diagnostic biomarker validation. 
2.2.4.1 Minimum reporting for metabolite assignments 
Concerns arising from the need to appropriately report evidence for structural assignments of 
metabolites, led several groups working on metabolic profiling to reach and publish a consensus on 
minimum reporting. The Metabolomics Standard Initiative has published a paper entitled ―Proposed 
minimum reporting standards for chemical analysis‖115 reporting suggested levels of metabolite 
identification: 
 Level 1: Identified compounds (two independent and orthogonal data relative to an authentic 
compound analyzed under identical experimental conditions) 
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 Level 2: Putatively annotated compounds (e.g. without chemical reference standards, based 
upon physicochemical properties and/or spectral similarity with public/commercial spectral 
libraries) 
 Level 3: Putatively characterized compound classes (e.g. based upon characteristic 
physicochemical properties of a chemical class of compounds, or by spectral similarity to 
known compounds of a chemical class) 
 Level 4: Unknown compounds — although unidentified or unclassified these metabolites 
can still be differentiated and quantified based upon spectral data 
There of course intermediate levels that could be achieved or one could even surpass the top levels 
if it is considered necessary. For example, while two independent and orthogonal measurements, 
matched to authentic standards, are considered sufficient for level 1 assignment, this would mean 
that m/z and retention time could be enough to accomplish top level of assignment. However, 
ms/ms spectra could provide more confidence to the assignment combined with m/z and retention 
time measurements. In rare cases it might be considered of importance to derivatise the compound 
and if the expected derivative is produced, provide additional support to the assignment, though this 
could usually be considered excessive. 
2.2.4.2 Workflow for accomplishing structural assignment in untargeted UPLC-MS 
metabolic profiling experiments 
There are several steps towards accomplishing the structural assignment. These steps are to guide 
the analyst towards the corresponding structure and at the same time provide support for the 
assignment: 
1. Accurate mass database search 
2. MS polarity mode of detection consistent with structure 
3. Biological matrix and species 
4. Sample preparation 
5. Retention time 
6. Charge number (z) 
7. Mass deficiency 
8. Elemental composition 
9. MS/MS  and MSE 
10. Authentic standards – matching to retention time and MS/MS of sample feature 
11. Considerations for the possibility of structural isomers 
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Although matching to accurate mass, retention time, ms/ms, and authentic standards are the most 
important steps of the workflow, there is still valuable information to be gained from every 
suggested step. 
2.2.4.2.1 Accurate mass database search 
Searching on relevant public databases for a specific accurate mass can provide vital direction 
towards the appropriate structure of an unassigned feature. Databases used should be relevant to the 
samples analysed, meaning that the analyst should use databases dedicated for biological matrices. 
The Human Metabolome Project (HMDB)
116
, Metlin
111
 and LipidMaps
117
 are some of the databases 
available online, relevant to biological matrices and offering searching based on mass accuracy 
measurements (Figure 2. 14). 
 
Figure 2. 14:The options offered by the Metlin database
111
, for searching using an accurate mass measurement. 
Online databases would generally offer options for polarity mode, relevant adducts and a mass 
window in Dalton (Da) and/or ppm (Figure 2. 14). Some of these databases offer calculations for 
dimer ions, which can also be the case for small molecules. They would not, however, provide 
matching of any isotopes, and they are focusing mostly on primary and parent ions. All of these 
manifestations of a molecule in the ionic state (adducts, dimers, isotopes) could make approaching a 
conclusive result more difficult, relaying on the experience of the analyst to rationally narrow down 
probable matching metabolites.  
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In Figure 2. 15, an example of database matching (Metlin database
111
) using accurate mass is 
illustrated for a feature detected with m/z of 140.0684. When covering a greater range of potential 
adducts (in this case adducts of ammonium, sodium, water and the protonated ion form) a total of 
36 metabolites match the searching criteria. However, when the potential adduct forms are 
restricted to only sodium, only 17 hits match the searching criteria. The analyst can acquire this 
information and restrict the search criteria by inspecting the m/z spectrum at the specific retention 
time. As can be seen in Figure 2. 15C another ion at 118.0852, is matching the possibility of the 
protonated ion. This can be further confirmed by chromatography (Figure 2. 15D) where it becomes 
obvious that the two ions at m/z 140.0684 and 118.0852 are coeluting, demonstrating with high 
confidence that these two ions are manifestations of the same molecule. 
 
Figure 2. 15: Reducing possible hits for metabolites matching the criteria for m/z 140.0684
111
. A) Using four possible 
adducts a total of 36 hits are obtained. B) When using only the possibility of sodium adduct hits are reduced to 17. C) 
Information about the adduct form can be obtained by the spectrum and D) chromatography can help verify that the 
two ions originated from the same molecule. 
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2.2.4.2.2 ESI polarity mode of MS detection 
When obtaining the search results from databases, the analyst should first enquire if the possible 
matching metabolites can actually ionise in the detected polarity mode. This piece of information is 
not available by databases, which might be just presenting possible calculations for aiding the user. 
Figure 2. 16 shows all the possible ion adducts as calculated by the Metlin database
111
 for stearic 
acid. Although the protonated ion is also demonstrated, it is known that carboxylic acids do not 
sufficiently ionise on positive mode. Therefore, the analyst should critically review results from 
databases and exclude matching to ions that cannot be practically formed. 
 
Figure 2. 16: An example of a database (Metlin
111
) calculating adducts that might not be necessarily formed for the 
polarity MS mode used for analysis. 
2.2.4.2.3 Biological matrix and species 
It is also essential to make sure that the matched metabolite is compatible with the analysed 
biological matrix and species. When it comes to the biological matrix, knowledge of basic 
biochemistry can be very helpful. For example, the detected m/z of 314.1241 was matched to two 
potential metabolites. One of them and with less mass error is a glucuronide. Keeping in mind that 
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the biological matrix in this case was a urine sample, where numerous non-polar compounds are 
excreted as glucuronides, the analyst could focus more on proving this as a possibility rather than a 
less polar match (norcisapride).  
On the other hand, differences on expressed metabolites between species, could also work on the 
analyst‘s advantage. For example, the metabolome of humans (Homo sapiens), Drosophila 
melanogaster, bacteria species, should be expected to have substantial diversion. The lipid class of 
sphingolipids, for instance, would manifest different lengths of backbone, with the 18 carbon chain 
largely detected in humans, whereas the 14 carbon chain would be detected in Drosophila 
melanogaster. For both species, the 16 carbon chain can be detected as the sphingolipid backbone. 
Lastly, before one excludes any metabolite as abnormal for a species/matrix, should first ask if they 
could be present due to environmental interactions, symbiosis or any sort of intervention. 
2.2.4.2.4 Sample preparation 
Sample preparation can also assist towards narrowing down possible metabolites, matched by 
databases. The most frequently applied extraction methodologies nowadays are liquid-liquid 
extraction and solid phase extraction (SPE). For liquid-liquid extraction, the solvents used can 
provide an idea of the physicochemical properties of the molecules extracted with high yield. On 
the other hand, if SPE is applied, the stationary phase and eluents can provide this information. 
Sample preparation can induce features due to materials and handling. In this case, the analyst can 
easily determine and exclude such ions by running preparation blank samples. This means that the 
same solvents and procedure would be applied without the additions of sample. In this manner, 
impurities from solvents and compounds generated from the procedure, such as plasticisers, can be 
identified. 
2.2.4.2.5 Chromatographic retention time 
The retention time of an ion could provide valuable information and guidance towards structural 
assignment, reflecting metabolite physicochemical properties and structure. This could be a tedious 
task as it requires experience, critical review of the chromatographic system used, especially 
stationary and mobile phase, and experimental characterisation of the method applied. However, 
some simple rules for specific chromatographic systems could further assist the analyst. For 
example, when a reversed phase system is used, one can expect that less polar compounds to be 
retained longer in the column (Figure 2. 17). On the other hand, when a HILIC system is used, 
molecules with higher polarity would generally be less retained in the column (Figure 2. 18); 
thought partition mechanisms with HILIC systems can be more complicated. A practical option 
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would be for the analyst to run mixtures of standards in order to understand the interactions 
occurring in chromatographic systems. 
 
Figure 2. 17: An example of reversed phase UPLC-MS analysis, where compounds with higher lipophilicity are 
retained longer in the column. 
 
 
Figure 2. 18: An example of HILIC UPLC-MS analysis, where compounds with less lipophilicity are retained longer in 
the column. 
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Finally, measurements such as the partition coefficient (logP), which is a measure of lipophilicity of 
a molecule, can provide a rough idea of the extent of the interactions that can occur in a 
chromatographic system. It can be used as a guide especially when comparing between compounds. 
Figure 2. 19 demonstrates how the logP value is consistent with the retention time in a reversed 
phase chromatographic system. 
 
Figure 2. 19: A demonstration of two compounds with different logP, and how this provides estimation for their 
distribution between the two phases formed in the column. 
2.2.4.2.6 Charge number 
Although in metabolomics the scientists generally deal with singly charged molecules, it is 
sometimes possible for a molecule to have a double (or higher) charge. For this to occur, more than 
one sites with structural groups that could ionise, are required. This is generally the case with 
macromolecules (Figure 2. 20A). Nonetheless, this is essential information for identifying the 
structure of a molecule and can be easily obtained by observing the isotopic profile of an ion. 
Keeping in mind that the MS measures the mass-to-charge ratio (m/z) a doubly charged molecule, 
unlike singly charged, will have the 
13
C isotope at an additional m/z of approximately 0.5 rather 
than 1 (Figure 2. 20B). This can provide additional assistance for structural assignment of detected 
ions. 
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Figure 2. 20: A) A polypeptide can form doubly charged ions due to several number of structural groups that can 
ionise. B) An example of a metabolite (cardiolipin), demonstrating that when there is a double charge, the second 
isotopic signal will be located at M+0.5 m/z. 
2.2.4.2.7 Mass deficiency 
Mass deficiency can be described as the difference between a compound‘s exact mass and its 
nominal mass. It is yet another benefit of high resolution/high mass accuracy MS. Mass defect can 
provide tremendous assistance in metabolite structural identification, from aiding assigning the 
corresponding elemental composition to detecting adducts. An example frequently encountered in 
metabolomics is assigning alkyl ether or alkyl ester to phosphatidylcholines (PC). The PC(O-
18:0/18:0) with molecular formula of C44H91NO7P+ (protonated ion), and PC(17:0/18:0) with 
molecular formula C43H87NO8P+ both have a nominal mass of 776. Additionally, they would 
experience similar range in retention times (provided that an untargeted method is used), and 
present similarities in characteristic fragments. However, their exact mass would be significantly 
different (ΔDa=0.0364), and easily detected by modern TOF instruments. The analyst could 
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therefore gain guidance on the structure and specifically the elemental composition of the PC 
detected. 
2.2.4.2.8 Elemental composition and isotopic pattern 
Calculating the elemental composition or even just being able to confirm the existence of a specific 
atom in a molecule could prove significantly useful. The existence of 
13
C will display an additional 
ion after the main, parent ion. Knowing that 
13
C is present at a percentage of 1.1% the number of 
carbons in a molecule can be calculated simple by dividing the proportion of 2
nd
 to 1
st
 parent ion 
isotopes by 1.1. Additionally, characteristic isotopic patterns can be obtained if chloride (Figure 2. 
21), bromide and sulphur are present. This would be the case even if they are present as adducts. 
Recently, software that can suggest an elemental composition for a specific isotopic pattern has 
been made available. However, the user has to be careful and check the quality of the data provided. 
High intensity saturated ion signals, as well as low intensity signals that their isotopic signals cannot 
rise above noise, could lead to a wrong result. Additionally, such software also uses mass accuracy 
for their calculations (generally provided as a ‗score‘), so the user should make sure that mass 
accuracy is satisfactory.   
 
Figure 2. 21: An example for the spectrum of adenosine in negative MS mode, where a chloride adduct is formed 
demonstrating a characteristic isotopic pattern.  
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2.2.4.2.9 Tandem MS 
Metabolite fragments and fragmentation patterns can be characteristic and very informative for the 
structure of a molecule. The information they can provide can be specific and by further use of 
tandem MS databases and/or authentic standards, could lead to structural assignment. The MS/MS 
and MS
E
 are the most frequently used approaches applied, as described in Section 2.2.2.3 . In 
Figure 2. 22 the example for ion 140.0684 from Section 2.2.4.2.1 (identified as sodium adduct) is 
used to illustrate how using fragments from the MS/MS spectrum of the ion, and matching them to 
fragments from an online database (Metlin
111
), led to the structural assignment for betaine. 
However, if such matching is not possible, then it lays on the skills of the analyst to decipher the 
structure of the analyte. Software and algorithms using basic fragmentation rules can assist when 
assembling a molecule from fragments is needed. 
 
Figure 2. 22: Matching the MS/MS spectrum of betaine to the MS/MS spectrum from Metlin database
111
. 
2.2.4.2.10 Matching to authentic standards 
In order to report a metabolite structure with confidence, it is of importance to match the detected 
metabolite to the authentic standard in terms of tandem MS spectrum, and retention time, when 
chromatography is used. Firstly, it is advised to opt for matching retention time, and then for 
 75 
 
matching to tandem MS spectrum. This is due to occasional difficulties of obtaining MS/MS spectra 
from samples as the concentration of the analyte can be low. In Figure 2. 23 the example for ion 
140.0684 from Section 2.2.4.2.1 (identified as a sodium adduct), demonstrates matching the ion of 
betaine to the corresponding authentic standard by retention time and MS/MS spectrum. This 
approach can provide the confidence needed for an assignment. 
 
Figure 2. 23: Matching betaine to the authentic standard. A) Matching retention time of betaine from standard and 
sample, and B) matching MS/MS spectra. 
2.2.4.2.11 Structural isomers 
An important parameter that needs to be addressed by the analyst is whether existing isomers 
(including stereoisomers) can be identified. This can be very important as they can show numerous 
biological interpretations. There are several occasions where isomers can be coeluting when 
chromatography is applied. Therefore, the analyst should be able to discriminate between different 
structural forms of isomers. This can occasionally be possible from MS/MS experiments. Figure 2. 
24A demonstrates how the two isomers of citrate and isocitrate present differences in their 
fragmentation pattern. However, this is not the case with butyrylcarnitine and isobutyrylcarnitine 
which have practically identical MS/MS spectra (Figure 2. 24B). In this case it should be 
determined if chromatographic separation can be achieved (Figure 2. 24C). If not, the possibilities 
should be investigated and reported.  
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Figure 2. 24: A) Spectra of citric acid and isocitrate
111
 present differences in formed fragments. B) Spectra of authentic 
standards for butyrylcarnitine and isobutyrylcarnitine present the same fragmentation pattern. C) Isomers for 
butyrylcarnitine and isobutyrylcarnitine can be resolved with chromatography. 
2.2.4.2.12 Examples of structural assignments 
2.2.4.2.12.1 Phosphatidylcholines 
Lipophilic compounds such as phosphatidylcholines (PC) can ionise very well with ESI-MS. They 
are therefore frequently detected by untargeted metabolic/lipid profiling analyses. Characteristic 
fragments for PCs can provide structural information for assigning. As an example the ion 784.59 
will be used. This ion is detected with two chromatographic peaks (Figure 2. 25). A database search 
(Metlin
111
) for this m/z provided 65 metabolites that could be matching in terms of mass (Da). 
These included phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines and 
phosphatidic acids. PCs can be easily detected by their characteristic fragment in tandem MS, of the 
loss of phosphocholine head-group (184.07 Da). This narrows results down to 43 PCs. What remain 
to be determined are the fatty acyl chains of the two detected PCs. Although in positive mode this 
can be possible by detecting the positively charged fragments after neutral loss of one of the chains, 
in negative mode the loss of the fatty chain can be sensitively detected. This presumes that both 
polarity modes are conducted with the same method, in order to easily identify by retention time, 
identical metabolites. For this example, the first ion was identified as PC(18:2/18:1) by positive 
mode MS/MS fragments (Figure 2. 26), to be further confirmed by negative mode (Figure 2. 27). 
The second ion was identified as PC(16:0/20:3) in the same way. In positive mode MS/MS spectra 
(Figure 2. 28) the difficulty for obtaining the length of the chains can be observed, due to the 
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reduced ability of the formed ions to ionise. On the contrary, in negative mode fatty acyl chain 
fragments can ionise very well and are well above the noise level (Figure 2. 29). 
 
Figure 2. 25: Extracted ion chromatograms for to isotopes detected with m/z of 784.59 in positive mode and 828.58 in 
negative mode. 
 
Figure 2. 26: The MS/MS spectrum of the first ion on positive mode. This ion can be easily identified as a 
phosphatidylcholine (PC). This information can be obtained from the ion formed by the loss of the phosphocholine head 
group (PC-HG). For identifying the fatty acyl chains the spectrum is noisy, but indicates the molecule is the 
PC(18:2/18:1). 
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Figure 2. 27: The MS/MS spectrum of the first ion on negative mode. This spectrum cannot assist for identifying the 
class of the lipid. However, it can provide clear information about the fatty acyl chains. 
 
Figure 2. 28: The MS/MS spectrum of the second ion on positive mode. This ion can be easily identified as a 
phosphatidylcholine (PC). This information can be obtained from the ion formed by the loss of the phosphocholine head 
group (PC-HG). For identifying the fatty acyl chains the spectrum is noisy, but indicates the molecule is the 
PC(16:0/20:3). 
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Figure 2. 29: The MS/MS spectrum of the second ion on negative mode. This spectrum cannot assist for identifying the 
class of the lipid. However, it can provide clear information about the fatty acyl chains. 
 
2.2.4.2.12.2 Sphingomyelins 
The lipid subclass of sphingomyelins (SM) is another group of metabolites detected with high 
sensitivity in ESI-MS. Like PCs, SMs have the characteristic fragment of phosphocholine head-
group loss, in MS/MS experiment. It is very easy to be discriminated from PCs since they will be 
detected as odd m/z values. This would be expected as they have two nitrogens atoms in the 
structure (nitrogen rule). Further on, sphingomyelins will present a loss of their fatty amide (Figure 
2. 30). Additionally, as it is the case with all sphingolipids, a characteristic fragment derived from 
the backbone of the molecule (Figure 2. 30) will complete the information needed to be able to 
assign a SM. 
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Figure 2. 30: The MS/MS spectrum of a sphingomyelin (SM) on positive mode. Characteristic fragments that can assist 
on structural assignment are the loss of the phosphocholine head group (not shown in figure), the loss of the d18:1 
ceramide backbone (m/z 264) and the loss of the fatty amide (m/z 280). This fragmentation pattern indicates that the 
molecule is the SM(d18:1/16:0). 
 
2.2.4.2.12.3 Structural assignment of lipids 
Several lipids have characteristic fragments that can provide information of their structure, lipid 
group, and chains incorporated. Table 2. 1 demonstrates characteristic fragments of lipid classes 
that can aid structural assignment. Additionally, retention time can assist as demonstrated in Section 
2.2.4.2.5  Lipid classes like triglycerides may not have a characteristic fragment to define their 
class, but their high lipophilicity, translated to an increase in retention time. They also have a 
fragmentation pattern that can provide the needed information for the fatty acyl chains incorporated, 
by providing positively charged ions after loss of one of their chains. By combining these fragments 
the needed information can be provided for assignment.  
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Table 2. 1: Table of tandem MS fragments and neutral losses, characteristic to specific lipid classes and subclasses. 
Lipid Class Characteristic 
Fragments 
(m/z) 
ESI+  
Phosphatidylcholines 
Sphingomyelins 
184 
Cholesterol esters 369 
Phosphatidylethanolamines 141 (neutral loss) 
acyl-carnitines 85 
  
ESI-  
Phosphatidylglycerols 171/153 
Phosphatidylinositols 241 
Phosphatidylserines 87 (neutral loss) 
 
2.2.5 UPLC-MS applications in metabolic profiling 
UPLC-MS was well-received from the metabolic profiling community from its early days
96
. UPLC-
MS provided the superior separation, robustness, reproducibility and sensitivity demanded for the 
metabolic profiling concept to move forward
114
. The fast turnaround time per sample turned UPLC-
MS into a tool appropriate for epidemiological studies greatly needed in the field of metabolic 
phenotype to surpass issues of biological variation, such as differences due to different gender, age, 
or ethnic background
118
. In combination with automation in data processing it is now considered a 
recognised platform for metabolic profiling studies with a wide range of applications 
119-121
 and in a 
wide range of biological matrices
16, 122
. 
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2.3 Nuclear Magnetic Resonance spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) is based on the physical phenomenon occurring with specific 
nuclei when they experience a magnetic field (Bo). This phenomenon occurs only to nuclei that 
have a spin quantum number (I) different to zero. This number is determined by the number of 
protons and neutrons of an atom (Table 2. 2). A nucleus with spin quantum number of I will have 
2I+1 energy levels in a magnetic field. These energy levels are described by the magnetic quantum 
number mI=I, I-1, I-2, ..., -I. 
Table 2. 2: Characteristics of different nuclei and effect on quantum number
123
 
Number of protons Number of neutrons Spin quantum number mode Example 
Even Even No spin 
12
C(0), 
16
O(0) 
Odd Even Half-integer spin 
1
H(½), 
31
P(½), 
23
Na(
3
/2) 
Even Odd Half-integer spin 
13
C(½), 
17
O(
5
/2) 
Odd Odd Integer spin 
2
H(1), 
14
N(1) 
 
The most frequently used atom for NMR, in metabolic profiling, is hydrogen (
1
H). Hydrogen has 
I=1/2, which means that in a magnetic field its nucleus has either of two energy levels with mI of 
1/2 and -1/2. The higher energy state (α) with mI=-1/2 is the one opposed to Bo, while the lower 
state (β) with mI=+1/2 is aligned with Bo (Figure 2. 31). 
 
Figure 2. 31: Scheme of energy states of a nucleus with I=1/2 (such as proton). Two energy states are present when the 
nucleus is inside a magnetic field. The highest energy α (mI=-1/2), and lowest energy β (mI=+1/2). The difference 
between the two energy states is described as ΔE. 
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When a population of protons are within a magnetic field, some of them will occupy the α state and 
some the β state. The population distribution between these two states is given by the Boltzmann 
distribution (Equation 2. 4). 
  
  
   
  
   
Equation 2. 4: Boltzmann distribution of nuclei populations between two energy states in a magnetic field. 
Where ΔE the difference in energy between the two energy levels, k the Boltzmann constant and T 
the temperature in degrees Kelvin.  
ΔE can be described as hν, where h is the Plank‘s constant and ν is the frequency. This means that, 
keeping in mind that an exact energy ‗package‘ is needed for a nucleus to get to a higher state 
(resonate), an exact frequency should be applied. Also, provided that the energy difference is 
related to the applied magnetic field (ΔE=γħBo; γ is a distinctive constant for each nucleus called 
magnetogyric ratio) the resonance frequency will also be proportional to the magnetic field 
(νres=γBo/2π). 
Energy is provided to the nuclei in a magnetic field using a short radiofrequency (RF) pulse. The 
nuclei will resonate and after the pulse stops the system will return to equilibrium. Equilibrium will 
be reached after a specific amount of time, called the relaxation time. During this time the energy of 
the nucleus will oscillate emitting an RF which referred to as the free induction decay (FID). This 
FID is converted into frequency (Hz) by Fourier transformation (Figure 2. 31). Note here that, as Bo 
can affect the resonance frequency, these are always normalised to account for different magnets. 
This is done by dividing the frequency of a nucleus to the frequency the magnet used. The resulting 
number is called chemical shift and is usually given in parts per million, ppm (or δ). 
 
Figure 2. 32: Stages of NMR acquisition procedure. From left to right: orientation of a nucleus in a magnetic field, 
application of RF and transition to a higher energy state, free induction decay to settle back to equilibrium, acquisition 
and Fourier transformation. 
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When a magnetic field Bo is applied to a nucleus, the magnetic field experienced by that nucleus is 
not of the same magnitude in all chemical environments. This is because of the magnetic fields 
created by electrons circulating the nucleus. This local magnetic field (B΄) is opposed to Bo and 
varies according to electrons surrounding the interrogated nucleus. This difference in electron 
environment is what provides the different chemical shifts that allow definition of the chemical 
environment for each nucleus. For example, for benzene, electrons are located, due to p orbitals, 
parallel to the benzene ring. However, protons will be located in the same plane as benzene. 
Therefore, protons will not be ‗shielded‘ by this local magnetic field from electrons and experience 
a higher overall field. This is why benzene protons will resonate in higher frequencies. This 
phenomenon aids the structural assignment of a molecule. 
Another feature of NMR that can provide additional structural information is spin-spin coupling. 
This phenomenon occurs intensively when two nuclei are in close proximity, and function as small 
independent magnetic fields. These two protons will interact with each other in addition to the 
magnetic field and this causes splitting of the signal. In proton NMR, the most frequently observed 
coupling is between proton nuclei that are three bonds away. A proton, HA, will experience a 
magnetic field from a proton, HB. However, the spin from a single proton (I=1/2) can have two 
energy states. Therefore, two signals will be detected for HA (Figure 2. 33). Respectively, if two 
(equivalent) HB protons existed then the possible energy state combinations would be four, with 
two being equal, and three peaks would be detected (Figure 2. 33).  
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Figure 2. 33: Representation of spin-spin coupling effect as detected from a proton (Ha), due a proton (Hb), three 
bonds away. On the left, only one Hb exists and therefore only two spin states. This will lead to a doublet chemical shift. 
On the right, two equivalent protons exist. Thus, in this case, four different spin orientations can occur. This will give a 
triplet structure. As two energy states are equal the middle peak which represents those, is larger. 
When additional structural information is needed 2-dimensional (2-D) NMR sequences are 
employed. 2-D NMR sequences, such as COSY (COrellation SpectroscopY), can provide 
relationships between signals of the same molecule. This makes them really useful for complex 
solutions, such as matrices commonly analysed by metabolic profiling methods. 
Overall, NMR is a useful tool in metabolic profiling approaches. Firstly, signal intensity is 
proportional to analyte concentration. Additionally, instrument stability and robustness, the non-
destructive sample format, the simultaneous structural information obtained, and the absence of 
signal suppression have it the method of choice for several years. However, some disadvantages are 
the low sensitivity in a number of compounds, the large sample quantity generally needed, and 
unavoidable slow scanning times needed due to the slow relaxation of small molecules. Still, NMR 
technology keeps advancing, with cryoprobe and other developments allowing enhanced sensitivity 
and it remains an irreplaceable tool for metabolic profiling methodologies. 
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2.4 Sample preparation for metabolic profiling studies 
Sample preparation is an important step preceding analysis with the described platforms (UPLC-MS 
and NMR). It involves applications performed in order to transform the samples in a state that 
allows achieving the full potential of the applied technique. This can be the case with debris and 
nonprecipitated proteins. In UPLC-MS this can cause blocking of the column, leading to poor 
chromatographic resolution, and increase in backpressure leading to system failure. Additionally, 
not properly prepared samples can cause accumulation of debris in the ESI source, leading to 
increase background of the MS detector. With NMR, debris and cloudy solutions can cause increase 
in background and poor resolutions. Protein precipitation using organic solvents, as well as filtering 
and centrifugation can solve these issues. However, on occasions it is recommended for the analyst 
to optimise sample preparation for the needs of the analysed matrix. 
Metabolite extraction, including solid-phase extraction methods
124
, can offer several of the 
requirements for sample preparation, such as protein precipitation. Additionally, it can be used to 
increase metabolite recovery used as a pre-concentration technique. However, the selectivity 
observed for extraction solvent systems can sometimes be a disadvantage. Liquid-liquid extraction 
is mandatory when metabolite extraction from tissue samples is required. In the following 
paragraph more information on metabolite extraction from tissue samples is presented. 
2.4.1 Tissue metabolite extraction for untargeted metabolic profiling studies 
Metabolite extraction applied on tissue samples can be a key step for a robust untargeted metabolic 
profiling analysis, and especially when total metabolome coverage is needed. The extraction 
conditions applied, including solvent polarity, temperature, pH, as well as tissue lysis procedures
17, 
104, 119, 125-127
. When it comes to options for tissue lysis, it appears that the high-throughputness of 
bead-beating is preferred
17, 126
, but also appears to be the method of choice as compared to other 
tissue lysis methods
104
. When it comes to solvent systems modifications of the Folch method
128
 and 
later the simpler and less exhaustive Bligh-Dyer method
129
 are currently applied. A simpler 
approach attempting to recover a range of metabolites using one solvent system in a single step 
extraction, for analysis in a cross-platform approach, has been described by Geier et al
104
. They 
report that for untargeted metabolic profiling analyses using GC-MS, UPLC-MS and NMR an 80% 
methanol solution is more fit for the purpose of their study. Masson et al
17
 described a two-step, 
consecutive extraction protocol, as being more reproducible than bilayer extraction protocols. The 
authors split the extraction into a polar metabolite extraction using a water/methanol solvent system, 
followed by a dichloromethane/methanol extraction for non-polar metabolites. Nonetheless, it is 
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apparent that the analyst should choose an extraction protocol based on platforms to be applied, and 
if literature findings are not conclusive or fulfilling, should optimise for the specific tissue of 
interest. For the experimental purposes of this thesis modifications of the protocol from Masson et 
al
17
 is applied. 
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2.5 Multivariate Data Analysis (MVDA) 
2.5.1 Statistical Analysis and MVDA 
Statistical analysis is important in order to allow one to make an inference of a measurement, to the 
wider population, after sampling a smaller group. Statistics can be used to define, especially with 
large datasets, the measured variables that make groups different, and (semi)quantify that 
difference. These tasks are difficult when datasets are large, and typically cannot be performed 
manually. Usually powerful computational algorithms are employed to cope with the calculations. 
The outcome is generally a number or figure that can provide a result within a measure of 
confidence to the scientist. 
MVDA is used in cases where a vast number of variables are obtained from an experiment with 
multiple samples, but are particularly relevant where the number of variables exceeds the number of 
samples, as typically encountered in ‗omic‘ datasets. MVDA is employed in order to provide a 
more comprehensive way (usually in terms of plots and model summary statistics) to extract 
information from complex datasets. It allows interacting variables to mutually define a class, 
making the analysis more robust than univariate statistical analyses. 
2.5.2 Principal Component Analysis (PCA) 
Principal Component Analysis (PCA) is a multivariate data analysis (MVDA) method and functions 
as an orthogonal (linear) transformation of the original variables. PCA can be used as an 
unsupervised pattern recognition method (meaning that no a priori knowledge about the dataset is 
used) employed to present (project) multivariate data reducing the number of dimensions in a 
dataset whilst retaining the important information, since visualisation starts to get difficult for more 
than three dimensions
130, 131
. 
For a dataset matrix (X), with each row representing a sample and each column a variable (Figure 2. 
34), PCA will assign every variable to one dimension in the Euclidean space (meaning the physical 
space/distances, as can be understood by the human mind, but also its generalisation to higher 
dimensions). Therefore, each sample will be represented by one point in as many dimensions as 
there are variables, and placed according to their values (Figure 2. 34 and Figure 2. 35). In PCA the 
first principal component, in this multidimensional system, will be the vector (direction) that 
explains the greatest variation of the data, or in other words provide the minimum of residual values 
(E) from the PComp to the observation (Figure 2. 35). This first PComp passes through the mean 
(Figure 2. 35). Usually for biological data, just one PComp cannot explain the variation of the 
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model sufficiently. Thus, subsequent PComps are employed to represent the remaining variation
130, 
131
 and are calculated orthogonally to the previous PComps and pass through the mean. It is 
important to note that every new PComp should be orthogonal to the previously calculated in order 
to avoid re-including variation already incorporated in the model.  
 
Figure 2. 34: A schematic representation of the basic steps of PCA adapted from Trygg et al 
131
. Three variables (X1, 
X2, X3) for each of the 13 samples are placed on three dimensions. Each dimension represents one variable. By 
applying PComp analysis, the variation extracted is displayed in terms of scores plots and loadings plots. Scores plot 
will provide differences and similarities between the samples after projecting each sample on the vector of the PComp. 
Loadings plots will provide the contribution of each variable to the model for each of the PComps.
131
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Figure 2. 35: A representation of the first PComp as generated in a three dimensional system adapted from Eriksson et 
al
130
. The PComp will capture the maximum variance of the samples, or in other words a minimum of the least 
squares.
130
 
Results from PCA are comprehensively expressed using scores and loadings plots (Figure 2. 34) to 
aid data interpretation. Every PComp will provide its respective scores and loadings. The scores (T) 
are the projections of the observations on the respective PComp (Figure 2. 36). The value of this 
projection of a PComp constitutes the score value (t), and when plotted represents the scores plot 
(Figure 2. 34). From scores plots one can, according to the variation explained by each PComp, 
visualise the extent of similarity or difference between samples and detect outliers or anomalies in 
the sample set. On the other hand, loadings (P) will provide the magnitude, the contribution, of each 
variable (in the case of spectral data the variable represents a signal and hence a metabolite) to the 
PComp. This is generally represented as p. Geometrically, they express the orientation of the 
corresponding PComp in the multi-dimensional system. This is given by the angles from the 
PComp to each variable, keeping in mind that each variable is represented by a dimension (Figure 
2. 37)
130, 131
. 
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Figure 2. 36: Scores for each principal component are calculated from the projection of each point on the 
corresponding principal component. Adapted from Eriksson et al 
130
. 
 
 
Figure 2. 37: Loadings for each principal component are calculated from the cosine of the angle of the corresponding 
principal component, to the axes of each variable. Adapted from Eriksson et al
130
. 
  
 92 
 
Algebraically, the matrix X can be modelled and described by the equation: 
        
Where X is the data, T is the scores, P´ represents the loadings (transposed), and E represents the 
residuals matrix. 
PCA displays the greatest variation of the model‘s variables. Thus for unscaled data a variable with 
a greater value range will dominate the variation and consequently the PCA model. In order to 
adjust the importance of each of the variables, one can apply scaling to the data. A scaling method 
that can attribute the same importance to all the variables is unit variance scaling (Figure 2. 38). For 
unit-variance scaling each value is divided by the standard deviation of the respective variable. 
Therefore, no variable can dominate over any other because of a larger range of its values. 
However, with unit variance scaling noise is given the same importance, and this could affect the 
interpretability of the model. 
A scaling method that can minimise the differences in range of values, but at the same time keep the 
order of the initial variance of each variable, is Pareto scaling (Figure 2. 38). Pareto scaling is 
conducted by dividing each value by the square root of the standard deviation. This way, placing 
this in the context of metabolic profiling analysis (e.g. when using UPLC-MS), data with high 
intensities are providing more impact to the model than low intensity and noise. 
Along with scaling procedures, regularly mean-centering is applied. As the name states, mean-
centering is a pre-processing method where the mean of each variable is centred, i.e. becoming the 
origin of axes. This is simply done by calculating the mean of each variable and subtracting it from 
each of the variable‘s values 130, 132. This procedure makes comparison between variables easier. 
The described preprocessing methods are shown schematically in Figure 2. 38. 
 93 
 
 
Figure 2. 38: A schematic representation of a dataset (A) prior to processing, (B) after mean-centering only, (C) after 
unit-variance scaling and mean-centering, and (D) after Pareto scaling and mean-centering. 
PCA is a robust MVDA method to acquire information from a dataset in an unsupervised manner. 
However, the information given will only represent the greatest variation in the dataset. Although 
sometimes the variation explained by the PCA model can explain the variance induced by, for 
example, a disease, or treatment, this is not always the case. When the main source of variation is 
not related to disease or biological class, for example sources of physiological variation such as 
gender or age may dominate a PCA model, supervised methods are employed to reveal this hidden 
response-related variance, and provide the hidden (latent) variables that could function as 
biomarkers. 
2.5.3 Partial Least Squares (PLS) 
PLS is a supervised MVDA method. PLS acronym is interpreted as Partial Least Squares; however 
it can also be interpreted as Projection to Latent Structures. The PLS is a regression technique used 
in order to model the association between two data matrices, X and Y. It is generally used in 
metabolic profiling to obtain a relationship between the dataset matrix X, and the response matrix 
Y. 
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When Y is a vector (matrix of one dimension), then the first PComp is going to be the direction, in 
the X-space, that, at the same time, describes the maximum variation for X (similarly to PCA), and 
best correlates to the Y-vector. Similarly to PCA, scores are obtained by projecting the position of a 
sample on this component. If the first PComp is inadequate to describe the variation of the Y vector, 
then a second PComp is employed. This, again similarly to PCA, will be the direction in the X-
space that describes the greatest (remaining) variation, passes through the origin, and is orthogonal 
to the first PComp. However, it will again try to correlate the PComp with the remaining variation 
of the Y vector (Figure 2. 39). 
 
Figure 2. 39: A schematic representation of the calculation of the first two PComp of a PLS model. Y is a vector and 
after addition of each PComp the extent of the explained response is shown. Adapted from Eriksson et al 
130
. 
PLS functions in the same way whether Y is a continuous response matrix (for example level of 
ALT corresponding to extent of liver damage), or whether it describes a discrete class (discriminant 
analysis). When Y is a matrix then what is correlated between X and Y are the principal 
components describing the greatest variation. 
2.5.4 Orthogonal-PLS (O-PLS) 
Orthogonal-PLS (O-PLS) is a variant of PLS designed to filter extraneous variation, not relevant to 
the biological class and to enhance interpretation of the variable contributions in defining a class. In 
this case the model is built initially with one PComp as described for PLS. This PComp is called 
predictive and is correlated as much as possible to the Y matrix. However, O-PLS goes a step 
forward and adds an orthogonal PComp to the model. This orthogonal component should be 
uncorrelated to Y as much as possible. Therefore, it is actually describing the unwanted systematic 
variation, not related to the Y matrix, which induce noise in the model. If a single orthogonal 
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component cannot explain all the noise in the dataset, more orthogonal components can be 
employed. 
2.5.5 Model Diagnostics and Validation 
2.5.5.1 R2 and Q2 
The R
2
 represents the variation explained by the model, and is also referred to as the ‗goodness of 
fit‘130. As it can be inferred by the terminology it represents the ability of the model to fully 
represent the dataset. This implies that for a high R
2
 value, the residual values are low. On the other 
hand, Q
2
 is the predictive ability of the model, also referred to as the ‗goodness of prediction‘130. It 
represents the ability of the model to predict an outcome, using a training set, a new set (test set) 
with data not previously used for building the model. Generally this is done by leaving outside the 
model a small portion of the data, and repeating this procedure for as many cycles needed to have 
each observation back-predicted once. For PCA R
2
 and Q
2
 refer to the X-data, while for PLS or O-
PLS, they refer to the Y-data. 
As expected, most of the time R
2
 will be higher than Q
2
 as model complexity increases, e.g. when 
the number of components increases. R
2
 will inevitably keep increasing, along with complexity, as 
more variation will be explained by the model (Figure 2. 40). However, Q
2
 will reach a peak 
whereby the number of PComps it takes to accurately predict a sample to a given class is optimal, 
and then starts declining. This is due to the fact that when more variation in the form of new 
PComps enter the model, more noisy uncorrelated variables are also added, which can actually lead 
to a reduction of class prediction (Figure 2. 40). This is why more PComps should not be added to a 
model when the Q
2
 value starts declining. Lastly, while high Q
2
 is always required, the R
2
 should 
not exceed Q
2
 by more than 0.2-0.3. A disproportionally high R
2
 would actually mean that the 
model is overfitted. This would be translated to an incorporation of noise variants in the model, 
making it unable to explain/predict test sets from another experiment/dataset and giving false 
confidence in the model. 
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Figure 2. 40: Plot describing the effect of increased complexity (A; x-axis) towards R
2
 and Q
2
.
130
 
2.5.5.2 Permutation testing and CV-ANOVA 
Permutation testing is a way of cross-validation of the model. It is conducted by shuffling the class 
values of the Y-matrix, and essentially deliberately mislabelling the samples. This means that when 
fitting any randomly created dataset, this randomly labelled model should have a lower predictive 
value Q
2
 and lower explained variation R
2
 than the model of the actual dataset. If the values 
obtained from the series of random dataset are plotted against the correlation of the random dataset 
to the real dataset, then a plot as in Figure 2. 41 would be obtained. Intercepts of Q
2
 and R
2
 to Y-
axes need to be as close to point of origin as possible. It is suggested that Q
2
 should intercept the y-
axis lower than 0.05 and R
2
 lower than 0.3-0.4
130
. Nonetheless, permutation testing can be used for 
diagnosis of non-valid models. Additionally, it can assist in decisions concerning the number of 
components to be used. 
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Figure 2. 41: Permutation plot showing the R
2
 and Q
2
 of randomly ‘mislabelled’ samples as a function of their 
correlation to the actual data. Optimally, all R
2
 and Q
2
 values should be lower than the real response, while intercept 
should be lower than 0.4 for R
2
, and 0.05 for Q
2
. 
Cross validation – analysis of variance (CV-ANOVA)133 is a significance testing of PLS and O-PLS 
models with one-dimension Y-vectors. To calculate the significance of the model, ANOVA testing 
is performed comparing the residuals obtained after fitting ‗cross-validated‘ models, to the residuals 
of the complete dataset model
133
. Cross-validation is described as the procedure of obtaining the Q
2
, 
where, as previously explained, part of the data are left out of the fitted model, and then back-
predicted to this model. 
2.5.6 S-plot 
The S-plot is used to assist when candidate biomarkers need to be obtained rather than a 
multivariate model. The model covariance is plotted on the x-axis against the model correlation on 
the y-axis. Therefore, order of magnitude and order of reliability can be visualised in a plot. This is 
very helpful in the field of metabolic profiling. Instrumentation can provide concentration detection 
of up to six orders of magnitude which will be fully exploited by a biological sample, where 
concentrations can range up to twelve orders of magnitude. As a result features with lower 
intensities can be missed, although they could act as good disease predictors (Figure 2. 42). On the 
other hand noise features, with very low concentrations should also be avoided as they could 
introduce false positives
134
. The optimal biomarker would be the feature that has both high 
covariance and high correlation, indicating less chance of a noise derived feature and with high 
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confidence. Nonetheless, the S-plot has become a very informative tool in statistical analysis and 
when determination of highly significant features to serve as candidate biomarkers is needed. 
 
Figure 2. 42: An example of how S-plot can assist in OPLS-DA analysis for the determination of candidate biomarkers. 
(A) S-plot where two features are highlighted having a high model correlation. (B) Loadings plot of the same OPLS-DA 
model where one feature can easily be located driving one of the groups while the other is hidden in noisy variables 
(Insert: Scores-plot of OPLS-DA model). 
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Chapter 3  Exploratory metabolic profiling 
methodologies for stratification of high risk 
for rupture carotid plaques 
3.1 Introduction 
Stroke is one of the major causes of death worldwide
45
, and the leading cause of disability in UK 
adults
135
. 15,000 strokes per year in the UK are caused by thromboembolism originating at a carotid 
plaque. This thrombus is caused due to the coagulation reaction of platelets, after the rupture of the 
fibrous cap of the atheromatous plaque
54
. It can become detached and travel along with blood flow, 
eventually causing blockage to smaller luminal calibre vessels (thromboembolism). This will reduce 
the oxygen supply to parts of the brain affected with the possibility of causing disabilities and death. 
Three-quarters of stroke patients will have been previously asymptomatic
136
. It is therefore of great 
importance to stratify the patient risk in order to monitor, predict and prevent the rupture of the 
plaque. In order to accomplish this, the experimental design will be based on the fact that patients 
with stroke symptoms are at high risk of an imminent life-threatening stroke. This risk declines with 
time after the symptoms which are nothing other than what can be characterised as a mini-stroke. 
On the contrary, asymptomatic patients are less likely to suffer plaque rupture and stroke
137
. 
This is a pilot study with the objective to develop and identify methods that can provide the most of 
information from carotid plaque samples. The capability of metabolic profiling to risk stratify 
patients is evaluated, in order to assess whether larger scale studies are worth pursuing. The study 
will be based on the comparison of recently symptomatic patients (high risk group; imminent life 
threatening stroke), and asymptomatic patients as the control group which are less likely to have a 
stroke. 
3.2 Methods 
3.2.1 Patient characteristics 
The carotid plaque samples used in this study were obtained from 10 patients from the Department 
of Vascular Surgery, Imperial College London. From these patients, 5 were asymptomatic 
 100 
 
(Asympt), and 5 were recently symptomatic (Sympt) of cerebrovascular symptoms occurring in the 
territory of the ipsilateral carotid circulation. At carotid endarterectomy surgery, diseased intimal 
arterial segments were retrieved, snap frozen in liquid nitrogen and stored at -80°C. Patients 
provided informed consent and the study was approved by the ethics committee. Patients clinical 
characteristics can be found in Table 3. 1. 
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Table 3. 1: Patients demographics from symptomatic and asymptomatic groups for stroke. 
 
Age Male BMI DM HTN PAD Renal failure ASA A2RA/ ACEI Statins Smoker/Ex 
            Symptomatic group 
           
 
67 Yes ~ No Yes No No Yes Yes Yes Yes 
 
78 Yes 34.3 No Yes No No Yes Yes Yes No 
 
69 Yes 30.5 No Yes No No Yes Yes Yes Ex 
 
91 Yes 26.6 No No No No No No No No 
 
74 Yes 32.3 Yes Yes Yes No Yes Yes Yes Ex 
Average / % 75.8 100% 
 
20% 80% 20% 0% 80% 80% 80% 20%/40% 
            Asymptomatic group 
           
 
72 Yes ~ No Yes No No Yes Yes Yes No 
 
78 Yes ~ No Yes Yes No Yes No Yes Ex 
 
59 Yes ~ No Yes No No No No Yes Yes 
 
78 No 29.3 No Yes No No Yes Yes Yes No 
 
75 Yes ~ No Yes Yes Yes Yes Yes Yes Ex 
Average / % 72.4 80% 
 
0% 100% 40% 20% 80% 60% 100% 20%/40% 
 
Key: BMI: Body mass index; DM: Diabetes Mellitus; HTN: Hypertension; PAD: Peripheral artery disease; ASA: Acetyl salicylic acid; A2RA/ACEI: 
Angiontensin receptor antagonist/Angiotensin-converting enzyme inhibitors 
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3.2.2 Sample Preparation 
Three segments of arterial tissue were obtained from each patient (Figure 3. 1). The central slice 
was obtained and stored for future MS-imaging analysis. The other two slices, weighing 
120mg±5% each, were placed into separate bead beating tubes (VWR, USA), which were preloaded 
with 1mm zirconium beads (Percellys 24, Germany). This was followed by a modified extraction 
protocol from Masson P et al
17
. 
 
Figure 3. 1. A schematic representation of the arterial tissue segmentation procedure applied for analysis. 
To obtain the aqueous extract, 1.5mL of chilled methanol (MeOH)/water (1:1) solution (methanol: 
HPLC gradient grade, Fisher; water: LC-MS grade, Fluka) were added to each tube after 
randomisation of the samples. Randomisation was conducted using free online software 
(http://www.random.org/sequences/). Samples were frozen on dry ice and loaded onto a bead beater 
(Bertin Technologies, Precellys 24), for 2 + 2 cycles, separated by freezing on dry ice. For each 
cycle, the beater was vibrating for 40 seconds at 6500Hz. Centrifugation (Biofuge Pico, Heraeus) 
was conducted at 13,000 rcf for 10 minutes, followed by aliquoting of supernatant into Eppendorf 
tubes (300μL x4). An aliquot of 70μL of each aqueous sample was combined to generate a pooled 
sample, which was mixed and split into four aliquots of 300μL each. This pooled sample is used for 
pre-run conditioning of the column and to assess instrumental performance. Additionally, the 
pooled sample can provide a good idea of the reconstitution volume prior to analyses, as this is the 
first time such tissue type has been assessed by the current instruments in our department. Samples 
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were then spun on a vacuum concentrator for 160 minutes (Eppendorf Concentrator Plus, 45°C, V-
AQ mode). Extracts were stored at -40°C until analysis. 
To obtain the organic extract, chilled 1.5mL solution of dichloromethane (DCM)/MeOH solution in 
proportions of 3:1 (DCM: HPLC grade, Sigma-Aldrich) were added to the precipitate of the sample 
from the aqueous extraction. They were then frozen and reloaded onto the bead beater for 2 cycles, 
vibrating at 6500Hz for 40 seconds per cycle. This was followed by centrifugation at 13,000 rcf for 
20 minutes. Extracts were then aliquoted into glass tubes (200μL x4). An aliquot of 50μL of each 
sample was combined to generate a pool sample, which was mixed and split into four aliquots of 
200μL. Samples were allowed to evaporate overnight at room temperature in a fume hood. Extracts 
were stored at -40°C until analysis. 
3.2.3 RP-LC-MS lipid analysis 
Tissue organic phase extracts were reconstituted in 250μL of MeOH (LC-MS grade, Fluka). 
Samples were vortexed for 30s, sonicated for 5min and vortexed again for 30s. This was followed 
by a 5min centrifugation (Eppendorf, Centrifuge 5417R, Germany) at 13,000rpm, 4
º
C. Samples 
were then transferred into LC-MS glass vials (Total Recovery Vials, Waters Corp, USA).  
Samples were re-randomised prior to loading on the autosampler of the UPLC system, and 
preserved at a temperature of 4
ºC. An aliquot of 50μL from each sample was combined to form a 
quality control sample (QC), and a QC-format run was conducted
114
. The purpose of the QC sample 
is to provide confidence of the analytical stability of the run for both UPLC and MS. It is later used 
during univariate and MVDA to assess reproducibility. 
First the column was conditioned by injecting the pooled sample, obtained during the extraction, 
several times, until data showed adequate stability. The QC sample was then injected thrice, 
followed by further injections every 4-5 samples. The run was completed by samples of dilutions of 
the QC sample at 1:2, 1:4 and 1:8, as well as extraction and solvent blank samples. Dilutions are 
used to assess how responsive our methodology is to fold changes. They are also used at a later 
stage in the analysis pipeline, during statistical analysis, to remove features where their intensities 
do not respond to dilutions. Similarly, features that were present in high intensity in blanks were 
removed from all samples. 
Chromatographic separation was conducted using an Acquity UPLC system (Waters Ltd, UK) and a 
HSS T3 C18 column (Waters Corp, USA), with dimensions of 2.1mm x 100mm, and particle size 
of 1.8μm. The protocol followed was described by Shockcor et al in an application note from 
 104 
 
Waters Corporation
138
. The UPLC column was maintained at 65°C with a flow rate of 0.5ml/min. 
Mobile phase A was constituted of ACN/water (40:60) and 10mM of Ammonium Acetate (AmAc). 
The mobile phase B constituted of Isopropanol/ACN (90:10) and 10mM AmAc. The UPLC 
gradient program of the system is presented on Table 3. 2. An aliquot of 10μL of the reconstituted 
sample was injected with a full loop setting with needle overfill. Samples were preserved at 4°C 
throughout the run. 
Table 3. 2: Gradient program of the chromatography of the lipid profiling UPLC-MS methodology. 
Time (min) %A %B Curve 
0.0 60 40 - 
0.5 60 40 6 
10.50 0 100 6 
12.5 0 100 6 
12.6 60 40 6 
20.0 60 40 6 
 
A Q-TOF Premier mass analyser (Waters MS Technologies Ltd., UK) was employed and coupled 
with the UPLC system using an ESI interface. Data were acquired in both positive and negative 
modes. The Mass Spectrometer was set at the following parameters: Capillary Voltage 
+3kV(positive mode) and -2.2kV(negative mode), source temperature 120
o
C, sampling cone 30V, 
desolvation gas temperature 400
o
C, desolvation gas flow 900L/h, collision energy 5eV, scan speed 
every 0.3s and mass range 50-1000m/z. Leucine Enkephalin (Sigma, HPLC grade) was used for 
lock-mass correction. Lock mass scans were acquired every 30s. For MS
E
 experiments, same 
parameters were used and with collision energy high voltage of 20eV. 
3.2.4 HILIC-MS analysis 
Tissue aqueous phase extracts (in random order) were reconstituted in 200μL of 1:1 solution of 
Acetonitrile (ACN)/water (ROMIL). Samples were vortexed for 30s, sonicated for 5min and 
vortexed again for 30s. This was followed by a 5min centrifugation at 13,000rcf; 4
O
C. Samples 
were then transferred into appropriate LC-MS glass vials (Total Recovery Vials, Waters Corp, 
USA). An aliquot of 50μL from each sample was combined to form a quality control sample (QC). 
Run setting was as described on the preceding paragraph.  
The UPLC setting was assembled using an Acquity UPLC system and a BEH HILIC column, 1.7 
μm, 2.1x100mm (Waters Corp, USA). Mobile phase A constituted of ACN/water 95:5, 10mM of 
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AmAc and 0.1% of formic acid (FA). The UPLC gradient program of the system is presented on 
Table 3. 3. An aliquot of 5μL of the reconstituted sample was injected using a 10μL loop, in a 
partial loop setting, with 4μL flashing. 
Table 3. 3: Gradient program of the chromatography of the HILIC-UPLC-MS methodology. 
Time (min) %A %B Curve 
0.0 99 1 - 
2.0 99 1 - 
14.0 45 55 6 
14.1 1 99 6 
18.0 1 99 - 
18.1 99 1 6 
25.0 99 1 - 
 
An LCT Premier (Waters MS Technologies, Ltd., Manchester, U.K.) mass analyser was employed 
and coupled with the UPLC system using an ESI interface. Data were acquired in both positive and 
negative polarities. The Mass Spectrometer was set at the following parameters: Capillary Voltage 
+3200V(positive mode) and -2400V(negative mode), source temperature 120
o
C, sampling cone 
35V, desolvation gas temperature 350
o
C, desolvation gas flow 800L/h, scan speed every 0.3s and 
mass range 50-1000m/z. Leucine Enkephalin was used for lock mass correction, with scans 
acquired every 30s. 
For MS/MS experiments that were conducted for acyl-carnitines the same UPLC parameters were 
used. For MS analysis the Q-TOF Premier mass analyser was used with parameters set as with the 
previous section. The collision energy was ramping between 20 – 40 eV. 
3.2.5 Data processing and statistical analysis 
Collected data from both analyses and both modes were analysed using the XCMS package version 
1.34.0 
112
 in R programming software version 2.15.2. The data processing workflow consisted of 
peak-picking, grouping, retention time (RT) correction, re-grouping (after RT correction), setting of 
zero values to background intensity, and normalisation to total intensity. Command lines used are 
summarised in Appendix 2. The resulting normalised intensity was multiplied by 10
9
. This 
multiplication was done in order to avoid the loss of significant digits, since the MVDA software 
(described in the next paragraph) does not handle more than 4 decimal places. 
 106 
 
Data were imported in SIMCA-P+ 12.0.1. The QC sample dilutions were used to filter out of the 
resulting models features that were not responding to these dilutions. Similarly, the extraction 
blanks were used to filter features resulting from the extraction procedure or solvent impurities. 
Principal component analysis (PCA) was used as an unsupervised multivariate data analysis 
(MVDA) method to visualise data and detect variation induced to the model by the studied groups 
(Symptomatic and Asymptomatic). Features driving the variance in the model were identified on 
loadings plots. All features were subjected to a 2-tailed t-test, assuming unequal variance. Fold 
change was calculated using the median of each group. 
Metabolite identification was conducted firstly by matching mass measurements to theoretical value 
from on-line databases. Databases used for this study were LipidMaps
139
, Metlin
111
 and HMDB
116
. 
In order to further elucidate the structure of the statistically significant metabolites the isotopic 
pattern of the features, MS
E 
spectra, in-house developed libraries of standards, and matching 
MS/MS spectra to MS/MS spectra from the Metlin database
111
 were used. 
3.3 Results 
3.3.1 Assessment of analytical reproducibility 
For both analytical methodologies conducted for this study, an assessment of reproducibility was 
carried out using the QC samples. In the PCA scores plots, very close grouping of QCs was 
observed indicating that analytical variability was acceptably low (Figure 3.2). In Figure 3.2 the QC 
samples are represented along with the studied samples. This is a good indication of the 
reproducibility of the method, instrumental stability, and an indication of good quality data. When 
univariate statistics were applied on metabolites, the reproducibility was also assessed by the 
coefficient of variation (CV% < 20;  < 30 for low intensities
119
).  
3.3.2 Characterisation of the metabolic profiling of the symptomatic 
atherosclerotic plaque 
3.3.2.1 Lipid Profiling 
Lipid profiling was conducted using a reversed phase (RP-) UPLC-MS based methodology, of the 
organic extracts of the atherosclerotic tissue. For the two groups studied, PCA scores plots showed 
good discrimination and grouping of the studied samples, and in both ESI polarity modes (Figure 3. 
5). Representative chromatograms of the method used can be viewed in Figure 3. 3 and Figure 3. 4.  
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Figure 3.2: Principal component analysis scores plots of atherosclerotic plaque tissue extracts. Lipid profiling of organic metabolite extracts in (A) positive ionization mode and (B) 
negative ionization mode. Hydrophilic interaction liquid chromatography coupled to mass spectrometry (HILIC-MS) profiling of aqueous extracts in (C) positive ionization mode 
and (D) negative ionization mode. The quality control (QC) samples are denoted in green and present a good indication of the reproducibility of the methodology and stability of the 
specific run. Samples obtained from the same plaque tissue are denoted by the same alphanumeric. Sample γ is represented by only one biological replicate. ESI: Electrospray 
Ionization. 
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The positive mode features showed group discrimination of Sympt and Asympt samples in scores 
plots of the 1
st
 and 2
nd
 PComp (Figure 3. 5.A), with separation mainly in the second component. 
These two components together constitute the 50% of the variation (R
2
X), with the 2
nd
 contributing 
23% to the variation. The negative mode data also presented good grouping with best results on the 
2
nd
 and 3
rd
 PComp (Figure 3. 5.B), with cumulative R
2
X of 35%, and the 2
nd
 PComp contributing 
23% of the variance. 
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Figure 3. 3:  A representative chromatogram from the positive mode of the UPLC-MS analysis, of the organic extracts of the tissue samples examined. The trace in red colour 
represents the total ion current, while in green are the base peak intensities (highest peaks within a retention time window). 
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Figure 3. 4: A representative chromatogram from the negative mode of the UPLC-MS analysis, of the organic extracts of the tissue samples examined. The trace in red colour 
represents the total ion current, while in green are the base peak intensities (highest peaks within a retention time window). 
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Figure 3. 5: A and B represent scores and loadings plots from the PCA model of the results obtained from the lipid profiling analysis of the organic extracts (A positive and B 
negative mode). Points represent samples. Samples connected with a line are biological replicates. C) Box-plots of selected metabolites showing high statistical significance. Colour 
code: green: QC; blue: Asymptomatic; red: Symptomatic; dark yellow circles: metabolites assigned; dark red circles: features identified to represent isotopes, adducts, or fragments 
of identified metabolites. 
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Using the loadings plots (Figure 3. 5), features that were driving the separation between Sympt and 
Asympt, were identified (Figure 3. 5 and Table 3. 4. These included a number of 
phosphatidylcholines (PCs), lysophosphatidylcholines (lysoPCs), phosphatidylethanolamine (PEs), 
diglycerides (DGs), triglycerides (TGs), sphingomyelins (SMs), ceramides (Cers), cholesterol-esters 
(CEs), oxidised Cholesterol-esters (oxCEs), and arachidonic acid (AA). Features that could not be 
assigned were marked as UKN with a suffix indicating the analysis and mode. Table 3. 4 presents 
the metabolites identified and unassigned features, along with UPLC-MS analysis feature 
characteristics, and results of univariate statistics. 
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Table 3. 4: List of assigned metabolites found to be driving the PCA, obtained from data of the tissue organic extracts. 
Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
 
 
        
 
Lipid Profiling 
Positive Mode 
 
        
 
Cer(d18:1/16:0) 4 
C34H66NO2+      
[M-H2O+H]+ 
6.85 520.5099 520.5094 -0.0005 -1 0.0784 -1.5 2 
LysoPC(16:0) 4 C24H51NO7P+ 1.77 496.3401 496.3403 0.0002 0 0.0735 1.5 4 
oxCE(16:0(OH)) 4 
C43H76O3Na+  
[M+Na]+ 
9.24 663.5738 663.5692 -0.0046 -7 0.6583 1.0 4 
PC(16:0/18:1) 4 C42H83NO8P+ 6.61 760.5855 760.5856 0.0001 0 0.0002 1.6 2 
PC(16:0/18:2) 4 C42H81NO8P+ 6.20 758.5718 758.5700 -0.0018 -2 0.2391 1.2 3 
PC(16:0/20:4) 4 C44H81NO8P+ 6.16 782.5714 782.5700 -0.0014 -2 0.0000 1.5 3 
SM(d16:1/16:0) 4 C37H76N2O6P+ 5.14 675.5452 675.5441 -0.0011 -2 0.2845 1.1 2 
SM(d18:2/16:0) 4 C39H78N2O6P+ 5.30 701.5619 701.5598 -0.0021 -3 0.5010 -1.2 2 
SM(d18:2/24:1) 4 C47H92N2O6P+ 7.16 811.6715 811.6693 -0.0022 -3 0.7966 -1.1 2 
SM(d35:1) 4 C40H82N2O6P+ 6.14 717.5929 717.5911 -0.0018 -3 0.5623 -1.3 5 
TG(16:0/16:0/18:1) 4 
C53H104NO6+    
[M+NH4]+ 
10.24 850.7866 850.7864 -0.0002 0 0.5008 1.3 3 
TG(16:0/16:0/18:2) 4 
C53H102NO6+    
[M+NH4]+ 
10.07 848.7731 848.7707 -0.0024 -3 0.1056 1.4 2 
TG(16:0/18:2/18:1) * 4 
C55H104NO6+    
[M+NH4]+ 
10.10 875.7933 875.7897 -0.0036 -4 0.6636 1.1 3 
TG(18:2/18:1/18:1) 4 
C57H106NO6+    
[M+NH4]+ 
10.13 900.8044 900.8020 -0.0024 -3 0.0359 1.5 4 
TG(18:2/18:2/18:1) 4 
C57H104NO6+    
[M+NH4]+ 
9.96 898.7900 898.7864 -0.0036 -4 0.1328 1.4 5 
UKN-LPP-1 n/a n/a 4.41 218.1037 n/a n/a n/a 0.0813 -2.4 2 
 
(Continued on next page)  
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Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
 
 
        
 
Lipid Profiling 
Negative Mode 
 
        
 
Arachidonic Acid 2 C20H31O2- 2.53 303.2311 303.2324 0.0013 4 0.00479 1.8 5 
Cer(d18:1/16:0) 4 C34H66NO3- 6.85 536.5053 536.5043 -0.0010 -2 0.16158 -1.2 4 
Cer(d18:1/18:0) 4 
C38H74NO5-    
[M+OAc-H]- 
7.39 624.5573 624.5567 -0.0006 -1 0.19005 -1.2 2 
Cer(d18:1/22:0) 4 
C42H82NO5-    
[M+OAc-H]- 
8.33 680.6210 680.6193 -0.0017 -2 0.91956 1.1 1 
Cer(d18:1/24:0) * 4 
C44H86NO5-   
[M+OAc-H]- 
8.73 709.6559 709.6540 -0.0019 -3 0.66147 1.1 11 
Cer(d18:1/24:1) 4 
C44H84NO5-    
[M+OAc-H]- 
8.34 706.6355 706.6350 -0.0005 -1 0.27655 1.2 2 
Cer(d18:2/16:0) 4 C34H64NO3- 6.38 534.4891 534.4886 -0.0005 -1 0.45521 -1.1 1 
DG(36:7) 1 C39H61O5- 5.49 609.4528 609.4519 -0.0009 -1 0.08409 3.3 3 
DG(42:5) 1 
C47H81O7-    
[M+OAc-H]- 
7.67 757.5996 757.5982 -0.0014 -2 0.27600 1.3 41 
DG(44:5) 1 
C49H85O7-    
[M+OAc-H]- 
8.05 785.6302 785.6295 -0.0007 -1 0.01075 4.5 4 
DG(44:7) 1 
C49H81O7-    
[M+OAc-H]- 
7.69 781.6006 781.5982 -0.0024 -3 0.09550 2.8 15 
lysoPC(18:1) 4 
C28H55NO9P-    
[M+OAc-H]- 
1.94 580.3619 580.3614 -0.0005 -1 0.03784 1.8 2 
lysoPC(18:2) 4 
C28H53NO9P-    
[M+OAc-H]- 
1.50 578.3465 578.3458 -0.0007 -1 0.36053 1.5 3 
PE(18:1/18:0) 4 C41H79NO8P- 7.31 744.5552 744.5543 -0.0009 -1 0.00294 1.6 4 
PE(O-16:1/20:4) 4 C41H73NO7P- 6.65 722.5131 722.5125 -0.0006 -1 0.01293 1.5 3 
PE(O-16:1/22:6) 4 C43H73NO7P- 6.54 746.5135 746.5125 -0.0010 -1 0.25238 1.7 10 
SM(d16:1/16:0) 4 
C39H78N2O8P-     
[M+OAc-H]- 
5.15 733.5498 733.5496 -0.0002 0 0.25122 1.1 2 
(Continued on next page)  
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Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
 
 
        
 
Lipid Profiling 
Negative Mode 
 
        
 
SM(d18:2/16:0) 4 
C41H80N2O8P-    
[M+OAc-H]- 
5.31 759.5652 759.5652 0.0000 0 0.30897 -1.3 6 
SM(d18:2/24:1) 4 C49H94N2O8P- 7.18 869.6743 869.6748 0.0005 1 0.69214 -1.1 4 
UKN-LPN-1 n/a n/a 6.55 792.5764 n/a n/a n/a 0.00799 1.5 8 
UKN-LPN-2 n/a n/a 8.46 690.6415 n/a n/a n/a 0.03247 2.2 3 
UKN-LPN-3 n/a n/a 8.30 693.5559 n/a n/a n/a 0.09041 3.5 46 
UKN-LPN-4 n/a n/a 8.00 690.6050 n/a n/a n/a 0.12380 -1.4 3 
*Statistics and assignment on second isotopic m/z 
 
The positions of double bonds and fatty acyl chains cannot be determined in DGs, PCs, PEs, lysoPCs and TGs; fatty acyl chains are presented from 
lowest to highest molecular weight (lower number of carbons to higher, and higher number of double bonds, to lower). 
Two-tailed t-tests were conducted, assuming unequal variance. 
RT: retention time; oxCE: oxidised cholesterol ester, Cer: ceramide, DG: diglyceride; PC: phosphatidylcholine; PE: phosphatidylethanolamine; SM: 
sphingomyelin; TG: triglyceride; UKN: unknown; OAc: acetate; n/a: not applicable 
LoA: level of assignment; 1: m/z matched to online databases; 2: m/z matched to online databases and prior knowledge for RT (in-house database of 
standards); 3: in-source fragmentation; 4: assignment based on MS
E
 mode spectrum. 
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Some metabolites appeared to drive the primary separation of the two groups in the model. From 
these, some showed increased statistical significance when compared between the two groups Box-
plots of the normalised intensities of these metabolites can be found in Figure 3. 5 C. These include 
PC(16:0/20:4), PC(16:0/18:1) and arachidonic acid (AA), which had a probability of p=0.00003, 
p=0.0002, and p=0.005, respectively indicating significant differences between the asymptomatic 
and symptomatic disease groups. 
Irrespective of MVDA, univariate statistics, using the t-test and fold-change, were applied to all the 
features. A number of features showed high statistical significance and therefore were further 
structurally assigned (Table 3. 5). These include an acyl-carnitine (AcC) the palmitoylcarnitine, and 
a TG, TG(58:6), whose normalised intensities were higher in Sympt, with p=0.00001 and 
p=0.00007, respectively, and with a fold-change of 2.5 and 3.1. Figure 3. 6 demonstrates the box-
plots of all the detected statistically significant metabolites of the lipid profiling analysis. 
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Figure 3. 6: Box-plots of significant metabolites obtained from univariate statistics of data from both organic and 
aqueous extracts. Two-tailed t-tests were conducted, assuming unequal variance. PC: phosphatidylcholine; TG: 
triglyceride; UKN: unknown. 
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Table 3. 5: List of assigned significant metabolites obtained from univariate statistics of data from both organic and aqueous extracts.  
Analysis - 
Mode 
Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
  
 
         
HILIC 
Positive 
Hexanoylcarnitine* 3 C13H26NO4+ 7.30 261.187 261.1894 0.0024 9 0.00003 1.9 20 
Lipid Prof 
Positive 
Palmitoylcarnitine 4 C23H46NO4+ 1.63 400.3426 400.3427 1E-04 0 0.00001 2.5 8 
Lipid Prof 
Negative 
PC(16:0/20:4) 4 
C46H83NO10P-  
[M+OAc-H]- 
6.19 840.5783 840.5755 -0.0028 -3 0.00002 1.5 6 
Lipid Prof 
Negative 
PC(O-16:0/16:0)* 4 
C42H85NO9P-    
[M+OAc-H]- 
6.91 779.6022 779.5996 -0.0026 -3 0.00007 1.7 5 
Lipid Prof 
Negative 
PC(O-38:5) 4 
C48H89NO9P-    
[M+OAc-H]- 
6.97 854.6302 854.6275 -0.0027 -3 0.00006 2.3 16 
Lipid Prof 
Positive 
PC(O-44:5) 4 C52H97NO7P+ 8.01 878.7051 878.7003 -0.0048 -5 0.00003 2.2 2 
Lipid Prof 
Positive 
TG(58:6) 2 
C61H110NO6+   
[M+NH4]+ 
10.22 952.8394 952.8333 -0.0061 -6 0.00007 3.1 3 
HILIC 
Positive 
UKN-HLP-4 n/a n/a 8.14 645.3829 n/a n/a n/a 0.00004 3.5 25 
*Statistics and assignment on second isotopic m/z 
 
The positions of double bonds and fatty acyl chains cannot be determined; fatty acyl chains are presented from lowest to highest molecular weight 
(lower number of carbons to higher and higher number of double bonds, to lower). 
Two-tailed t-tests were conducted, assuming unequal variance. 
RT: retention time; PC: phosphatidylcholine; TG: triglyceride; UKN: unknown; OAc: acetate. 
LoA: level of assignment; 1: m/z matched to online databases; 2: m/z matched to online databases and prior knowledge for RT (in-house database of 
standards); 3: in-source fragmentation; 4: assignment based on MS
E
 mode spectrum. 
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3.3.2.2 Aqueous Extracts 
The aqueous extracts of the atherosclerotic tissue were run using a HILIC-MS method. Similarly to 
the lipid profiling methodology, the two diseased groups studied also showed discrimination in the 
PCA scores plots (Figure 3. 5). Representative chromatograms of the method can be viewed in 
Figure 3. 7 and Figure 3. 8. The positive mode spectra demonstrated good group discrimination in 
scores plots of the 1
st
 and 2
nd
 PComps (Figure 3. 5.A). These two components together constituted 
42% of the variation (R
2
X), with the 1
st
 PComp contributing 23% to the variation. The negative 
mode also presented good grouping in 3 PComps, 1
st
, 2
nd
, and 3
rd
 (Figure 3. 5.B). They explain a 
total variation of 50%, with the 1
st
 and 2
nd
 PComps contributing with 23% and 14%, respectively 
indicating that the difference between the symptomatic and asymptomatic lipid profiles were 
responsible for a large part of the variance in the metabolic profiles. 
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Figure 3. 7: A representative chromatogram from the positive mode of the UPLC-MS analysis, of the aqueous extracts of the tissue samples examined. The trace in red colour 
represents the total ion current, while in green are the base peak intensities (highest peaks within a retention time window) 
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Figure 3. 8: A representative chromatogram from the negative mode of the UPLC-MS analysis, of the aqueous extracts of the tissue samples examined. The trace in red colour 
represents the total ion current, while in green are the base peak intensities (highest peaks within a retention time window). 
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Figure 3. 9: A and B represent scores and loadings plots from the PCA of the results obtained from the lipid profiling analysis of the organic extracts (A positive and B negative 
mode). C) and D) Box-plots of selected metabolites showing high statistical significance. Colour code: green: QC; blue: Asymptomatic; red: Symptomatic; dark yellow circles: 
metabolites assigned; dark red circles: features identified to represent isotopes, adducts, or fragments of identified metabolites. 
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Table 3. 6: List of assigned metabolites driving the separation of symptomatic and asymptomatic samples in the PCA loadings plots obtained from data of aqueous extracts.  
Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
 
 
        
 
HILIC Positive  
        
 
(iso)Butyrylcarnitine 3 C11H22NO4+ 8.36 232.1522 232.1549 0.0027 12 0.00059 2.8 3 
Acetylcarnitine 3 C9H18NO4+ 9.23 204.1245 204.1236 -0.0009 -4 0.16980 1.1 4 
Adenosine 3 C10H14N5O4+ 2.11 268.1068 268.1046 -0.0022 -8 0.05133 -1.4 9 
Carnitine 2 C7H16NO3+ 9.75 162.1123 162.1130 0.0007 4 0.64011 1.1 4 
Glycerophosphocholine 3 
C16H41N2O12P2+   
[2M+H]+ 
11.36 515.2134 515.2135 0.0001 0 0.49445 1.0 7 
lysoPC(18:1) 3 C26H53NO7P+ 6.97 522.3514 522.3560 0.0046 9 0.21956 1.4 95 
lysoPC(18:2) 3 C26H51NO7P+ 6.80 520.3374 520.3403 0.0029 6 0.85518 1.0 74 
lysoPC(O-16:0) 3 
C24H52NO6PNa+ 
[M+Na]+ 
8.13 504.3422 504.3430 0.0008 2 0.00663 2.3 4 
lysoPC(O-18:1) 3 C26H55NO6P+ 8.04 508.3755 508.3767 0.0012 2 0.04835 1.8 6 
PC(34:1) 3 C42H83NO8P+ 0.98 760.5934 760.5856 -0.0078 -10 0.83316 1.0 13 
PC(34:2) 3 C42H81NO8P+ 0.98 758.5769 758.5700 -0.0069 -9 0.16903 -1.4 13 
PC(36:4) 3 C44H81NO8P+ 0.97 782.5764 782.5700 -0.0064 -8 0.55840 -1.1 13 
PE(36:7) 3 C41H69NO8P+ 1.54 734.4712 734.4761 0.0049 7 0.17197 1.4 12 
4-(Trimethylammonio)but-2-enoate 2 
C14H26N2O4Na+  
[2M+Na]+ 
7.90 309.1791 309.1790 -0.0001 0 0.34349 3.1 4 
UKN-HLP-1 n/a n/a 10.10 616.1784 n/a n/a n/a 0.13546 2.2 17 
UKN-HLP-2 
*
 n/a n/a 12.58 729.4158 n/a n/a n/a 0.15598 2.4 13 
UKN-HLP-3 n/a n/a 0.74 324.1407 n/a n/a n/a 0.17574 -3.3 9 
(Continued on next page)  
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Met Name LoA 
Mol Formula 
[complex adduct] 
RT 
(min) 
m/z 
(found) 
m/z 
(theor) 
ΔDa Δppm p [t-test] 
Fold 
Change 
CV% 
 
 
        
 
 
 
HILIC Negative 
 
        
 
Adenosine 3 
C10H13N5O4Cl-  
[M+Cl]- 
2.13 302.0673 302.0656 -0.0017 -6 0.17377 -1.3 6 
Glycerophosphocholine 3 
C9H21NO8P- 
[M+FA-H]- 
11.37 302.1007 302.1005 -0.0002 -1 0.26149 -1.1 3 
Glycerophosphoethanolamine 3 C5H13NO6P- 9.55 214.0477 214.0480 0.0003 1 0.86287 1.0 3 
Glycerophosphoglycerol 3 C6H14O8P- 7.99 245.0434 245.0426 -0.0008 -3 0.07132 1.4 11 
Glycerophosphoinositol 3 C9H18O11P- 9.22 333.0596 333.0587 -0.0009 -3 0.67020 -1.1 4 
Inosine 3 
C11H13N4O7-   
[M+FA-H]- 
3.12 313.0789 313.0784 -0.0005 -2 0.03082 1.4 4 
UKN-HLN-1 n/a n/a 8.53 728.2135 n/a n/a n/a 0.00217 -2.3 12 
UKN-HLN-2 n/a n/a 0.75 448.9498 n/a n/a n/a 0.02408 -1.4 4 
UKN-HLN-3 n/a n/a 7.03 271.0026 n/a n/a n/a 0.11986 1.3 10 
Uric Acid 1 C5H3N4O3- 5.19 167.0196 167.0205 0.0009 5 0.11678 -1.1 2 
Uridine 3 
C10H13N2O8-   
[M+FA-H]- 
1.47 289.0681 289.0672 -0.0009 -3 0.04614 1.1 1 
* Assigned as the [2M+Na]+ adduct of 365.2049  
PCs and lysoPCs the positions of double bonds and fatty acyl chains cannot be determined; fatty acyl chains are presented from lowest to highest 
molecular weight (lower number of carbons to higher and higher number of double bonds, to lower). 
Two-tailed t-tests were conducted, assuming unequal variance. 
RT: retention time; PC: phosphatidylcholine; PE: phosphatidylethanolamine; UKN: unknown; FA: formate. 
LoA: level of assignment; 1: m/z matched to online databases; 2: m/z matched to online databases and prior knowledge for RT (in-house 
database of standards); 3: in-source fragmentation; 4: assignment based on MS
E
 mode spectrum.
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Features that were driving this separation can be seen in the loadings plots (Figure 3. 9) and 
included short-chain AcCs, carnitine, lysoPCs, PCs, glycerophosphocholine, 
glycerophosphoethanolamine, glycerophosphoinositol, adenosine, inosine and uridine. Features that 
could not be assigned are marked as UKN (Figure 3. 9 and Table 3. 6). Table 3. 6 presents the 
metabolites identified, and unassigned features, along with UPLC-MS analysis feature 
characteristics, and results of univariate statistics. Metabolites that appeared to drive the separation 
of the two groups are presented with box-plots on Figure 3. 9C and D. These include (iso-
)butyrylcarnitine and lysoPC(O-16:0) with p=0.0006 and p=0.007, respectively. 
Univariate statistics (Table 3. 5) demonstrated two highly significant features. One unidentified 
(UNK-HLP-4) with p=0.00004, and hexanoylcarnitine (detected as the second isotope) with 
p=0.00003, and FC of 1.9. Of note, the first isotope of hexanoylcarnitine was detected with 
p=0.0003 and FC of 1.7. The box-plots of all the detected statistically significant metabolites of the 
aqueous extract HILIC-MS analysis are provided in Figure 3. 6. 
3.4 Discussion 
Patients with symptoms of mini-stroke (symptomatic) have a higher risk of a life threatening stroke 
in the immediate future after the presenting mini-stroke symptoms
137
. Thus, it is of supreme 
importance for risk related markers to be provided to the clinic. In this study, a metabolic profiling 
discrimination of symptomatic and asymptomatic carotid plaque tissue is shown for the first time 
using multivariate statistical analysis. Furthermore, highly significant individual markers of 
symptomatic plaques are also reported. A number of them showed p<0.0001 in the two-tailed t-test 
and greater than 2-fold change in normalised intensity (Table 3. 4, Table 3. 5 and Table 3. 6). From 
literature, previous efforts using a shotgun lipidomics approach to accomplish multivariate 
statistical discrimination between symptomatic and asymptomatic carotid plaque tissue proved 
unsuccessful
140
. 
Metabolic profiles generated from NMR analyses of aqueous and organic extracts of the same 
samples did not show significant separation of Sympt and Asympt. The same for aqueous extracts 
ran with an RP-UPLC-MS method. It could be hypothesised that platforms, which were unable to 
deliver disease related profiles, may be more sensitive, or otherwise appropriate, for metabolites 
that do not show high statistical significance between the groups studied here. Therefore, the two 
methodologies presented herein (RP-UPLC-MS on organic extracts and HILIC UPLC-MS on 
aqueous extracts) will be the methods of choice for further analyses of larger sample sets. Using the 
combined power of both these analysis methods, these two methods can provide detection of a 
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range of compounds with wide physicochemical properties, wherein it was possible to structurally 
assign up to 50 metabolites. These methods were proven to be robust, as evidenced by the tight 
grouping of QC samples in MVDA (Figure 3.2). Additionally, the coefficient of variation calculated 
by the 7 injections of the QC sample through the run, gave further confidence in the analytical 
quality of the model as most of the CV% were typically <10%.  
By applying the lipid profiling methodology to analyse the tissue organic extracts, a number of lipid 
moieties, from 5 different lipid classes, were structurally assigned. These classes are: fatty acids, 
glycerolipids, glycerophospholipids, sphingolipids and sterol lipids. The identified lipids represent a 
wide range of lipid subclasses. These include a number of PCs and lysoPCs, SMs and Cers, CEs, 
TGs and DGs, PEs, AA, and also a long-chain AcC. 
On the other hand, due to the properties of HILIC columns, good interaction with the polar 
structural groups of metabolites could be achieved. Polar metabolites are retained and subjected to 
good chromatographic separation. Good retention would be an issue with conventional RP-UPLC 
methods for these metabolites
92
. Metabolites detected driving the models and/or being statistically 
significant were structurally identified. These included three purines, adenosine, inosine and uric 
acid, as well as uridine, a pyrimidine. Additionally, carnitine and a number of AcCs were detected, 
namely acetylcarnitine, (iso-)butyrylcarnitine (note that there is difficulty in the determination 
between butyryl- and isobutyryl- isomers by MS) and hexanoylcarnitine. Three major 
glycerophosphates were detected, glycerophosphocholine, glycerophosphoethanolamine and 
glycerophosphoinositol. A number of glycerophospholipids was detected, which is not surprising 
provided that the aqueous extraction was conducted using a 50% MeOH solution and therefore 
acted as a solvent for some organic molecules. Lastly, features that could not be assigned are 
reported in MVDA and univariate statistics.  
An important part of the experimental design was to explore if the metabolic fingerprint from 
different locations but within the same plaque was comparable.  However, biological reproducibility 
was very difficult to assess as it is hard to obtain multiple biological replicates of the tissue, and in 
good amounts, in order to perform such a study. It was however possible to obtain two tissue 
specimens from almost all of the carotid plaque samples. In PCA Figure 3. 5 and Figure 3. 9, 
duplicates are shown connected with a line. Some of the duplicates indeed displayed low variation. 
However, the variation of some of the duplicates was high. Nevertheless, despite these differences 
in the composition of samples from the same plaque, only on one occasion did the variation 
observed from a biological replicate affect the disease-related grouping of the samples in PCA. This 
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observation of intra-plaque variability was to some extent expected, as different pathophysiological 
conditions can coexist within the same plaque tissue giving rise to structural heterogeneity. 
Therefore, the potentially high variation within the same tissue sample should be considered in 
further studies. 
The current study functions as an exploratory study on a small sample set (n=10; five patients per 
group). This study was designed with the objective of obtaining pilot data demonstrating feasibility 
and ability to provide disease-related information. The small sample set and the use of biological 
duplicates is the reason the statistical analysis was limited to only unsupervised MVDA as 
supervised methods of MVDA are susceptible to overfitting on small sample sets. Additionally, the 
use of t-test and fold-change comparisons between metabolites should be considered indicative of 
the potential and not definitive. Further analyses of larger sample groups should validate these 
findings. 
As discussed, because of the small sample group size it would be risky to try to biologically 
interpret some of the detected statistically significant metabolites. However, some of differentially 
detected metabolites are members of the same biological pathways. This provides some extra 
confidence to these findings, and should also guide future experimentation employing targeted 
approaches that could validate the presented findings. 
One of the most important differences between samples from symptomatic and asymptomatic 
patients was the finding of higher intensities of AA in Sympt.  Higher intensities of this 20:4 free 
fatty acid and a 20:4 fatty acyl-chain bearing PC, PC(16:0/20:4), were detected in this study and are 
likely to indicate differences in the same metabolic pathway. PC(16:0/20:4) was detected with 
statistical significance in both ESI modes. PC(16:0/20:4) can release AA after being hydrolysed by 
the enzyme Phospholipase A2 (PLA2). At the same time AA is the precursor molecule of a wide 
spectrum of inflammation-related compounds, the eicosanoids. This is in concordance with 
literature findings. It has been reviewed by Libby et al that plaques in high risk of rupture 
experience higher inflammation
52, 54
. This is very intriguing and although the results are not 
conclusive on this matter, it provides a good hypothesis for future experimentation.  
Another interesting trend is the higher intensities of short, medium, and long-chain AcC. The (iso-
)butyrylcarnitine, hexanoylcarnitine and palmitoylcarnitine were all detected in higher normalised 
intensities in Sympt. However, acetylcarnitine and carnitine were unaffected. The fact that carnitine 
remains unaffected provides more evidence pointing towards dysregulation of the pathway of β-
oxidation. The β-oxidation takes place in the mitochondria, and consists of the catabolism of free 
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fatty acids after penetrating the mitochondrial membrane as acyl-carnitines. However, if this 
process is somehow down-regulated in Sympt, it still cannot explain why all AcC are higher while 
acetylcarnitine, the final product of this reaction remain unaffected. It could be possible that other 
catabolic pathways are able to counterbalance for this reduction as they can produce acetyl groups 
in the form of acetyl-CoA, or these are the pathways that are upregulated, and as a result fatty acid 
catabolism remains unused. 
In summary, the findings demonstrated here provide good proof of the ability of these metabolic 
profiling technologies to risk stratify patients with carotid atherosclerotic plaques, in danger of 
rupture and thromboembolism. Such findings could assist towards identifying candidate biomarkers 
that could be detected via in-vivo imaging, or targeted in bodily fluids such as blood. The potential 
of indentifying pathways that can be targeted for therapeutic purposes is also possible and should be 
explored. Taken together, the results from this analysis provide good evidence to further pursue a 
larger sample study of symptomatic and asymptomatic patients. The untargeted methodologies that 
were applied and succeeded on delivering results towards the discrimination of symptomatic 
patients should form the core of this study. Additionally, targeted approaches should be employed 
to investigate systemic evidence of involvement of pathways such as the eicosanoid and β-oxidation 
pathways. 
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Chapter 4  Application of a metabolic 
profiling approach to identify latent 
metabolites and interactions of 
atherogenesis. Distinct profiles detected 
between carotid and femoral plaques. 
4.1 Introduction 
Atherosclerosis is the number one cause of death in the western world
45
. Most adverse health events 
associated with atherosclerosis develop alongside plaque formation. Existing pharmaceutical 
schemes appear to fail in providing a positive outcome in primary prevention, while the scientific 
community still struggles to find appropriate dose or drug regimes
141
. 
Atherosclerosis is a multicentric, multistage and systemic disease. Cell populations such as vascular 
smooth muscle cells and leukocytes are known for their involvement in the manifestation of the 
disease. These cells participate in microenvironmental interactions in the arterial tissue. To 
understand the role of these interactions in disease aetiology and progression, they need to be 
positioned in a holistic framework in order to assist towards the generation of much needed novel 
hypotheses.  
Metabolic profiling can be an effective systems biology approach. By using multivariate data 
analysis to analyse complex spectral metabolite profiles, global information for the disease of 
interest can be obtained through identification of dysregulated metabolites and can lead to 
identification of dysregulated pathways. In this study, the metabolic changes of the progression 
from intimal thickening to plaque formation are explored. Tissue extracts from carotid and femoral 
plaque samples were compared to intimal thickening extracts using two different ultra performance 
liquid chromatography coupled to mass spectrometry (UPLC-MS) methodologies, covering a wide 
range of metabolites, and with substantial diversity in physicochemical properties. Both the global 
metabolic profile of plaque formation, as well as metabolic differences attributed to anatomical 
location, have been characterized. Previously unassociated, as well as recognized, metabolites and 
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biological pathways related to atherogenesis, are demonstrated, both globally and distinctively to 
the two tested locations. Finally, significant statistical interactions between detected biomarkers and 
biological pathways in relation to the disease are assessed. 
Additionally a novel experimental design is followed for this study. The concept of the 
experimental design is to explore the metabolic alterations of the metabasis to the lipid-laden lesion, 
within the arterial wall. The atherosclerotic lesion is the ‗culprit‘ of the adverse health events. For 
this, intimal thickening tissue (INT) (n=17) was used as control. Using INT comes with several 
advantages: 1) INT, rather than normal tissue, is detected at plaque prone sites from the early years 
of a person‘s life, 2) it is the immediate stage prior to progression to the lesion, thus the 
experimental model can provide a more realistic course of the disease, and 3) normal tissue is 
difficult to obtain for obvious ethical reasons. Further, plaque lesions from two different anatomical 
locations in the arterial tree, constituting the major sites of atherogenesis, were used: carotid and 
femoral. Establishing the metabolic phenotype for these sites addresses the necessity of correlating 
patients‘ outcome to pharmaceutical schemes. The efficacy of drugs, such as statins could be 
evaluated, in the context of differences in metabolic phenotype and lipid texture of the lesions, e.g. 
lipophilic properties of drugs. Additionally, metabolic profiling should be assessed based on the 
different hemodynamic properties of these anatomical locations. Lastly, comparisons between these 
anatomical locations are rare in literature and non-existent in the case of metabolic profiling studies. 
 
4.2 Methods 
4.2.1 Patients 
The tissue plaque samples used in this study were obtained from a total of 78 patients from the 
Department of Vascular Surgery, Imperial College London. Segments were retrieved, snap frozen 
in liquid nitrogen and stored at -80°C at surgery. These segments were obtained from 52 patients 
who underwent carotid endarterectomy (CAR), and 26 who underwent femoral endarterectomy 
(FEM). From these samples, tissues without atheroma, but with obvious evidence of thickening of 
the intima vessel layer (INT), were harvested (9 samples from carotid and 7 samples from femoral 
tissue). Intima thickening tissue was found at the shoulder of forming atheromas, and in this study 
serves as control tissue. Patients‘ clinical characteristics can be found in Table 4. 1.  
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Table 4. 1: Patients demographics of carotid, femoral, and intimal thickening groups. 
 
Carotid Femoral Intima thickening 
Number of Samples 52 26 16 
Age, Median (range) 69 (44-87) 74 (60-91) 69 (58-91) 
Gender, Male (%) 40 (77) 17 (65) 13 (81) 
Statin (%) 40 (82) {3} 19 (73) 13 (87) {1} 
Antiplatelet (%) 43 (86) {3} 22 (85) 14 (93) {1} 
HT (%) 32 (68) {5} 13 (50) 7 (47) {1} 
DM (%) 11 (22) {3} 7 (27) 6 (40) {1} 
Ever smoker (%) 25 (52) {4} 18 (69) 11 (73) {1} 
BMI, Median, Range 25.5 (17.4–41.2) {9} 23.0 (21.6–33.3) {13} 25.4 (21.0-47.7) {6} 
Key: HT: Hypertension; DM: Diabetes mellitus; BMI: Body Mass Index; {} number of missing 
patients 
4.2.2 Tissue Extraction 
Parts of plaque tissue, and intima tissue adjacent to plaque, were dissected and harvested for 
metabolite extraction. Effort was made to include as much plaque tissue as possible. Tissue weights 
were in the range of 416-153mg. Tissue samples were loaded into appropriate bead beating tubes 
(Percellys Steel-Kit, Germany) along with steel beads, and subjected to metabolite extraction by 
tissue lyses.  
4.2.2.1 Aqueous extraction 
Pre-chilled methanol/water solution (1:1) (methanol HPLC gradient grade, Fisher; water LC-MS 
grade, Fluka), was added to the tissue samples. The volume of the solution was adjusted according 
to weight of the sample starting at a maximum weight with 1.5mL, and reducing proportionally to 
sample weight. Samples were frozen on dry ice and loaded onto a bead beater (Bertin Technologies) 
vibrating at 6500Hz, 40 seconds, 4 cycles separated by freezing on dry ice. Centrifugation 
(Eppendorf, Centrifuge 5417R, Germany) followed at 13,000 rcf for 20 min; at 4
O
C. Aliquots of 
100μL of supernatant were pipetted into Eppendorf tubes. Samples were spun on a vacuum 
concentrator for 2 hours at 45°C (Eppendorf Concentrator Plus, V-AQ mode). Samples were stored 
at -40°C until analysis. 
4.2.2.2 Organic extraction 
Following decanting of the supernatant from centrifuged aqueous samples, a solution of pre-chilled 
dichloromethane (DCM, CH2Cl2)/methanol (3:1) (methanol HPLC gradient grade, Fisher; DCM 
HPLC grade, Sigma-Aldrich) was added. The volume of the solution was proportional to the sample 
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weight (as described in previous paragraph; aqueous extraction). Samples were frozen on dry ice 
and re-loaded into the bead beater (2 cycles, 6500Hz, 40 seconds). Samples were centrifugation at 
13,000 rcf for 20 minutes, followed by aliquoting of organic phase supernatant into glass vials. 
Samples were allowed to evaporate at room temperature in an extractor hood overnight and stored 
at -40°C for analysis. 
4.2.3 HILIC-UPLC-MS analysis of Aqueous Extracts 
4.2.3.1 UPLC-MS Analysis 
Samples were reconstituted in 200uL of solvent mixture of H2O/acetonitrile (5:95) (LC-MS grade, 
Fisher Scientific, USA), and transferred into Total Recovery vials (Waters, USA), after 
centrifugation for 20min at 13000 rcf, 4°C. 
UPLC separation was conducted using an Acquity UPLC System (Waters Corp, USA). An Acquity 
UPLC BEH HILIC 2.1x100mm, 1.8um, column (Waters Corp, USA) was used. Column 
temperature was set at 35°C. An injection volume of 10uL was used for both positive and negative 
ionization polarity modes. The auto-sampler was set at 4°C. Mobile phase A consisted of 
acetonitrile/water (95:5) and mobile phase B acetonitrile/water (50:50). In both solutions 
ammonium formate (98%, Fluka, USA) was diluted to 10mM and formic acid (MS grade, Fluka, 
USA) to 0.1%. The chromatographic gradient program is summarized in Table 4. 2.  
Table 4. 2: Gradient program of chromatography of HILIC UPLC-MS method of Aqueous Extracts 
Time (min) Flow rate ml/min %A %B Curve 
0.0 0.4 99 1 - 
2.0 0.4 99 1 - 
8.0 0.4 45 55 6 
9.0 0.4 1 99 6 
9.1 0.8 1 99 6 
11.0 0.8 1 99 - 
11.1 0.8 99 1 6 
19.0 0.8 99 1 - 
19.1 0.4 99 1 6 
23.0 0.4 99 1 - 
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Detection of eluting UPLC fractions was achieved using a Premier Q-TOF (Waters MS 
Technologies Ltd., UK). Scans were acquired with scan time of 0.20 s and interscan time of 0.02 s. 
Leucine Enkephalin was used for lock mass correction. Lock mass data were collected with scan 
time of 0.20 s and scan frequency of 30 s. Conditions in positive mode:  m/z range:50-1000, cone 
voltage 30V, capillary voltage 3kV, Source Temperature 120
O
C, Desolvation Temperature 400
O
C, 
Desolvation Gas Flow 800L/h. Conditions in negative mode:  m/z range: 50-1000, cone voltage 
30V, capillary voltage 2.5kV, Source Temperature 120
O
C, Desolvation Temperature 350
O
C, 
Desolvation Gas 800L/h. 
A QC format 
114
 was used for the UPLC-MS analysis. Briefly, a pooled sample (referred to as 
Quality Control Sample, QC) of the reconstituted extracts was prepared. This sample was re-
injected 10 times before initiating the run to condition the column. Then the sample was re-injected 
once at the beginning, every 10 injections of samples, and at the end of the run (total of 13 
injections).  
 
4.2.3.2 Data Processing 
Collected data were subjected to peak-picking and grouping using MarkerLynx XS (Waters Inc, 
v4.1) software, using the following parameters: 
Positive mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.50, Final 
Retention Time: 10.00, Low Mass: 50.00, High Mass: 1000.00, XIC Window 0.10 Da, Peak Width 
at 5% Height: 25s, Marker Intensity Threshold: 60counts, Mass Window: 0.10Da, Retention Time 
Window: 0.50 
Negative mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.40, Final 
Retention Time: 9.10, Low Mass: 50.00, High Mass: 1000.00, XIC Window 0.10 Da, Peak Width at 
5% Height: 25s, Marker Intensity Threshold: 30counts, Mass Window: 0.10Da, Retention Time 
Window: 0.50 
For Both Modes: Noise Elimination Level: 6.00, Peak-to-peak Baseline Noise: Auto, Replicate % 
Minimum: 0.00, No relative retention time, No Smoothing, No Deisotoping. 
Values were reported as height of intensity peaks. Samples were normalized to total intensity. 
Values were multiplied by 10 000 prior to statistical analyses. The dilution series was used here to 
remove peaks that were not responding to dilution. This was done by applying multivariate statistics 
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on the QC samples and dilutions and removing features (variables) that were not responding to the 
dilutions. Additionally, features attributed to lidocaine and hydroxyl-lidocaine were removed. 
Lidocaine is administered locally prior to carotid endarterectomy. 
4.2.4 Lipid Profiling 
4.2.4.1 UPLC-MS analysis 
Samples were reconstituted in 500uL of solvent mixture of H2O / isopropanol / acetonitrile (1:2:1) 
(Optima, LC-MS grade, Fisher Scientific, USA), and transferred into Total Recovery vials (Waters, 
USA), after centrifugation for 10min at 5g and 4°C. 
UPLC separation was conducted using an Acquity UPLC System (Waters Corp, USA). An Acquity 
UPLC CSH C18 2.1x100mm, 1.7um, column (Waters Corp, USA) was used. Column temperature 
was set at 55
o
C, flow rate of 0.4mL/min. Injection volume of 3uL and 7uL were used for positive 
and negative ionisation modes respectively. The auto-sampler was set at 4°C. Mobile phase A 
consisted of acetonitrile/water (60:40) and mobile phase B Isopropanol/acetonitrile (90:10). In both 
solutions ammonium formate (LC-MS grade, Fluka, USA) was diluted to 10mM and formic acid 
(MS grade, Fluka, USA) to 0.1%. The chromatographic gradient program is summarized in Table 4. 
3.  
Table 4. 3: Gradient program of chromatography of the lipid profiling UPLC-MS methodology. 
 
Time (min) %A %B Curve 
0.0 60 40 - 
2.0 57 43 6 
2.1 50 50 1 
12.0 46 54 6 
12.1 30 70 1 
18.0 1 99 6 
18.1 60 40 6 
20.0 60 40 - 
 
Detection of eluting UPLC fractions was achieved using a Xevo G2 QTof 
(Waters MS Technologies, UK). Both MS and MS
E
 data scans were acquired for 0.200 s every 
0.214 s. MS
E
 data were collected after ramping the collision energy from 30 to 40V.  Leucine 
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Enkephalin was used for lock mass correction. Lock mass data were collected every 0.3 s for 0.2 s. 
Conditions in positive mode:  m/z range:150-1200, cone voltage 30V, capillary voltage 2kV, Source 
Temperature 120
O
C, Desolvation Temperature 550
O
C, Desolvation Gas 900L/h. Conditions in 
negative mode:  m/z range: 50-1200, cone voltage 30V, capillary voltage 1kV, Source Temperature 
120
O
C, Desolvation Temperature 550
O
C, Desolvation Gas 900L/h. 
As with HILIC-UPLC-MS analysis, the QC format was used, as described in the previous 
paragraph. 
4.2.4.2 Data Processing 
After acquisition, data were centroided (m/z spectra peaks are automatically detected and their 
centroid is calculated based on the average m/z value and weighted by the intensity). This was 
followed by peak-picking and grouping using MarkerLynx XS (Waters Inc, v4.1) software, using 
the following parameters: 
Positive mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.40, Final 
Retention Time: 17.00, Low Mass: 150.00, High Mass: 1200.00, XIC Window 0.10 Da, Peak 
Width at 5% Height: 20s, Marker Intensity Threshold: 1000counts, Mass Window: 0.10Da, 
Retention Time Window: 0.50 
Negative mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.45, Final 
Retention Time: 17.00, Low Mass: 50.00, High Mass: 1200.00, XIC Window 0.10 Da, Peak Width 
at 5% Height: 20s, Marker Intensity Threshold: 400counts, Mass Window: 0.10Da, Retention Time 
Window: 0.50 
For Both Modes: Noise Elimination Level: 6.00, Peak-to-peak Baseline Noise: Auto, Replicate % 
Minimum: 0.00, No relative retention time, No Smoothing, No Deisotoping. 
Values were reported as area of intensity peaks. Saturated peaks were removed, prior to total area 
normalisation. Values were multiplied by 10 000 prior to statistical analyses. 
4.2.5 Statistical analysis  
Multivariate data analysis (MVDA) for UPLC-MS data was conducted using the SIMCA-P+ (v. 
12.0.1.0.; Umetrics) package. Principal Component Analysis (PCA) and Orthogonal Projection to 
Latent Structures – Discriminant Analysis (OPLS-DA) were applied to the processed Pareto-scaled 
data. Model validation was carried out using CV-ANOVA testing 
142
.  
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In order to extract putative biomarkers from UPLC-MS, features (corresponding to metabolites) 
with correlation coefficient (Note: correlation coefficient that refers to correlation of samples to 
disease classes will be refer to as: p(corr)) greater than 0.5 in absolute value were initially chosen. 
This cut-off provides confidence greater than 99% (based on the number of samples). These 
features were further subjected to two-tailed t-test assuming unequal variance with a threshold of p 
< 0.05
143, 144
 and fold-change comparison. Features were reported as significant and structurally 
identified if: 1) both p(corr) and t-test p-value met the thresholds , 2) were reproducible through the 
run, with a coefficient of variation (CV%) of the QCs less than 30%, and 3) pass the 
chromatographic peak shape assessment. A brief flowchart of the conditions a feature has to pass in 
order to be considered statistically significant is summarized in Figure 4. 1. 
 
Figure 4. 1: The workflow of conditions a feature has to fulfil in order to be considered statistically significant and 
forwarded to structural assignment. 
4.2.6 Metabolite Identification of Candidate biomarkers 
For structural elucidation of significant features UPLC-MS
E
 and UPLC-MS/MS data were used. For 
the lipid profiling MS
E
 data were collected through the run as described for the UPLC-MS analysis, 
while for the HILIC-UPLC-MS analysis MS
E
 data were collected on pooled samples (QCs) at the 
end of the run.  
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The same conditions described for each run were the ones used for MS/MS analysis that was 
conducted using data dependent acquisition (DDA) or by targeting specific ions. MS/MS data were 
collected with collision energy ramping from 30 – 50eV for lipid profiling and 20 - 40eV for HILIC 
analysis. Apart from fragmentation patterns, structural elucidation was assisted by matching 
accurate m/z measurements to metabolites from online available databases
111, 116, 139
. In some cases 
isotopic patterns also proved useful as well as an in-house library
92
. 
Where stated (Table 4. 6 - Table 4. 8) authentic standards were used to validate metabolite 
structural assignment. This included retention time matching of the authentic standard to the 
analyte, as well as matching of ms/ms spectra. This is accordingly stated by the level of assignment 
(LoA). 
4.2.6.1 Analytical Standards 
Standards were analytically grade with typical purity of >99%. Acetyl-DL-carnitine hydrochloride, 
adenosine, arachidonic acid sodium salt, benzoic acid, cholesterol sulphate, 2-deoxyuridine, 
guanosine, hypoxanthine, inosine and 1-methylnicotinamide, were purchased from Sigma. Linoleic 
acid, 5-methyluridine, and L-proline were purchased from Aldrich. Oleic acid, palmitic acid sodium 
salt, and stearic acid were purchased from Sigma-Aldrich. Creatine, 6-methylnicotinamide, 
niacinamide, sphingosine, uracil, and uridine were purchased from Fluka. Butyryl-L-carnitine 
chloride, decanoyl-L-carnitine chloride, isobutyryl-L-carnitine chloride, oleoyl-L-carnitine chloride, 
and valerylcarnitine-L-carnitine chloride were purchased from Larodan Fine Chemicals. 
Lauroylcarnitine chloride and propionylcarnitine chloride were purchased from TOCRIS 
bioscience, elaidic acid and N-acetyl-L-methionine from Alfa Aesar,  and linoelaidic acid from 
Cayman Chemical Company. Free cholesterol was purchased from Nu-Chek Prep, Inc. 
 
4.2.7 Pathway Analysis 
4.2.7.1 Correlation network analysis 
Correlation coefficients (Spearman) between pairs of candidate biomarkers were calculated using R 
(2.13.2) programming language (Note: Correlation coefficients that describe the Spearman 
correlation between two metabolites will be referred to as: r). For network visualization, of 
significant metabolites characterizing either of CAR or FEM plaques, CytoScape (v.3.0.0-beta1) 
software was used. The cut-off for correlation was at all circumstances higher that 99% confidence. 
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4.2.7.2 Metabolite Mapping 
Initial metabolite mapping was conducted by importing statistically significant metabolites in 
KEGG database
24
. A number of metabolites were mapped based on literature findings described. 
4.2.7.3 Venn Diagrams 
Venn diagrams were constructed using online available software 
(http://bioinfogp.cnb.csic.es/tools/venny/). 
4.3 Results and Discussion 
4.3.1 Metabolic profiles of plaque formation 
For the first time the metabolic phenotype of plaque formation is assessed, from tissue of human 
patients, by comparison to INT. Metabolic profiles for the plaque tissues were determined using 
multivariate statistics. PCA shows, in an unsupervised fashion, differences in the profiles between 
tissue of INT and plaque lesions from the CAR and FEM locations (Figure 4. 2). It was however 
obvious that the metabolic profile of CAR tissue was more similar to the profile of INT, than FEM, 
forming distinct groups. 
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Figure 4. 2: Scores plots of principal component analysis (PCA) of the tissue extracts. (A) Positive mode PCA of lipid profiling, (B) negative mode PCA of lipid profiling, (C) 
Positive mode PCA of aqueous extracts using HILIC-MS analysis, (D) negative mode PCA of aqueous extracts using HILIC-MS analysis. (Each point represents a sample; Blue 
rhombus: Intima thickening samples, Red dot: Carotid plaque samples, Black square: Femoral plaque samples. 
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Further supervised MVDA modelling was employed for comparison of each of the plaque tissues 
separately. Orthogonal projection to latent structure – discriminant analysis (OPLS-DA) fitted 
models displayed high predictive values indicating distinctive metabolic profiles for each class, and 
diagnostics showed well-fitted and valid models, as assessed by model characteristics (Table 4. 4). 
Cross-validated scores plots of the samples included in the analysis are shown in Figure 4. 3. Using 
the constructed models, and in conjunction with univariate statistical analysis, significant features 
were structurally assigned to metabolites. Features were considered significant if their statistical 
characteristics met two criteria. Firstly, a good correlation, in absolute value, to the disease group 
vector in MVDA (|p(corr)|>0.5), and secondly from univariate statistics a p-value of t-test of < 0.05. 
In this study, structural assignments of > 150 unique metabolite identities were made on features 
that were found statistically significant in differentiating two or more groups (Table 4. 6, Table 4. 7, 
Table 4. 8; end of chapter). A large number of the metabolites have been detected as statistically 
significant in more than one polarity modes, or UPLC-MS analyses (Figure 4. 4 , Figure 4. 5 and 
Figure 4. 6). Metabolites detected include 5 different lipid classes and 17 subclasses
38
. Metabolites 
detected with statistically significance are presented in Table 4. 6, Table 4. 7 and Table 4. 8, at the 
end of this chapter. 
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Table 4. 4: Summary of model characteristics from OPLS-DA multivariate statistical analyses of data obtained from all analysed and polarity modes. 
 
 
Groups CAR vs INT FEM vs INT CAR vs FEM 
Analysis Lipid Profiling HILIC Aqueous Lipid Profiling HILIC Aqueous Lipid Profiling HILIC Aqueous 
Polarity Mode 
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative 
Comp 
(pred+orthog) 
1 + 1 1 + 2 1 + 0 1 + 1 1 + 1 1 + 1 1 + 1 1 + 0 1 + 1 1 + 1 1 + 1 1 + 0 
R2X 0.280 0.412 0.131 0.215 0.423 0.383 0.209 0.193 0.377 0.441 0.205 0.173 
R2Y 0.609 0.786 0.496 0.721 0.861 0.834 0.895 0.846 0.78 0.668 0.823 0.638 
Q2Y 0.432 0.502 0.356 0.467 0.755 0.746 0.703 0.797 0.658 0.576 0.648 0.575 
CV-ANOVA 1x10-6 4x10-7 1x10-6 2x10-7 3x10-10 6x10-10 5x10-9 2x10-13 7x10-16 2x10-12 3x10-15 2x10-13 
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Figure 4. 3: OPLS-DA cross-validated scores plots of tissue extracts. Columns represent group comparisons, and rows different UPLC-MS analyses and polarity modes. 
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Figure 4. 4: Venn diagram indicating identical metabolites detected statistically significant in the comparisons between 
carotid plaques and intimal thickening samples. Metabolites detected with the same trend in more than one analysis 
and/or polarity mode are shown. 
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Figure 4. 5: Venn diagram indicating identical metabolites detected statistically significant in the comparisons between 
femoral plaques and intimal thickening samples. Metabolites detected with the same trend in more than one analysis 
and/or polarity mode are shown. Tentatively assigned metabolites are indicated with an asterisk. 
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Figure 4. 6: Venn diagram indicating identical metabolites detected statistically significant in the comparisons between 
carotid plaques and femoral plaque samples. Metabolites detected with the same trend in more than one analysis 
and/or polarity mode are shown. Tentatively assigned metabolites are indicated with an asterisk. 
 
Statistically significant metabolites detected in both CAR and FEM after individual comparisons to 
control samples are shown in Figure 4. 7. These metabolites were detected following the same 
trends in both disease locations. Common perturbed metabolites can provide a good overview of the 
dysregulated metabolic procedures of plaque formation and will be the main focus of analysis and 
discussion in the following paragraphs. 
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Figure 4. 7: Venn diagram indicating identical metabolites detected statistically significant in both diseased anatomical 
locations (carotid and femoral) after separate comparisons to intimal thickening controls. Metabolites were detected 
with the same trends. Metabolites in red are the ones detected in higher intensities in disease and in blue are detected in 
lower. Tentatively assigned metabolites are indicated with an asterisk. 
4.3.2 Distinct Metabolic Profiles Detected Between Plaques but Not Between 
Intima Thickening from Different Anatomical Locations 
MVDA detected distinct metabolic profiles between CAR and FEM. OPLS-DA (Figure 4. 3) 
showed high predictive values in all analyses and polarities (Table 4. 4). Some of the most 
comprehensive findings were the several TG moieties, mostly incorporating 16 and 18 carbon 
chains, being significantly higher in FEM plaques. A number of lysoPCs also showed differential 
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levels with high statistical significance, reaching t-test p-values of 3.5E-16, with higher intensity 
levels in CAR (Table 4. 6). Other highly significant metabolites include FFAs, adenosine and PGs.  
In order for these findings to be attributed to differences of disease progression, rather than 
anatomical location, a comparison was conducted to determine whether INT from these locations 
displayed metabolically related differences, prior to plaque manifestation. Efforts to fit multivariate 
statistical models using the two groups (INT groups of CAR and FEM origin) fell short, as models 
were unable to be statistically validated. This gave an initial proof of the two groups bearing no 
differences in the control stage. Additionally, for every univariate comparison between features 
showing statistical significance of the three groups, a t-test between the two anatomical sites of 
intimal thickening was also conducted.  Out of 292 t-tests conducted in all analyses with p-values 
<0.01 only 6 t-tests showed p-values of <0.01 (but always larger than 0.001) when comparing the 
corresponding INT from different anatomical locations. Moreover, for the analysis comparing 
between FEM and CAR groups, where metabolic differences between the two locations could 
directly be detected, only 3 metabolites showed a p-value of <0.01 (but larger than 0.001) (Figure 4. 
8 and Table 4. 5), as compared with the p-values of t-test comparisons of plaques from the two 
anatomical locations. 
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Figure 4. 8:  Assessment of the difference of intimal thickening tissue from the carotid and femoral locations. For every metabolite detected statistically significant, a corresponding 
comparison was conducted between intimal thickening tissues from the two anatomical locations using the t-test. P-values for all comparisons are indicated. 
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Table 4. 5: Assessment of the difference of intimal thickening tissue from the carotid and femoral locations. For every 
metabolite detected statistically significant, a corresponding comparison was conducted between intimal thickening 
tissues from the two anatomical locations using the t-test. Frequencies of p-values for all t-test comparisons are 
indicated. 
T-test p-
value 
frequencies 
INT-CAR vs  
INT-FEM 
(CAR vs FEM 
comparison) 
CAR vs FEM 
comparison 
INT-CAR vs  
INT-FEM  
(CAR vs INT 
comparison) 
CAR vs INT 
comparison 
INT-CAR vs  
INT-FEM  
(FEM vs INT 
comparison) 
FEM vs INT 
comparison 
1E-15 0 1 0 0 0 0 
1E-14 0 2 0 0 0 0 
1E-13 0 0 0 0 0 0 
1E-12 0 1 0 0 0 0 
1E-11 0 2 0 0 0 1 
1E-10 0 6 0 0 0 0 
1E-09 0 6 0 0 0 1 
1E-08 0 12 0 2 0 4 
1E-07 0 12 0 2 0 5 
0.000001 0 13 0 9 0 12 
0.00001 0 20 0 11 0 19 
0.0001 0 16 0 14 0 20 
0.001 0 14 0 15 1 22 
0.01 3 8 0 27 2 15 
0.1 10 1 16 15 8 5 
1 101 0 79 0 93 0 
 
Studies describing differences between CAR and FEM are limited in literature. A study by Bianda 
et al describes differences on plaque remodelling
145
. Additionally, a study by Herisson et al. 
demonstrates differences between CAR and FEM plaques, with FEM described as being more 
prevalent to ectopic calcification
146
. Plaque calcification is considered a progression of 
atherosclerosis
147
 and this may also be the explanation of the distinct and distant metabolic profiles 
of FEM from CAR and INT. Evidence of Ca
2+
 dysregulation was supported by findings of the 
present study. For FEM vs INT the levels of PI(18:0/20:4) were detected being significantly lower 
in plaques with a fold change of 2.5, while in the comparison of CAR vs FEM, PI(18:0/22:6) was 
also lower with 2.9 fold-change. Phosphatidylinositols (PIs) are precursor molecules of inositol-
triphosphate (IP3), known for its role in calcium homeostasis. Increase of IP3 can induce export of 
Ca
2+
 from the endoplasmic reticulum 
43
. Haemodynamic differences are more likely to be 
responsible for this disease variation observed along atheroma manifestation. In the following 
paragraphs discussion on the significantly dysregulated pathways is expanded, and specific 
metabolite differences between groups are discussed further. 
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4.3.3 Presence of cholesterol and oxidised cholesterol esters in atheromas 
Cholesterol and cholesterol derivatives are nowadays considered well-established risk factors of 
atheromatogenesis
148
. In this study free cholesterol (Cho) was detected elevated in both CAR and 
FEM as compared to INT. Moreover several oxidized cholesterol ester (oxCE) moieties were 
detected in higher levels. The oxCEs were detected with higher statistical significance and fold-
change than Cho. Additional involvement of the cholesterol pathway is shown in FEM, where 
cholesterol sulphate was also found to be higher by 2-fold. Although the detection of higher levels 
of Cho and derivatives does not constitute a novel finding, it does provide good validation of the 
experimental design and findings.  
All oxCEs detected in higher levels were esterified only with 18C fatty acyl chains. These chains 
were detected with 1-3 oxygen molecules. Free radicals have been suggested to promote the 
production of oxCE
149, 150
. The oxCEs are also known to contribute to foam cell formation
151
, which 
are the cells forming the lipid-laden lesion. Lipid peroxidation is caused by ROS and affects 
unsaturated fatty acids as well as cholesterol esters (CE) and Cho itself
150
. It can eventually lead to a 
chain reaction and result to cell membrane damage
149
. Lipid oxidation is also recognized to play a 
role in the progression of atherogenesis. Structures of detected oxCEs moieties are in concordance 
with literature
152
. 
4.3.4 Purine and pyrimidine pathway dysregulation 
Purines and pyrimidines have been known for their involvement in atherosclerosis for many 
years
153
. Triphosphates of adenosine (ATP) and uridine (UTP) are released from endothelial cells in 
response to sheer stress
154
. They are controlling vascular tone
154,155
, a process related to hypoxia. A 
number of them, such as adenosine and inosine, are known for their anti-inflammatory effects
156, 157
. 
Purine and pyrimidine inhibition can lead to apoptosis
158
, while on the other hand they are essential 
for cell proliferation
158
. Metabolites of purine and pyrimidine pathways are components or 
precursors of RNA and DNA. Herein, a large number of molecules of these two pathways were 
detected with lower intensities in both disease groups. These include uridine, inosine, hypoxanthine, 
guanosine and methyluridine (Table 4. 6 and Table 4. 7). These results provide yet another form of 
validation to the current study, since they are well-established to be involved in atherosclerosis. 
The elevation of adenosine levels only in FEM becomes rather intriguing as it was not detected with 
statistical significance in CAR. Adenosine, apart from its anti-inflammatory abilities, is acting as a 
highly potent vasodilator and vasoconstrictor
24, 155
. This process is also connected to Ca
2+
 channels, 
and could explain the high correlation (r=-0.57) of adenosine to PI(18:0/20:4), also known for their 
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involvement in Ca
2+
 homeostasis. The differential amount of shear stress and stretch applied to 
these different anatomical locations may provide insights into this detected difference. It can be also 
claimed that the lower and higher levels of inosine and adenosine in FEM, respectively, are to some 
extent independent to their directly connecting enzyme, adenosine deaminase, known to be present 
in vessels. This claim is based on the inverse correlation between these two metabolites (r=-0.56), 
which reflects some sort of association, but the correlation is not as strong as would be expected for 
a direct reaction. Adenosine was detected with high fold change in FEM in both positive and 
negative polarity modes of the HILIC analysis. 
4.3.5 Ceramide pathway suffers complete homeostatic loss 
The ceramide (Cer) pathway is known for its involvement in atherosclerosis 
159
. This can be 
expected due to the role of the Cer pathway in apoptosis
160
, and connections to (pro-) inflammatory 
factors, reactive oxygen species (ROS) and nitric oxide (NO)
159
. In the present study, a global 
reduction of the levels of a number of sphingomyelin (SM) moieties was detected. This observation 
along with the detected elevated levels of Cers may indicate the involvement of the 
Sphingomyelinase (SMase) enzyme. SMase catalyses the production of Cer by hydrolysis of the 
phosphoesteric bond of the phosphocholine head-group of SMs. 
Glycosphingolipids, another sphingolipid subclass were also found to be dysregulated. From 
literature review, studies detecting glycosphingolipid involvement in atherogenesis go 40 years 
back
161
. They have been implicated as signalling molecules in cell proliferation after oxidative 
conditions in vascular cells
162
 and platelet activation and adhesion to the vessel wall
163
. In the 
present study, tetra- and tri- hexosylceramide (HexCer) were detected in reduced levels, both in the 
form of d18:1/16:0. Specifically, tetraHexCer was detected with high p(corr) values  in MVDA in 
both diseases (p(corr)= -0.82 CAR; p(corr)= -0.89 FEM) (Figure 4. 9). Findings indicate a more 
intense involvement of tetraHexCers, and these being highly correlated to triHexCer (r=0.81 CAR; 
r=0.84 FEM). On the other hand, two monoHexCers were detected with higher intensities and only 
in CAR. The dysregulation of monoHexCers with an opposite trend and only in CAR indicates 
involvement of yet another biochemical reaction independent to tri- or tetraHexCer. This is also 
designated by lack of correlation to tetra- and tri-HexCer, while strong correlations were detected to 
Cers.  
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Figure 4. 9: A-D S-plots of the OPLS-DA analyses of  lipid profiling analysis of tissue extracts of (A) positive mode of carotid against intimal thickening, (B)  positive mode of 
femoral against intimal thickening, (C) negative mode of carotid against intimal thickening, and (D) negative mode of femoral against intimal thickening tissue extracts. (E) box-
plots of metabolites indicated on S-plots that demonstrated high statistical significance in both statistical comparisons.  
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Other differential sphingolipids were sphingosine and C16-sphingosine, showing a 3.5- and 7.6- 
fold change, only in CAR, and Phosphatidylethanolamine-Ceramides (PE-Cer) with lower levels in 
both anatomical locations, compared to INT. PE-Cer involvement is considered to be a novel 
finding of this study, crucial to the pathological process, and it will be further discussed in the 
following paragraphs. 
4.3.6 PE-Cer a new candidate biomarker in atherogenesis  
Despite the vast amount of research focused on atherosclerosis PE-Cers have not been investigated 
in the context of plaque formation. Specifically, apart from p-values as low as 9.8x10
-12
 in t-tests 
(Table 4. 6 and Table 4. 7), PE-Cers showed indications of high correlation to the disease (p(corr)≥-
0.94) (Figure 4. 9), using well-validated multivariate models, with high predictive values. They 
were detected in the form of PE-Cer(d18:1/16:0) and PE-Cer(d18:1/24:1). PE-Cer involvement in 
the progression of plaque formation was evident in both anatomical locations (CAR and FEM), and 
is a significant finding as it demonstrates common basis of disease manifestation. PE-Cers are 
found only in trace concentrations in mammalian cells
164
. However, this lipid has been reported to 
be essential to ceramide homeostasis in humans
165
. 
A selective synthase called sphingomyelinase synthase1 – related (SMSr), is the enzyme 
responsible for PE-Cer synthesis by transferring the phosphoethanolamine group from PE to Cer. 
Therefore, the inverse correlation of PE-Cer to Cer is in concordance with the corresponding 
biochemical reaction
24
. However, PEs did not share the same trend as Cer. On the contrary, PEs had 
a high positive correlation to PE-Cers. This correlation should be further investigated in the context 
of the possibility of a positive feedback loop with additional biological effects. For CAR the highest 
correlation occurred with 20:4 FAC bearing PEs, while for FEM with 22:6. PE-Cers also showed 
high correlations with members of the pyridine and pyrimidine pathways, such as inosine, uridine 
and guanosine.  
As expected, correlation networks revealed connections between PE-Cers and metabolites, 
members, of the ceramide pathway. These included high positive correlations to tetraHexCer, 
triHexCer, and SMs and inverse correlations to Cers and monoHexCers. An interesting observation 
is that correlations to tetraHexCer were generally higher than triHexCer, and in the same level as 
Cers. This association should be further explored since Cers and triHexCer would represent 
intermediate products of the reaction from PE-Cer to tetraHexCer, according to reference pathways. 
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4.3.6.1 Structural assignment of PE-Cers 
Despite the fact that PE-Cers are known to exist in the human lipidome, they are not ubiquitously 
found in MS databases
111, 116
. PE-Cers were detected as statistically significant with the negative 
mode of the lipid profiling methodology. A search for the PE-Cer(d18:1/24:1) (m/z on 
neg=769.6202) returned no results while for the PE-Cer(d18:1/16:0) ) (m/z on neg=659.5125) two 
PE-Cers were returned (as [M-H]-) with however different fatty acyl chains (Figure 4. 10) and 
reported as previously detected only in Drosophila melanogaster
166
. However, due to the high mass 
accuracy (Δppm=0) to the detected ion this possibility was further explored. 
A first indication was the low intensity of the metabolite. As mentioned, PE-Cers are detected in 
trace concentrations in humans. Positive mode was used and an ion representing the [M+H]+ was 
detected at the same retention time. The MS
E
 mode was then utilised to confirm characteristic 
fragments of PE-Cers (these ions were not picked from DDA for MS/MS due to their low 
intensities), in combination with in source fragments. These would be a neutral loss of 141 
(phosphoethanolamine loss), and a 264 (backbone of d18:1 ceramide)
166
. These ions were detected 
and matched relatively well to the chromatographic peak profile, considering the low intensity of 
the ions (Figure 4. 11).  
Additional MS/MS experiments were conducted on positive mode, using samples with high 
intensities of this signal and further verified the metabolites to be as such based on their 
fragmentation profile (Figure 4. 12 and Figure 4. 13). Characteristic fragments that led to the 
structural assignment of these PE-Cers were: 1) the neutral loss of phosphoethanolamine (141), 2) 
the backbone fragment of d18:1 (m/z = 264) and 3) the fatty amides corresponding to the specific 
metabolites (m/z = 280 and 390). 
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Figure 4. 10: Results of accurate mass search for 659.5125 m/z, detected on negative mode of the lipid profiling 
analysis, in the lipid maps
139
 database. (Search conducted March 2013) 
 
Figure 4. 11: Extracted ion chromatograms of characteristic fragments of metabolite that was initially tentatively 
assigned as PE-Cer(d18:1/16:0), and further verified as such by MS/MS experiments. Extracted ion chromatograms 
were smoothed using the Savitzky-Golay method.  
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Figure 4. 12: MS/MS spectrum of the PE-Cer(d18:1/16:0) indicating the characteristic fragments used for structural assignment. 
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Figure 4. 13: MS/MS spectrum of the PE-Cer(d18:1/24:1) indicating the characteristic fragments used for structural assignment. 
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4.3.7 PE-Cer levels are inversely correlated to cholesterol 
Probably the most biologically important observation is the high inverse correlation of PE-Cers to 
Cho and subsequently to the detected oxCEs. PE-Cer(d18:1/16:0) for the CAR group achieved 
correlation values of r= -0.84 and for the FEM group r= -0.86, while PE-Cer(d18:1/24:1) r=-0.56 
and -0.81, respectively (Figure 4. 14, Figure 4. 15, Figure 4. 16, Figure 4. 17). Although Cho did 
appear to have high correlation to some of the members of the Cer pathway, they were lower 
compared to PE-Cer indicating more of an effect rather than a cause. This was further verified by 
correlation analysis for metabolites found dysregulated in both groups (n=94) (Figure 4. 18). As can 
be seen by the correlation network (Figure 4. 19), cholesterol was highly correlated only to PE-
Cer(d18:1/16:0). From these findings it is hypothesised that PE-Cers and most likely only PE-
Cer(d18:1/16:0) is the factor of the Cer pathway having the closest interaction to Cho. 
It has previously shown that SMs can form Cho-enriched domains in the cell membrane, while PE-
Cers do not favour formation of such domains
167, 168
. This observation may not provide an adequate 
explanation for the high absolute value of correlation between PE-Cers and Cho, but it may explain 
the inverse nature of the correlation. Additionally, the fact that PE-Cers have been found to be 
responsible for controlling Cer levels
165
 can add confidence to the hypothesis.  
As mentioned, the Cer pathway is known for its involvement in atherosclerosis
159
. Thus, efforts to 
connect the Cer pathway to Cho have previously been conducted
169, 170
 since Cho represents a 
traditional risk-factor for atherosclerosis, and associations of metabolites of the Cer pathway to Cho 
have previously been shown
171
. Connections between the Cer pathway and Cho have been the 
centre of attention in the manifestation of diseases such as Alzheimer
172
 and cancer
173
. Therefore, 
PE-Cers carry the potential of being the missing link, and thereby bringing the quest of integrating 
Cho and Cer pathways, and consequently the elucidation of the pathophysiology of plaque 
formation, a step closer to a resolution. 
 
4.3.8 Dysregulation of metabolic oxidation is detected via truncation of β-
oxidation and unsaturated lipid consumption  
In both CAR and FEM tissue, acyl-carnitines (AcC) with short acyl chains were detected with lower 
intensities, while, on the contrary, AcCs with medium or long chain AcC levels were increased. 
AcC are involved in the translocation of fatty acyl chains through the mitochondrial membrane. 
This finding implicates mitochondrial metabolism and specifically the β-oxidation. From these 
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results, it could be hypothesised that β-oxidation is somewhat truncated reducing the production of 
short-chain AcC, while at the same time medium- and long-chain AcCs are accumulated. 
Additionally, a number of highly unsaturated lipids were detected in lower intensities in the disease 
groups. As discussed in preceding paragraphs unsaturated fatty acyl chains can react under 
oxidative stress with their oxidation occurring in the peroxisome rather than the mitochondria. 
Highly unsaturated lipids were detected with inverse correlations to oxCEs (CAR r>-0.70; FEM r>-
0.78) (Figure 4. 14 and Figure 4. 16). Yanes et al demonstrated that high concentrations of long-
chain AcCs along with low concentrations of unsaturated lipids are present after maturation of 
embryonic stem cells
174
. In this context, processes imitating embryonic differentiation, such as 
ectopic ossification
147
, are well known to take place in advanced atherosclerotic lesions. Findings 
also support this further, since FEM showed more intense dysregulation of β-oxidation. FEM have 
been previously shown to experience more intense calcification than CAR
146. From literature, β-
oxidation and oxidative conditions, in general, are linked to inflammation
175
. Although oxidative 
stress is known to be involved in the manifestation of atherosclerosis
148, to our knowledge, β-
oxidation and acyl-carnitines have not been previously associated with atherogenesis.
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Figure 4. 14: A heatmap representation of the correlation matrix obtained from Spearman correlations of metabolites 
detected statistically significant in the comparison of carotid plaques to intimal thickening. Intensity of red colour 
represents positive correlation and intensity of blue represents negative correlation of the biomarker pair. 
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Figure 4. 15: Correlation network of metabolite pairs found to have a Spearman correlation value of more than 0.70 in 
absolute value. These metabolites were found to be statistically significant in the comparison of carotid to intimal 
thickening tissue. 
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Figure 4. 16: A heatmap representation of the correlation matrix obtained from Spearman correlations of metabolites 
detected statistically significant in the comparison of femoral plaques to intimal thickening. Intensity of red colour 
represents positive correlation and intensity of blue represents negative correlation of the biomarker pair. 
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Figure 4. 17: Correlation network of metabolite pairs found to have a Spearman correlation value of more than 
0.80 in absolute value. These metabolites were found statistically significant in the comparison of femoral to 
intimal thickening tissue. 
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Figure 4. 18: A heatmap representation of the correlation matrix obtained from Spearman correlations of the common 
metabolites detected statistically significant in separate comparisons of carotid and femoral plaques to intimal 
thickening. Intensity of red colour represents positive correlation and intensity of blue represents negative correlation 
of the biomarker pair. 
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Figure 4. 19: (A) Correlation network of metabolite pairs found to have a Spearman correlation value of more than 
0.65 in absolute value. These metabolites were commonly found as statistically significant in separate comparisons of 
carotid and femoral plaque tissue to intimal thickening. (B) Box plots of highlighted metabolites from the correlation 
network. These metabolites are considered important due to the central role (hubs) to the network or prior knowledge 
of importance in the studied disease, according to literature. 
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In FEM, along with the increase of AcCs, accumulation of free fatty acids (FFA) is also detected 
and indicates low FFA oxidation as well as presence of oxidative conditions. Detected FFAs were 
in the range of 16-18 carbon chains, and can be only moderately associated with detected 
dysregulation of β-oxidation (r~ 0.4 - 0.55 to medium-chain AcCs; r~ -0.50 - -0.55 to short-chain 
AcCs). The accumulation of 16 and 18 carbon chains explains the high abundance of 16 and 18 
carbon chain TGs (r<0.69). Correlations of FFAs in the range of 0.61 – 0.80 with the oxCE bearing 
one oxygen, and in the range of 0.51 – 0.59 to the oxCE bearing two oxygens demonstrates further 
their association to oxidative stress. Another observation is the very high inverse correlation of 
these 16 and 18C TGs to tetra- and tri-HexCer (r > -0.86). TGs also showed high correlations to 
Cers and high negative correlations to SMs and PE-Cers, with, however, lower absolute values. 
Accumulation of FFA has been shown to lead to toxic pathways and apoptosis in pancreatic β-
cells
176
. The reasons of the FFA accumulating only in FEM could be sought to the different 
haemodynamics between FEM and CAR, since muscle contraction has been shown to induce FFA 
uptake
177
. 
4.3.9 Presence of acyl-cholines in CAR 
In the CAR higher intensities of acyl-cholines (choline esters) were observed. This was based on 
accurate m/z measurements and presence of an N, N, N-trimethyl loss on MS/MS analysis, which is 
characteristic of acetylcholine
178
. These esters incorporated fatty acyl chains of 16:0, 18:2, 18:1, 
18:0 and 20:4. High pairwise correlations between these molecules (typically r>0.9) is a good 
indication of a direct connection, which may be a common synthesizing enzyme. They also 
manifested high correlation to lysoPCs and high inverse correlation to some of the PEs and lysoPEs. 
Such a finding is reported for the first time. However, due to the fact that it represents an 
observation in only one of the groups it was further assessed. The major concern for this matter is 
that a local anaesthetic, lidocaine, is locally administered only during carotid endarterectomies. 
However, the detected molecules were not correlated to lidocaine (Figure 4. 14). Still, 
cholinesterases are known for their involvement in metabolising anaesthetics and therefore this 
finding should be further evaluated and validated
179
. 
4.4 Conclusions 
The choice of the two UPLC-MS methods used (Reversed-phase – UPLC for organic extracts and 
HILIC-UPLC for aqueous extracts) provided a wide coverage of metabolites, from lipids and 
extremely lipophilic molecules, such as TGs and CEs, to polar molecules such as carnitine and 
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creatine. A number of metabolites were detected as statistically significant from more than one 
analysis and polarity modes (Figure 4. 4). Good QC grouping in multivariate statistics, translated to 
low coefficient of variation (CV%), indicated a high reproducibility through the run, ensuring good 
quality data. The detection of metabolites known to exist in trace concentrations in human is 
another evidence of the impact new technological achievements have in the area of metabolic 
profiling. 
The experimental design and especially the choice of intimal thickening tissue as the control group 
gives the confidence of detecting significant metabolites from pathological processes involved in 
plaque formation. The only drawback of the study was the usage of lidocaine, during surgery, only 
for carotid endarterectomies. This does not affect findings, as discussed, as the major focusing of 
the study is on metabolites common to both groups. Additionally, the drug, all the features 
structurally related to the drug, and a metabolite of the drug, were removed prior to statistical 
analysis. Moreover, lidocaine intensities were included in correlation analysis, as a further check, 
and showed no significant correlations to any of the statistically significant metabolites (Figure 4. 
14). Keeping in mind that the drug is injected only a few minutes prior to excising the tissue, it is 
unlikely to cause any severe effect to the tissue biology. Specifically, no correlation between the 
bioavailability of the drug and tissue profile in CAR samples was observed in unsupervised (Figure 
4. 20) or supervised MVDA. Lastly, the fact that the INT samples from the two locations did not 
show any differences further indicates that lidocaine administration does not induce major 
biological differences. 
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Figure 4. 20: PCA scores plots of only the carotid samples in all analysis and polarity modes with colouring indicating the bioavailability of the local administered anaesthetic drug 
lidocaine in the plaque tissue. Colour coding: Red: Intensities over the +1SD, Grey: Intensities within the ±1SD, Green: Intensities lower than -1SD, and Blue: Samples with 
undetectable levels of lidocaine. 
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For the current study, an initial validation was performed by demonstrating concordance with 
literature and well-established risk factors. Specifically, Cho and oxCEs which were detected with 
higher intensities in plaques are known to be in elevated concentrations in atheromas
148, 152
. The 
involvement of purine and pyrimidine pathways provide further confidence to our results and 
experimental design, as they are also known to be dysregulated in atherosclerosis. 
Distinct metabolic profiles were detected from plaque tissue harvested from the carotid and femoral 
locations. However, the pathological origins of plaque formation, are more likely to be based on the 
common dysregulated biological pathways of CAR and FEM. Therefore, common and to some 
extent novel, findings are further elucidated. The involvement of PE-Cers and their strong statistical 
connections to plaque formation, Cho and CEs, represent a novel finding and common in both 
anatomical locations. At this point it is difficult to provide a hypothesis from the current 
information. It could be claimed that the reduction of PE-Cers in the cell membrane (CM) gives rise 
to Cho, as the CM can incorporate more Cho and Cho production in the endoplasmic reticulum 
continues. However, the trace amounts of PE-Cers in the human cell may be inconsistent with this 
hypothesis, and show some sort of signalling function to the molecule. PE-Cers are connected to the 
Cer pathway, and they may have a role in apoptosis of the cell, thus depositing Cho within the 
intima layer of the vessel. Nonetheless, this association to cholesterol can provide further insights 
into manifestation of disease but also might be able to explain ineffectiveness of cholesterol-
lowering drugs. 
Tetra- and tri-HexCers, are also universally dysregulated and may provide additional insides to the 
disease. Tri- and tetra-HexCers showed strong statistical power and high association to PE-Cers. 
The dysregulation of the Cer pathway, in general, was also common supporting the ubiquitous 
involvement of apoptosis in atherosclerosis. Additionally, the interruption of β-oxidation as inferred 
by the differential intensities of acyl-carnitines, and along this the recruitment of highly unsaturated 
fatty acids, reveal previously undemonstrated findings. 
Differences between the two plaque tissues should also be taken into account. For FEM, the most 
intense differential findings were the more obvious dysregulation of β-oxidation, involving AcCs, 
FFAs and TGs, and the elevation of adenosine. For CAR it was the elevation of lysoPCs and 
members of the ceramide pathway, such as mono-HexCers, and sphingosines, and the elevation 
acyl-cholines. These are findings that should not be neglected as they may convey significant 
mechanistic and translational information by providing the biological rationale for cases of drug 
resistance/inefficiency. Reasons for these differences could be sought in the differential amount of 
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shear stress and stretch applied in these regions. Another possibility could be the different 
embryonic origins of vascular smooth muscle cells in the two anatomical locations which has been 
shown to phenotypically effect different cardiovascular diseases
180
. 
An important and, at the same time, difficult part of the present study was to provide rational 
interactions between pathways detected being dysregulated. Correlation analysis, pathway mapping 
and literature review provided information that could be used towards deconvolution of the 
complex pathology of this disease. In this top-down systems biology approach a number of 
interactive pathways were detected, with the connection of the Cho and Cer pathways being the 
highlight of the analysis. 
Further experiments will seek to validate results and identify connections between pathways using 
bottom-up approaches and in a larger number of samples. Absolute quantification of metabolites 
involved, with a special interest in d18:1/16:0 sphingolipids, along with transcript expression and 
activity of involved enzymes, will also be part of future work. 
4.4.1 Closing remarks 
Atherosclerosis is a multicentric and multistage disease. Health threatening events can occur as a 
result of plaque formation. These are generally caused by blood flow limitation, stroke and heart 
attack. Current therapeutic agents function towards cholesterol lowering. Cholesterol is known to be 
in the centre of advancement of the disease, but still prescribed drugs appear inadequate to mitigate 
stenosis or plaque rupture. For these reasons, there is an urgent unmet need for the scientific 
community to identify novel biomarkers/pharmaceutical targets to increase the potential of 
therapeutic treatment. This is potentially a rather difficult task, since atherosclerosis has been in the 
centre of scientific attention for many years now. However, in this study, new biochemical 
pathways have been identified as being involved in the progression to plaque formation from 
intimal thickening. This could be credited to the novelty of methodologies, modern instrumentation 
and experimental design. Systems biology approaches, by using multivariate statistics, can provide 
global information for the disease of interest and can identify or infer dysregulated pathways. 
Although the detected candidate biomarkers and inferred interactions from this study need further 
validation, they definitely constitute a step forward for the elucidation of the mechanisms of plaque 
formation in the arterial wall. 
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Table 4. 6: List of structurally assigned statistically significant metabolites obtained from the analysis of tissue extracts, after comparison of the carotid to the intimal 
thickening group.  
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* Standard compound of isobutyrylcarnitine exhibited different RT 
† Standard compound of 6-methylnicotinamide exhibited different RT 
‡ Molecular formula as calculated using the isotopic pattern (tentative) 
 
LoA: Level of Assignment; 1: Tentative assignment; 2: Tandem MS spectrum matched to database or literature; 3: RT matched to standard 
compound; 4: MS/MS spectrum and RT, matched to standard compound. 
RT: Retention time. 
HILIC: Hydrophilic Interaction (Liquid) Chromatography. 
P(corr) refers to the correlation coefficient of metabolites to disease classes. 
Two-tailed t-tests were conducted, assuming unequal variance. 
Coefficient of variation (CV%) is calculated based on thirteen injections of the same pooled quality control (QC) sample, acquired throughout 
the run. 
The position of double bonds and the position of fatty acyl chain cannot be determined in lipid moieties (Cer, HexCer, PC, PE, PG, and SM). 
Fatty acyl chains are presented from lowest to highest molecular weight (lower number of carbons to higher, and higher number of double bonds 
to lower). 
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Cer: ceramide; FA: formate; Hex: hexosyl; na: not applicable; oxCE: oxidised cholesterol ester; PC: phosphatidylcholine; PE: 
phosphatidylethanolamine; PG: phosphatidylglycerol; SM: sphingomyelin; ud: unable to determine; UKN: unknown.  
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Table 4. 7: List of structurally assigned significant metabolites obtained from analysis of tissue extracts, after comparison of the femoral to the intimal thickening group.  
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* Standard compound of elaidic acid (stereoisomer of oleic acid) exhibited different RT 
† Standard compound of linoelaidic acid (stereoisomer of linoleic acid) exhibited different RT 
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‡ Detected as a fragment of parent ion 
§ Standard compound of 6-methylnicotinamide exhibited different RT 
 
LoA: Level of Assignment; 1: Tentative assignment; 2: Tandem MS spectrum matched to database or literature; 3: RT matched to standard 
compound; 4: MS/MS spectrum matched to standard compound. 
RT: Retention time. 
HILIC: Hydrophilic Interaction (Liquid) Chromatography. 
P(corr) refers to the correlation coefficient of metabolites to disease classes. 
Two-tailed t-tests were conducted, assuming unequal variance. 
Coefficient of variation (CV%) is calculated based on thirteen injections of the same pooled quality control (QC) sample, acquired throughout 
the run. 
The position of double bonds and the position of fatty acyl chain cannot be determined in lipid moieties (Cer, DG, HexCer, PC, PE, PG, PI, SM, 
and TG). Fatty acyl chains are presented from lowest to highest molecular weight (lower number of carbons to higher, and higher number of 
double bonds to lower). 
Cer: Ceramide; DG: diglyceride; FA: formate; Hex: Hexosyl; na: not applicable; oxCE: oxidised cholesterol ester; PC: phosphatidylcholine; PE: 
Phosphatidylethanolamine; PG: Phosphatidylglycerol; PI: phosphatidylinositol; SM: sphingomyelin; TG: triglyceride; ud: unable to determine; 
UKN: unknown.  
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Table 4. 8: List of structurally assigned significant metabolites obtained from analysis of tissue extracts, after comparison of the carotid to the femoral plaque group.  
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* Statistics and assignment on second isotope 
† Molecular formula as calculated using the isotopic pattern (tentative) 
‡ Standard compound of elaidic acid (stereoisomer of oleic acid) exhibited different RT 
§ Standard compound of linoelaidic acid (stereoisomer of linoleic acid) exhibited different RT 
¶ Detected as a fragment of parent ion 
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LoA: Level of Assignment; 1: Tentative assignment; 2: Tandem MS spectrum matched to databases or literature; 3: RT matched to standard 
compound; 4: MS/MS spectrum matched to standard compound. 
RT: Retention time. 
HILIC: Hydrophilic Interaction (Liquid) Chromatography. 
P(corr) refers to the correlation coefficient of metabolites to disease classes. 
Two-tailed t-tests were conducted, assuming unequal variance. 
Coefficient of variation (CV%) is calculated based on thirteen injections of the same pooled quality control (QC) sample, acquired throughout 
the run. 
The position of double bonds and the position of fatty acyl chain cannot be determined in lipid moieties (Cer, HexCer, PC, PE, PG, PI, SM, and 
TG). Fatty acyl chains are presented from lowest to highest molecular weight (lower number of carbons to higher, and higher number of double 
bonds to lower). 
Cer: Ceramide; FA: formate; Hex: Hexosyl; na: not applicable; oxCE: oxidised cholesterol ester; PC: phosphatidylcholine; PE: 
phosphatidylethanolamine; PG: phosphatidylglycerol; PI: phosphatidylinositol; SM: sphingomyelin; TG: triglyceride; ud: unable to determine; 
UKN: unknown. 
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Chapter 5  A metabolic profiling approach 
to explore candidate biomarkers and 
pathways of cardiovascular calcification 
5.1 Introduction 
Vascular and valvural calcifications are pathological conditions of ectopic bone formation. Vascular 
calcification can coexist with atherosclerosis. However, there is no clear knowledge of whether it 
can actually be the cause, effect, or a co-progression
57, 60
. Nonetheless, evidence of independent 
mechanisms of these two conditions also exist
57
. Elucidation of the pathology of vascular 
calcification, as well as biomarker discovery studies, become more important due to contradictory 
reports of prognostic significance of calcification in cardiovascular events
57, 59, 60
. Aortic valve 
calcification is the second most common indication for cardiac surgery
61
, and the first for valve 
replacement in the United States
62
. Calcific aortic valve disease is also associated with 
atherosclerosis
62
. The failure of conventional risk factors and drugs, the absence of easy-to-apply 
screening-biomarkers, along with the severity of the disease, declare the critical need for alternative 
technologies.  
Calcification is no longer regarded as a passive calcium deposition, degenerative disease. It is now 
widely considered to be an active biological process of ossification
60, 62, 181, 182
. Bone morphogenetic 
proteins (BMPs), matrix Gla protein (MGP), osteoprotegerin, osteopontin, osteonectin are some of 
the bone-formation related factors known to be involved
57, 60, 181, 182
. For this reason, calcification is 
now believed to recapitulate orthotopic embryogenic osteogenesis
57, 60, 181
. Inflammation also plays 
a crucial role in calcification. Cells such as macrophages and lymphocytes can penetrate epithelial 
tissue (and plaque) and release inflammatory factors such as cytokines
57, 60, 62
. Apoptosis is yet 
another process suggested to be involved in vascular calcification
60, 181, 182
. Dysregulation of levels 
of inorganic pyrophosphate and phosphate, vitamin D, alkaline phosphatase and reactive oxygen 
species (ROS), are also considered to be some, but definitely not all, of the mediators of 
calcification
57, 60, 181, 182
. 
 203 
 
The aim of this study is to apply cross-platform untargeted techniques to profile the metabolome of 
a cohort of patients with exertional symptoms presenting various degrees of coronary calcification, 
but no flow limiting lesions. These patients were compared to patients with no indications of 
calcified lesions. Additionally, a comparison to a parallel class of patients, with aortic stenosis due 
to valve calcification, was also conducted in order to ascertain whether there is a different metabolic 
signature for the two calcific diseases. Ultimate objectives of this study are 1) to obtain candidate 
biomarkers in order to deliver on early and accurate diagnostics, and risk stratification to guide for 
appropriate intervention, and 2) to generate hypotheses and follow through with an elucidation of 
disease pathways in large population studies (targeted or untargeted) and bottom-up approaches. To 
the best of our knowledge, this is the first metabonomic application on calcific cardiovascular 
disease, in any matrix (blood, tissue or cells).  
5.2 Methods 
5.2.1 Patients 
Serum samples were collected from patients that visited the clinic (Heart Centre and Department of 
Public Health and Clinical Medicine, Umea University, Umea, Sweden) with exertional angina 
pain. No patient had prior myocardial infarction or coronary artery intervention (PCI). No patient 
had valve disease, heart failure or renal dysfunction. A parallel class of aortic stenosis patients were 
recruited before aortic valve replacement surgery. The two groups of patients underwent a 
multislice CT scan of the chest from which coronary Calcium Score (CS) was measured using the 
Agatston score and Hounsfield units. Patients for whom no calcium was detected served as the 
control group. Patients completed a clinical questionnaire investigating their lifestyle, prior clinical 
conditions, and medications. 
A research nurse explained the program to the patients who signed an informed consent to 
participate in the study. The study protocol was approved by the Regional Ethics Committee of 
Umea. Subsequently patients had a needle inserted in one of the veins in the cubital fossa and an 
experienced nurse took a blood samples. The sample left to clot for 30min, centrifuged, and 
separated serum was stored at -40
O
C. Patients demographics are summarized in Table 5. 1. 
. 
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Table 5. 1: Patients demographics for all four patient groups included in present studies. CCAD: Calcific coronary 
artery disease, CAVD: Calcific aortic valve disease. 
Class No Calcification 
Mild Calcification 
(CCAD) 
Severe 
Calcification 
(CCAD) 
CAVD 
Number of patients 26 27 17 9 
Calcium Score Median 
(range) [No. of missing] 
0 (n/a) [0] 50 (4-219) [0] 
801 (254-1840) 
[0] 
694 (248-2454) 
[4] 
Median Age (range) 61 (50-74) 67 (50-80) 67 (48-83) 79 (68-83) 
Male gender (%) 7 (27) 11 (41) 11 (65) 4 (44) 
Median BMI (range) 26.4 (21.5-37) 26.4 (19.2-41.4) 27.8 (23.3-37.3) 27.8 (20.7-31.0) 
Median of blood pressure, 
mm Hg (range) 
    
                   Systolic 138 (110-180) 140 (104-172) 138 (120-178) 139 (116-184) 
                   Diastolic 84 (62-100) 80 (66-96) 82 (62-100) 82 (64-88) 
Hypertension (%) 16 (62) 20 (74) 15 (88) 7 (78) 
Smoker 
    
                yes (%),  1 (4) 3 (11) 2 (12) 0 (0) 
                former (%) 12 (46) 13 (48) 10 (59) 5 (56) 
Diabetes Mellitus (%) 4 (15) 3 (11) 5 (29) 1 (11) 
Hereditary (%) 17 (65) 18 (67) 14 (82) 1 (11) 
Osteoporosis (%) 2 (8) 2 (7) 1 (6) 1 (11) 
Hypercholesterolemia (%) 13 (50) 23 (85) 17 (100) 5 (56) 
Statins (%) 10 (38) 21 (78) 15 (88) 4 (44) 
Aspirin (%) 11 (42) 21 (78) 13 (76) 0 (0) 
Metoprolol (%) 6 (23) 11 (41) 9 (53) 5 (56) 
Nitrates (%) 10 (38) 9 (33) 9 (53) 2 (22) 
Amlodipin (%) 3 (12) 4 (15) 5 (29) 1 (11) 
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5.2.2 Lipid Profiling using Ultra-Performance Liquid Chromatography – 
Mass Spectrometry (UPLC-MS) Analysis 
5.2.2.1 Serum Liquid-Liquid Extraction 
An aliquot of 100μL of serum was mixed with 600uL of organic solvent mixture in an Eppendorf 
tube. The organic solvent mixture consisted of 3:1 dichloromethane (Chromasolv, LC-MS grade, 
Fluka, Germany) and methanol (Chromasolv, LC-MS grade, Fluka). After intense vortexing for 
30s, samples were centrifuged for 10min at 12g and 4
O
C . A volume of 500uL of the organic layer 
was then transferred to a glass vial and left to evaporate overnight in a fume hood. Extracts were 
stored at -40
O
C until analysis. 
5.2.2.2 UPLC-MS analysis 
Samples were reconstituted in 400uL of solvent mixture of H2O/ isopropanol/acetonitrile (1:2:1) 
(Optima, LC-MS grade, Fisher Scientific, USA), and transferred into Total Recovery vials (Waters, 
USA), after centrifugation for 10min at 5g and 4
O
C. 
UPLC separation was conducted using an Acquity UPLC System (Waters Corp, USA). An Acquity 
UPLC CSH C18 2.1x100mm, 1.7um, column (Waters Corp, USA) was used. Column temperature 
was set at 55
O
C, flow rate of 0.4mL/min. Injection volume of 3uL and 7uL were used for positive 
and negative ionisation mode respectively. Mobile phase A consisted of acetonitrile/water (60:40) 
and mobile phase B Isopropanol/acetonitrile (90:10). In both solutions ammonium formate (LC-MS 
grade, Fluka, USA) was diluted to 10mM and formic acid (MS grade, Fluka, USA) to 0.1%. The 
chromatographic gradient program is summarized in Table 5. 2. 
Table 5. 2: Gradient program of chromatography of the lipid profiling UPLC-MS methodology. 
Time (min) %A %B Curve 
0.0 60 40  
2.0 57 43 6 
2.1 50 50 1 
12.0 46 54 6 
12.1 30 70 1 
18.0 1 99 6 
18.1 60 40 6 
20.0 60 40 - 
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Detection of eluting UPLC fractions was achieved using a Xevo G2 QTof 
(Waters MS Technologies, UK). Both MS and MS
E
 data scans were acquired for 0.200 s every 
0.214 s. MS
E
 data were collected after ramping the collision energy from 30 to 40V. Leucine 
Enkephalin was used for lock mass correction. Lock mass data were collected every 0.3 s for 0.2 s. 
Conditions in positive mode: m/z range:150-1200, cone voltage 30V, capillary voltage 2kV, Source 
Temperature 120
O
C, Desolvation Temperature 550
O
C, Desolvation Gas 900L/h. Conditions in 
negative mode: m/z range: 50-1200, cone voltage 30V, capillary voltage 1kV, Source Temperature 
120
O
C, Desolvation Temperature 550
O
C, Desolvation Gas 900L/h. 
A QC format 
114
 was used for the UPLC-MS analysis. Briefly, a pooled sample (referred to as 
Quality Control Sample, QC) of the reconstituted extracts was prepared. This sample was re-
injected 10 times before initiating the run to condition the column of 10 injections. Then the sample 
was re-injected once at the beginning, every 10 injections of samples, and at the end of the run (total 
of 9 injections). A tight grouping of the QC samples in MVDA, and a Coefficient of Variation 
percentage (CV%) of less than 30% for candidate biomarkers 
17, 92
 formed the quality control 
criteria. 
5.2.2.3 UPLC-MS Data Processing 
After acquisition, data were centroided (m/z spectra peaks are automatically detected and their 
centroid is calculated based on the average m/z value and weighted by the intensity). A post-
acquisition calibration was conducted on negative mode data, to adjust for mass accuracy. 
Calibration was conducted using m/z of peaks with known m/z. 
This was followed by peak-picking and grouping using MarkerLynx XS (Waters Inc, v4.1) 
software, using the following parameters: 
Positive mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.40, Final 
Retention Time: 17.00, Low Mass: 150.00, High Mass: 1200.00, XIC Window 0.10 Da, Peak 
Width at 5% Height: 20s, Marker Intensity Threshold: 1000counts, Mass Window: 0.10Da, 
Retention Time Window: 0.50 
Negative mode: Function: 1, Analysis Type: Peak Detection, Initial Retention Time: 0.45, Final 
Retention Time: 17.00, Low Mass: 50.00, High Mass: 1200.00, XIC Window 0.10 Da, Peak Width 
at 5% Height: 20s, Marker Intensity Threshold: 400counts, Mass Window: 0.10Da, Retention Time 
Window: 0.50 
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For Both Modes: Noise Elimination Level: 6.00, Peak-to-peak Baseline Noise: Auto, Replicate % 
Minimum: 0.00, No relative retention time, No Smoothing, No Deisotoping. 
Values were reported as area of intensity peaks. Saturated peaks were removed, prior to total area 
normalisation. Values were multiplied by 10 000 prior to statistical analyses. 
5.2.2.4 Statistical analysis and validation  
Multivariate data analysis (MVDA) for UPLC-MS data was conducted using the SIMCA-P+ (v. 
12.0.1.0.; Umetrics) package. Principal Component Analysis (PCA) and Orthogonal Projection to 
Latent Structures – Discriminant Analysis (OPLS-DA) were applied to the processed Pareto-scaled 
data. Model validation was carried out using CV-ANOVA testing 
142
 and permutation (n=999) 
testing. Permutation testing is the process of deliberately randomizing the sample labelling such that 
the class descriptor has no meaning and recalculating their predictive values. Randomly classified 
models should demonstrate predictive values that are lower than those derived from the actual 
model using correct classifiers. 
In order to extract putative biomarkers from UPLC-MS, features (corresponding to metabolites) 
with correlation coefficient (Note: correlation coefficients that refer to correlation of samples to 
disease classes will be refer to as: p(corr)) greater than 0.5 in absolute value were initially chosen. 
This cut-off provides confidence greater than 99%. These features were further subjected to two-
tailed t-test assuming unequal variance with a threshold of p<0.05
143, 144
 and fold-change 
comparison. Features were reported as significant and structurally identified if: 1) both p(corr) and 
t-test p-value met the thresholds , 2) were reproducible through the run, with a coefficient of 
variation (CV%) of the QCs less than 30%, and 3) pass the chromatographic peak shape 
assessment. 
For structural elucidation of significant features UPLC-MS
E
 and UPLC-MS/MS data were used. 
MS
E
 data were collected through the run as described for the UPLC-MS analysis. These conditions 
were the ones used for MS/MS data additional analysis that was conducted using data dependent 
acquisition (DDA) or by targeting specific ions. MS/MS data were collected with collision energy 
ramping from 30 - 50V. Apart from fragmentation patterns, structural elucidation was assisted by 
matching accurate m/z measurements to metabolites from online available databases
111, 116, 139
. In 
some cases isotopic patterns also proved useful. 
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5.2.2.5 Structural Identification of signals discriminating controls from case detected in 
UPLC-MS 
For structural elucidation of significant features UPLC-MS
E
 and UPLC-MS/MS data were used. 
MS
E
 data were collected through the run as described for the UPLC-MS analysis. These conditions 
were the ones used for MS/MS data additional analysis that was conducted using data dependent 
acquisition (DDA) or by targeting specific ions. MS/MS data were collected with collision energy 
ramping from 30 - 50V. Apart from fragmentation patterns, structural elucidation was assisted by 
matching accurate m/z measurements to metabolites from online available databases
111, 116, 139
. In 
some cases isotopic patterns also proved useful. 
5.2.3 1H NMR spectral acquisition 
5.2.3.1 Sample preparation 
An aliquot of 350μL of serum was diluted in 350ul of phosphate buffer. Phosphate buffer (pH=7.4) 
was prepared by dissolving 4.56g of NaH2PO4 and 43.46g of Na2HPO4 per litre of D2O. A total of 
600μL of the diluted serum was transferred into a 5mm outer diameter NMR tubes.  
5.2.3.2 Standard one-dimensional spectra acquisition 
1
H NMR spectra of serum samples were acquired on a 600MHz Bruker Avance spectrometer 
(Bruker Biospin, Rheinstetten, Germany) operating at 600.13 MHz and a temperature of 300K, 
using a standard 1D pulse sequence (recycle delay (RD)-90
o
-t1-90
o
-tm-90
o
-acquire free induction 
decay(FID)) with water suppression applied during RD of 2 s and mixing time (tm) of 100 ms. The 
90
o
 pulse was set at 16.75 μs, with a power level of 1.0 dB. Spectra were acquired using 256 scans 
into 64K data points with a spectral width of 20 ppm. The FIDs were multiplied by an exponential 
function corresponding to 0.3 Hz line broadening before applying Fourier transformation. 
5.2.3.3 NMR Data processing 
Spectra were subjected to automatic phasing, calibration to the β-anomeric glucose peak (δ 5.233), 
and background correction, using an in-house developed software. Bin size was set at δ 0.0003364. 
Spectra from δ -0.6 - 10.0 excluding the region containing the residual water signal (δ 4.700 - 
4.895) were subjected to global alignment and median fold change normalisation
183
 using an in-
house algorithm. 
5.2.3.4 Statistical analysis and cross-validation of NMR data  
MVDA for NMR data was conducted using Matlab programming language (R2011a) and in-house 
developed code. PCA and OPLS-DA were applied on the processed data. In all MVDA scaling to 
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unit variance was applied. For model validation permutation testing was applied (n=10000). 
Features with p(corr) greater than 0.5 in absolute value (>99% confidence) were considered 
significant. These features were subjected to further analysis using univariate statistics, which were 
conducted on the corresponding integrated peaks, instead of bin intensity. Univariate statistics 
consisted of two-tailed t-test (assuming unequal variance) with a threshold of p<0.05
143, 144
, and 
fold-change comparison. Features were reported as significant if both p(corr) and t-test p-value met 
the thresholds and forwarded for identification. Identification of statistically significant features was 
based on two-dimensional (2D) NMR correlation experiments of a pooled sample
14
, internal 
184
 and 
online databases
116
. 
5.2.4 Pathway Analysis 
5.2.4.1 Correlation and Network analysis 
Correlation coefficients (Spearman) between pairs of candidate biomarkers were calculated using R 
(2.13.2) programming language (Note: Correlation coefficients that express the Spearman 
correlation between two metabolites will be referred to as: r). For network visualization, of 
significant metabolites characterizing disease, CytoScape v.2.8.3 software was used. A correlation 
of r=0.5 and 0.4 in absolute values was used for calcific coronary artery disease (CCAD) and 
calcific aortic valve disease (CAVD), respectively, when constructing the inference pathways. In 
both cases, the cut-off for correlation was higher that 99% confidence. However, for CCAD the cut-
off was raised as the network was too complex to interpret based on the number of significant 
features detected.  
5.2.4.2 Metabolite Mapping to Key Pathways 
Metabolite mapping to pathways was manually conducted. Pathway information was retrieved from 
KEGG database 
23, 24
, and relevant literature (see Discussion). 
5.3 Results 
5.3.1 Metabolic characterization of calcific coronary artery disease (CCAD) 
The NMR analysis did not provide strong biomarkers through either MVDA or univariate analyses. 
Preliminary MVDA of the UPLC-MS data suggested there were three basic groups within the data. 
Accordingly CCAD samples were divided into three classes of CS of zero (No Calcification, NC), 
1-250 (Mild Calcification, MC), and over 250 (Severe Calcification, SC). A UPLC-MS 
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chromatogram and NMR spectrum of pooled sample can be found at Figure 5. 1 and Figure 5. 2, 
respectively. 
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Figure 5. 1: A representative chromatogram obtained from the positive mode analysis. The chromatogram was generated from a quality control (pooled) sample of organic extracts 
of blood serum. Red colour represents the total ion current, while the green colour represents base peak intensities, showing the most intense peaks in each retention time window. 
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Figure 5. 2: A representative spectrum obtained from the 
1
H NMR analysis of a pooled serum sample. Insert represents an expansion of 2.8 – 4.8 ppm. H2O peak at 4.700 - 4.895 
ppm has been removed from the spectrum and subsequent analysis. 
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For UPLC-MS analysis of the organic extracts of the serum samples, it can be easily observed with 
PCA analysis (unsupervised) scores plots, that better grouping could be accomplished when the two 
extreme classes (NC and SC) were compared (Figure 5. 3B). The intermediate class (MC) was 
scattered throughout both extreme groups (Figure 5. 3A). Additionally, in OPLS-DA analysis 
(supervised) valid and validated models were only observed when comparing samples from the NC 
class to the SC class  (Figure 5. 4 A, B and Figure 5. 5A, B). A model using one predictive 
component was found to be significant. Model characteristics are summarized in Table 2. The 
dataset acquired in negative ionization mode gave models with better predictive value (Q
2
Y). 
Multivariate Statistics found no statistically significant differences between NC and MC classes. 
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Figure 5. 3: Scores plots of principal component analysis (PCA). Data for the analysis were derived from UPLC-MS of organic extracts, of serum samples. (A) Positive mode PCA 
of NC, MC and SC classes, (B) positive mode PCA conducted only on NC and SC classes. (C) Negative Mode PCA of NC, MC and SC classes, (B) negative mode PCA applied only 
with NC and SC classes. (Each point represents a sample; Blue rhombus: No Calcification (NC), Black square: Mild calcification - calcific coronary artery disease (MC), Red dot: 
Severe calcification - calcific coronary artery disease SC). 
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Figure 5. 4: OPLS-DA scores plots; (A-D) derived from UPLS-MS of organic extracts, and (E) from 
1
H NMR analyses 
of serum samples. UPLC-MS positive mode (A), and negative mode (B) of no calcification versus severe calcification 
(calcific coronary artery disease) class. UPLC-MS positive mode (C), and negative mode (D) of no calcification versus 
calcific aortic valve disease class. Cross-validates scores (tcv) plots can be found in Supplementary data Figure S3. 
(Each point represents a sample; Blue rhombus: No Calcification, Red dot: Severe calcification - calcific coronary 
artery disease, Green triangle: Calcific aortic valve disease). 
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Figure 5. 5: Cross-validated OPLS-DA scores plots. (A-D) were derived from UPLS-MS of organic extracts, and (E) 
from 
1
H NMR analyses of serum samples. UPLC-MS positive mode (A), and negative mode (B) of no calcification 
versus severe calcification (calcific coronary artery disease) class. UPLC-MS positive mode (C), and negative mode 
(D) of no calcification versus calcific aortic valve disease class. (Each point represents a sample; Blue rhombus: No 
Calcification, Red dot: Severe calcification - calcific coronary artery disease, Green triangle: Calcific aortic valve 
disease). 
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Table 5. 3: Summary of model characteristics from (unsupervised; OPLS-DA and PLS-DA) multivariate statistical analyses of data obtained from serum samples.  
 
OPLS-DA 
   
 
 
 PLS-DA  
Group 
comparison NC vs SC NC vs SC 
NC vs 
CAVD 
NC vs 
CAVD 
NC vs 
CAVD 
SC vs 
CAVD 
SC vs 
CAVD 
NC vs SC 
vs CAVD 
NC vs SC 
vs CAVD 
Mode, 
No of Comp 
POS, 
1 Comp 
NEG, 
1 Comp 
POS, 
1 Comp 
NEG, 
1 Comp 
1
H NMR, 
1+2 Comp 
POS, 
1 Comp 
NEG, 
1 Comp 
Pos, 
2 Comp 
Neg, 
2 Comp 
R
2
X(cum) 0.175 0.140 0.106 0.107 0.393 0.183 0.106 0.251 0.190 
R
2
Y(cum) 0.396 0.513 0.540 0.714 0.881 0.509 0.760 0.395 0.565 
Q
2
Y(cum) 0.168 0.303 0.121 0.373 0.455 0.222 0.480 0.116 0.321 
CV-ANOVA 0.025139 0.000736 0.126912 0.000572 n/a 0.055402 0.000546 0.297803 0.000283 
Permutation 
Testing 
0.005005 < 0.001001 0.031031 < 0.001001 0.000500 0.0190190 < 0.001001 0.005005 < 0.001001 
Robustness of the models was characterized using the following model parameters: R
2
X, variation of the X-matrix (data) explained by the model; R
2
Y, 
predicted percentage; and, Q
2
Y cross-validated predicted percentage. 
Cross-validation parameters are also demonstrated. These parameters show the validity of the models and the likelihood of overfitting. 
Pos and Neg refer to positive and negative polarity. Comp is the number of validated principal components. 
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A global reduction of the sphingomyelin (SM) lipids in the diseased class was observed with high 
statistical significance (NC vs SC). This class of lipids did not show statistical significance, from t-
test comparison, of NC against MC. In contrast, a comparison between MC and SC showed that 
SMs were significantly different in these two classes (Table 5. 4 and Figure 5. 6). 
A number of phosphatidylcholine (PC) moieties appeared to be dysregulated. In contrast to the 
observation of SM behaviour, PCs did not follow a global trend. PC(16:0/20:4) was detected in 
higher intensities in the SC diseased class, while PC(18:2/18:0), PC (O-16:1/18:2), PC(15:0/18:2), 
PC(18:2/18:2) and PC(16:0/18:3) showed a reduction in the SC class compared to the NC group 
with t-test statistical significance of p< 0.05. PCs were the only lipid class that showed a statistical 
trend through univariate statistics for NC vs MC classes. Although not highly significant, the fact 
that such a trend is observed only with PCs, and follows the same pattern (Figure 5. 6) for each 
individual PC as with the SC class is noteworthy. The t-test p-values were as follows: 
PC(16:0/20:4): p=0.0238; PC(18:0/20:4): p=0.0902; PC(16:0/18:3): p=0.0566; PC(18:2/18:2): 
p=0.0743. 
More biomarker lipid classes found to be discriminatory between NC and SC included triglycerides 
(TGs), with TG(16:0/18:1/22:5) and TG(18:1/18:1/20:4) being higher. These two lipids coelute and 
have the same m/z value. Therefore, further analysis is needed to assess if one is more significant 
over the other. TG(16:0/18:1/18:1) was also found in higher intensities in but barely met 
significance criteria (Table 5. 4). Lastly, lysoPC(20:4) and serum concentrations of 
phosphatidylinositol(18:2/18:0) (phosphatidylinositol, PI) were also found to be higher and lower, 
respectively, in the disease class. 
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Figure 5. 6 (part 1): Box-plots of all metabolites found to be statistically different in any of the comparisons between all 
classes, in both UPLC-MS and NMR analysis. Metabolites are presented in alphabetical order. The analytical platform 
from where the metabolite was detected is designated (Pos: Positive mode UPLC-MS; Neg: Negative mode UPLC-MS). 
Each box represents one class: Blue: No Calcification (NC), Black: Mild calcification - calcific coronary artery disease 
(MC-CCAD), Red: Severe calcification - calcific coronary artery disease SC-CCAD, Green: Calcific aortic valve 
disease (CAVD), Grey: Quality controls (QC). 
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Figure 5. 6 (part 2): Box-plots of all metabolites found to be statistically different in any of the comparisons between 
classes, in both UPLC-MS and NMR analysis. Metabolites are presented in alphabetical order. The analytical platform 
from where the metabolite was detected is designated (Pos: Positive mode UPLC-MS; Neg: Negative mode UPLC-MS). 
Each box represents one class: Blue: No Calcification (NC), Black: Mild calcification - calcific coronary artery disease 
(MC-CCAD), Red: Severe calcification - calcific coronary artery disease SC-CCAD, Green: Calcific aortic valve 
disease (CAVD), Grey: Quality controls (QC). 
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5.3.2 Metabolic characterization of calcific aortic valve disease (CAVD) 
For the CAVD class, patients with a CS known to be <200, were excluded. OPLS-DA generated 
good models for the NMR and UPLC-MS negative mode data sets (Table 5. 3). Similarly to the 
comparison between SC and NC (CCAD), positive polarity UPLC-MS analysis did not show as 
high predictive value, although models were valid. In UPLC-MS analysis, OPLS-DA of both 
positive and negative mode showed only one component to be significant with no orthogonal 
components indicating that the disease class accounted for the main source of variation in the data. 
OPLS-DA models can be found in Figure 5. 4 C-E and Figure 5. 5 C-E for cross-validated models. 
As with CCAD, PCs showed a mixed trend of dysregulation in the two classes with some PCs in 
higher and others with lower intensities in the disease group(Table 5. 5). Only two SM moieties 
were found to be dysregulated, and with a mixed trend. The intensity of the peak corresponding to 
SM(d18:1/24:1) was higher with a t-test p-value of 0.0299, while SM(d18:1/22:0) was found to be 
lower in the disease class with p-value of 0.0004. Additionally, a metabolite that could not be 
assigned (UKN) and citrate were higher in the disease class. Citrate was detected from NMR 
analysis, where a good model was observed with OPLS-DA from the comparison between NC and 
CAVD. The model possesses good predictive value and was well validated using permutation 
testing (Table 5. 3). Citrate peaks had the highest p(corr) and above the threshold Table 5. 5 and 
Figure 5. 7). Citrate was detected from a characteristic chemical shift of the two groups of CH2- 
hydrogens in the standard one dimensional NMR spectra
184
 and the COSY experiment (Figure 5. 8). 
T-test was applied on all four peaks of the citrate signal after integration (Table 5. 5). 
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Figure 5. 7:Plot derived from OPLS-DA of NMR analysis of serum samples of the comparison of CAVD to the control group. Colouring of NMR peaks indicates correlation to the 
disease p(corr). Apart from citrate, choline is also demonstrating a correlation to class but did not pass the threshold criteria. 
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Figure 5. 8: 2D 
1
H-
1
H COSY NMR spectra demonstrating the correlated peaks of citrate.  
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5.3.3 Comparison of serum metabolite profiles from calcific coronary artery 
disease and calcific aortic valve disease patients. 
In order to establish whether the markers of coronary disease are general or whether CAVD and 
CCAD indeed have different mechanisms, a direct comparison between the two disease classes was 
carried out. Features can become statistically significant when two classes are compared directly. 
MVDA comparing between the two disease classes (SC vs CAVD) revealed different profiles for 
each disease (Figure 5. 9 and Table 5. 3).  
Table 5. 6 summarises metabolites found to be significantly different between the two disease 
groups. An interesting addition to the candidate biomarkers identified from the comparison of a 
single disease group with control is a differential PI moiety PI(18:0/20:4), which was detected in 
lower intensities in CAVD. PC(16:0/20:4), PC(18:0/20:4) and PC(18:0/22:4) were also lower in 
CAVD, as compared to the SC class. On the other hand, six SMs (with p-values ranging between 
0.0001 to 0.04), and PC(15:0/18:2), PC(16:0/16:0) and PC(16:0/18:2) were lower in the SC class. 
The only noticeable similarity between the two diseases was two PCs, PC(18:2/18:0) and 
PC(18:2/18:2), and SM(d18:1/22:0). 
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Figure 5. 9: OPLS-DA scores plots from comparison of calcific coronary artery disease and calcific aortic valve disease. (A and B) Plots derived from UPLS-MS of organic extracts 
in positive and negative mode, respectively. (C and D) The corresponding cross-validated scores plots from positive and negative mode, respectively. (Each point represents a 
sample: Green triangle: Calcific aortic valve disease; Red dot: Severe calcification - calcific coronary artery disease). 
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Additionally, valid models via PLS-DA analysis showed good grouping of the three classes tested 
(NC, SC, CAVD) (Figure 5. 10 A and B) with the UPLC-MS data. Model characteristics can be 
found in Table 5. 3. Again, the negative mode models showed superior predictive value. Loadings 
plots (Figure 5. 10 C and D) can informatively show the metabolites responsible for the separation 
of each of the three classes (Table 5. 7). It was also noticed that metabolites that were not 
statistically significant when comparing either of the disease classes, SC or CAVD, to the NC class, 
appeared driving the models. A good example is the three TGs, and the two PEs, which can be seen 
in positive and negative mode loadings plots respectively (Figure 5. 10 C and D). 
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Figure 5. 10: PLS-DA analysis of UPLS-MS of organic extracts of serum samples. (A) Scores plots and (C) loadings plots from positive mode. (B) Scores plots and (D) loadings 
plots from negative mode analysis. For A and B, each point represents a sample; Blue rhombus: No Calcification, Red dot: Severe calcification - calcific coronary artery disease, 
Green triangle: Calcific aortic valve disease. For C and D, each point represents a feature included in the analysis, whereas a feature is circled in brown colour the identity of the 
metabolite is demonstrated, while green circle represents features that have been identified to be isotopes, adducts, or fragments of metabolites already assigned in the figure, or 
artefacts. 
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5.4 Discussion 
This is the first metabonomic approach to be applied in calcific disease. Most of the detected 
metabolites and lipid classes are presented here for the first time for cardiovascular calcification. 
Metabolite dysregulation was specific to particular FACs. Although specific FACs in the form of 
fatty acids have been implicated before in calcification
185, 186
, this is the first study to provide 
evidence of extensive dysregulation in a range of FACs. Additionally, a number of FAC are 
reported to be involved in the mechanism of disease for the first time. More importantly, the panels 
of metabolites differentiating CCAD and CAVD from control samples were different in each of the 
two diseases studied. Evidence supporting apoptosis, such as SM reduction, was only present in 
CCAD. Lastly, from present findings Ca
2+
 channel and TCA cycle intermediates also appear to be 
dysregulated. 
5.4.1 Metabolic characterization of calcific coronary artery disease (CCAD) 
From all the lipid classes found to be discriminatory, SMs were the most statistically significant. 
SMs are found in the epithelial cell (EC) membrane in high concentrations. The lower level of all 
significant discriminatory SMs in the SC class, along with their apparent high r between each other, 
is consistent with dysregulation of their common enzyme Sphingomyelinase. This potentially 
implicates the ceramide pathway, a pathway well known for involvement in signalling pathways of 
inflammation and apoptosis
43
. It has been suggested that apoptosis is a potential mechanism of 
calcification
181, 182
. However, these consistent lower levels of SMs were observed in the SC class 
only. In fact, a comparison of the levels of SMs between the SC and MC class, proved to be 
statistically different (Table 5. 4). This suggests that their use as biomarkers may only apply to later 
stage disease. This could mean that apoptosis contributes to the mechanism of the calcification 
process at a later stage, or otherwise affects severely calcified lesions. Although the SMs may 
implicate the ceramide pathway in CCAD, ceramides themselves were not detected as candidate 
marker. This is not surprising given the low abundance of ceramides in the blood. Ceramides do not 
have a polar head-group and are therefore not found in the blood in concentrations of the magnitude 
of SMs. Molecular concentration of ceramides, compared to SMs, has been reported to be 30 times 
less
40
. From studies conducted in atherosclerotic tissue (Chapter 4), it was observed that the 
reduction of SMs was accompanied with an elevation in ceramides, validating the assumption that 
Sphingomyelinase is the likely enzyme responsible for this biological finding. 
One of the most interesting perturbed lipid classes in the CCAD is that of PCs. PCs are major 
constituents of the cell membrane, and are involved in metabolism and signalling. Although several 
lipids were statistically different between CCAD and controls, PCs were the only molecules to 
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show some sort of trend towards differentiating the intermediate (MC) class from controls, and 
therefore may have potential relevance as biomarkers at an early diagnosis. Based on the group size 
in the current study (n=70), this observation would require further validation in future population 
studies to establish the utility of this set of PCs as early calcification markers. Nonetheless, this 
observation could provide important information when it comes to dysregulated biological 
mechanisms of disease manifestation. The PCs did not follow a global trend, rather than a trend 
being affected by the characteristics of the FAC. As will be discussed in the following paragraphs, 
PCs essentially function as fatty acid carriers, thus it could be inferred that FAC, and fatty acids, 
play an important role in CCAD.  
Prior to establishing a mechanistic explanation for disease manifestation, the possibility that some 
of the discriminating molecules may reflect confounding factors such as diet or lifestyle rather than 
the direct aetiology of the underlying disease must be considered. Additionally, trends in the plasma 
lipidome have been previously shown to be due to BMI, diabetes or hypertension status
39
. As can be 
seen in the patients‘ characteristics table (Table 5. 1), an effort to match the groups in these aspects 
was also conducted, although perfect matching of the disease and control groups was not possible. 
Initial focus was given to explaining the dysregulation of the PCs. A schematic representation of a 
hypothesis derived from the results can be found in Figure 5. 11. Levels of PC(16:0/20:4) were 
higher in the disease class, in combination with a reduction in 18-carbon fatty acyl chain (FAC) 
PCs. These molecules can release arachidonic acid (AA) through hydrolysis of their ester bonds. 
Arachidonic acid can be released directly, in the case of PC(16:0/20:4)
43
, while for the rest of the 
PCs, AA can be produced after hydrolysis and free fatty acid (FFA) elongation 
23, 24
. A well known 
enzyme that can hydrolyse the sn-2 bond of PCs is Phospholipase A(2) (PLA2)
187
. A group of IVA 
PLA2 enzymes is specific for only AA hydrolysis from ester bonds
187
 which can explain the 
different trend to rest of PCs. Of note, PIs also function as donors of FACs (again through PLA2 
enzyme catalysis), and could also be mechanistically implicated as such
187
. Downstream of AA lays 
the network of eicosanoids, well known for their involvement in inflammation. 
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Figure 5. 11: Pathway analysis networks. Schemes (A) and (B) represent networks constructed using Spearman correlation coefficients (r) of candidate biomarkers of calcific 
coronary artery and calcific aortic valve disease respectively. Circles (nodes) are labelled according to the metabolite they represent. Lines’ (edges) colours represent positive (red) 
or negative (blue) correlation. Thickness of the edge represents increase in absolute value. (C) Pathway assembled using candidate biomarkers and literature information. Black 
arrows represent direction of canonical metabolism; green arrows represent direction of equilibrium shifting due to disease. Blue and red arrows represent reduction or increase of 
metabolite level. Solid arrows represent direct reactions, and dashed indirect. Orange boxes represent detected metabolites. PC: Phosphatidylcholine, SM: Sphingomyelin, TG: 
Triglyceride, PI: Phosphatidylinositol, AA: Arachidonic Acid, LA: Linoleic Acid, LNA: Linolenic Acid, SA: Stearic Acid, PAF: Platelet-Activating Factor and PLA: Phospholipase 
A. Note that position of double bonds cannot be determined. 
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According to this hypothesis PCs and PIs containing 18-carbon chains should be found in lower 
intensities in the disease class as they are transformed into AA through the fatty acid elongation 
pathway. There are actually four 18-carbon containing PCs and PI(18:2/18:0) that were found to be 
present in lower intensities in the SC class. This hypothesis is consistent with the fact that there are 
enzymes specific to the hydrolysis of only linoleic acyl-containing ester bonds (such as the group 
IVD of PLA2)
187
. A trend was also observed with PC(16:0/18:2), which was detected with lower 
intensity in the disease group. This PC presented a p(corr) of -0.63, but did not meet the t-test 
threshold, with p=0.16. 
On the other hand, an otherwise normal pathway of AA release, by hydrolysis of the 20:4 FAC of 
the corresponding PC, will move the equilibrium to compensate with this increase in AA. This will 
cause an increase in the corresponding PC. As mentioned levels of PC(16:0/20:4) were higher. The 
PC(18:0/20:4) also presented the same trend but again did not meet the t-test threshold of 0.05 
(p(corr)=0.68, p-value=0.08). The mechanistic rationale can also be supported by the high negative 
r of PC(16:0/20:4) to other PCs (Figure 5. 11A and Figure 5. 12). Moreover, lysoPC(20:4) and 20:4 
FAC containing TG were also detected in higher intensities in the disease group.  
 232 
 
 
 
Figure 5. 12: A heatmap representation of the correlation matrices obtained from Spearman correlations. (A) The calcific coronary artery disease candidate biomarkers correlation 
matrix, with all three groups included in the analysis, and (B) the calcific aortic valve disease candidate biomarkers correlation matrix. Intensity of red colour represents positive 
correlation and intensity of blue represents negative correlation of the biomarker pair. 
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A product of PC hydrolysis is a lysoPC with the remaining FAC as a FFA. It has been previously 
shown by Chaudhuri et al, that an increase of intracellular Ca
2+
 can be induced by lysoPCs 
(lysoPC(16:0) was used for those experiments)
188
. This mechanism also appears to cause 
upregulated expression of Calpain 
188
. Calpain is involved in apoptotic pathways
139
. Additionally, 
authors show inhibition of EC migration, a mechanism of repair of the vessel wall, with lysoPC 
increase. 
Another important molecule implicated in inflammation is the Platelet Activating Factor (PAF). 
PAF is produced by acetylation of the free position of ether-linked lysoPCs. One of the PCs found 
to be present in lower concentrations in the SC class was PC(18:2/O-16:1). This reduction infers a 
production of lysoPC(O-16:1) which is the direct precursor of PAF or PC(P-16:0/2:0). 
Ideally, in addition to deriving mechanistic information from this study, it would be essential to 
explore the utility of the CCAD discriminating metabolites as biomarkers. Present findings come 
from blood samples, which is a minimal invasive and highly accessible matrix. Additionally, 
individuals at risk of cardiovascular diseases are subjected to routine blood test for related markers. 
Therefore, collection of samples could be tied into existing protocols. Overall statistical models 
from MVDA gave good predictive values (Table 5. 3). The high statistical power of SMs in 
differentiating CCAD from control is obvious, with p-values as low as 0.000001. Some of the PCs 
were also significant in discriminating case from control with p-values starting at 0.001. Although 
the PCs are not such strong candidate biomarkers as the SMs for differentiating CCAD, the 
statistical trend found for PCs, to discriminate between the NC and MC class is important as it 
carries the potential of early diagnosis and currently further samples in order to validate this 
observation are collected. 
5.4.2 Metabolic characterization of calcific aortic valve disease 
A smaller number of statistically significant molecules were detected for CAVD, which made the 
elucidation of disease-specific mechanisms difficult, as information was limited. A mixed trend in 
levels of PCs was observed. PCs with 18:0 and 18:2 FACs were found in lower levels in the serum 
of CAVD patients. Interestingly, two PCs with a 20:3 FAC were also found in lower intensities in 
the CAVD class. The higher levels of the PC(16:0/22:6) may have mechanistic significance and 
maybe able to assist in connecting some of the other disease related findings. The mechanism could 
be similar to the one proposed for CCAD (Figure 5. 11C), i.e. in the disease state, enzymes release 
FACs (in this case 20:3, 18:2 and 18:0), which are elongated causing elevation FAC of healthy 
pathways (in this case 22:6 bearing PC) as a response to maintain equilibrium. This is further 
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supported by the correlation analysis and network (Figure 5. 11C and Figure 5. 12), where 
PC(16:0/22:6) is found to be highly and inversely correlated to the metabolites found to be in lower 
levels in the CAVD class. Additionally, a low r=0.20 was found between PC(16:0/16:0) and 
PC(16:0/22:6). This further excludes the possibility of the 16:0 FAC being involved rather than 
22:6. The class of inflammation-related molecules of docosanoids is derived from the 22:6 fatty 
acid and thus higher levels of lipid moieties with a 22:6 FAC could implicate this group of 
molecules in the pathophysiology of the disease. 
From the preceding paragraph it becomes obvious that in CAVD fatty acid metabolism is, as with 
CCAD, dysregulated. However, different FACs are involved in this case. The significance of the 
different involvement of FACs may lie in the metabolism of unsaturated fatty acids. In the case of 
the metabolism of the n-3 family of unsaturated fatty acids, enzymes that can metabolise chains that 
have up to six double bonds are commonly involved. On the contrary, in the metabolism of the n-6 
family of unsaturated FFAs, only production of FFAs bearing up to five double-bonds is possible
23, 
24
. Unfortunately, this analytical MS format is inadequate in providing information concerning the 
location of the double bonds. 
The elevation of citric acid, a product of the tricarboxylic acid cycle (TCA cycle), is also 
mechanistically intriguing. It is produced after donation of an acetyl group from acetyl-CoA to 
oxaloacetic acid. The TCA cycle is an integral step in the degradation of a number of metabolites 
and processes, such as glycolysis, gluconeogenesis, fatty acid/ phenylpropanoid/ terpenoid/ steroid/ 
BCAA biosynthesis and degradation. From the correlation analysis of the candidate biomarkers, the 
metabolite most highly correlated with citrate was PC(18:2/18:0) (r= -0.426), which may indicate 
that the altered levels of citrate in CAVD may be associated with perturbation in FFA metabolism. 
Reduction of inorganic pyrophosphate (PPi)
60, 181
 and elevation of the Reactive Oxygen Species 
(ROS)
181
 are known to be inducing osteoblastic phenotype, and are affected by dysregulations in the 
TCA cycle.  
Despite the small numbers of patients in the CAVD disease group, the MVDA models were valid, 
as evidenced by model diagnostics (Table 5. 3) and generated a series of potential biomarkers with 
good t-test p-values, which would be good candidates for further validation (Table 5. 5). Again, a 
number of PCs showed statistical significance, with PC(16:0/22:6) correlation to the disease group 
with p(corr)=0.8 and a p=0.009. Although the most significant metabolite was found to be 
SM(d18:1/22:0) (p-value=0.0004), the fact that it is the only SM with a lower levels in the disease 
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class, and the presence of another SM with the opposite trend, is worrying. This could mean that 
apoptotic pathways are not implicated in the calcification process of the aortic valve. 
5.4.3 Comparison of serum metabolite profiles from calcific coronary artery 
disease and calcific aortic valve disease patients. 
A comparison between the two groups is very interesting as it can provide evidence of differences 
between seemingly analogous disease phenotypes and help in answering the question as to whether 
these two conditions are mechanistically distinct. When directly compared, the two different classes 
of patients demonstrated systematic metabolic differences. The two disease groups essentially 
showed a different profile (). Lower serum levels of SM were apparent in CCAD patients but not in 
samples from CAVD patients, and this constitutes a major difference between the two groups. 
Additionally, two PCs and a PI constituted of a 20:4 chain were amongst the lipids detected to be 
higher in the CCAD, but not CAVD, further supporting the involvement of eicosanoids only in 
CCAD. The two PCs, PC(18:2/18:0) and PC(18:2/18:2), were the only similarities between the two 
groups (Figure 5. 13), and as stated the release of 18-carbon FACs is considered by present findings 
to play a key role to the initiation of both diseases, by activation of their Phospholipase A enzyme. 
 
Figure 5. 13: Venn diagram indicating identical metabolites detected statistically significant in separate comparisons 
between CCAD serum samples and CAVD serum samples to controls. Metabolites detected with the same trend in both 
analyses are indicated.  
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PLS-DA analysis of the two disease groups and the control class in the same model demonstrated 
some very interesting results. All assigned metabolites can be found in Table 5. 7. Starting with the 
PC lipid class, which showed mixed trends, the loadings plots of the PLS-DA analysis showed that 
PCs bearing the same acyl chain behave similarly. This becomes evident by their proximity in the 
loadings plots (Figure 5. 10 C and D). Some examples of PCs bearing the same FACs are, the 
PC(18:2/18:0) and PC(18:2/18:2), PC(16:0/20:4) and PC(18:0/20:4), PC(16:0/20:3) and 
PC(18:0/20:3). At the same time, their mixed trends are also demonstrated by their appearance in 
multiple and opposite directions of the plots. 
Similarities in FAC behaviour were observed in other lipid classes, namely PE(16:0/22:6) and 
PE(18:0/22:6), and TG(16:0/18:1/18:1), TG(16:0/18:1/18:2) and TG(16:0/16:1/18:1). These 
observations suggest that FACs are important in characterising calcific disease and that these FACs 
are differentially dysregulated between CCAD and CAVD. 
5.4.4 Evidence of Calcium involvement 
Ca
2+
 signalling is crucial in normal and pathological conditions. For both calcification diseases 
studied here, evidence is consistent with Ca
2+ 
signalling dysfunction. Phosphatidylinositols (PIs) are 
intermediate products towards the production of inositol-triphosphate (IP3), known for its role in 
calcium channels, as increase of IP3 can induce the export of Ca
2+
 from endoplasmic reticulum
43
. In 
this study, PI(18:2/18:0) was detected in lower levels, in the SC class compared to the control (NC) 
class.  
As previously mentioned, lysoPCs can increase the amount of Ca
2+
 in the cell. One part of this 
hypothesis is that increase amounts of Ca
2+
 in the cell might be causing a process known as 
mitochondrial calcium overload, and the effect of this is cell death. Signals of cell death do not 
point to the same pathway of cell death for both CCAD and CAVD disease. CCAD cell death is 
suggested via apoptosis inferred by the lower levels of SM in the diseased class. In the case of 
CAVD evidence of apoptosis are not present, but other means of cell death may be involved, such 
as necrosis. Apoptotic or necrotic cells can release amongst other factors, Ca
2+
 and inorganic 
phosphate. The increase of these factors in the microenvironment of the cells in the area could be 
the signal initialising the osteoblastic phenotype
57, 60, 181
 inducing the ectopic calcification 
phenotype. Matrix vesicles from apoptotic or necrotic cells are known for their ability to function as 
the initial site of calcification
182
.  
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Citrate has the ability to bind and form a complex with Ca
2+
. In this context, the elevation of citrate 
may have an effect on calcium homeostasis. If this is indeed the case, citrate could be produced as a 
response in order to reduce the free active form of Ca
2+
. 
 
5.4.5 Correlation and Network analysis 
Technologies that can produce a tremendous amount of data can assist in the effort of the scientific 
community to escape the reductionist approach to attain a more global, systemic level of 
understanding of physiological and pathological processes. However, such technologies typically 
generate vast amounts of data that require systematic mathematical analysis with subsequent 
linkage to biological networks to facilitate interpretation, and the amount of data can be 
overwhelming. Network analysis can provide information on a system as a whole and represent the 
molecular complexity of disease
189
. In the current study, correlation analysis was applied to 
metabolites that were found to be statistically different between case and control for each of the two 
diseases or between CCAD and CAVD in order to infer connections between metabolites in the 
network, and subsequently to the analysed system. High correlation values (r) between detected 
candidate biomarkers that are known to operate in the same or associated metabolic pathways can 
also provide more confidence to the analysis. 
 Lipid networks can interact significantly due to their common downstream targets and enzymes 
43
. 
Network analysis from this study extracted associations between several biologically connected 
molecules and, despite the overwhelming appearance of such a network, was useful in identifying 
differential pathways implicated in CCAD and CAVD. Firstly, the global trend of the SMs was 
verified with high correlations between them (Figure 5. 11A and Figure 5. 12). Also, known 
biological interactions, from reference pathways, verified results, e.g. the connection between TGs, 
lyso-PCs and PCs. Other interesting findings are the inverse correlation between 20:3 and 22:6 FA 
PCs, and between 20:4 and 18 carbon FAC PCs. This might be suggestive of competing pathways. 
Lastly, although it is know that PIs and PCs can share common enzymes for ester bond hydrolysis, 
the correlation between them in this dataset was quite low. As can be seen from Figure 5. 11A 
PI(18:2/18:0) is quite excluded from the PC sub-network. This may suggest, as previously 
mentioned, involvement in other pathways, such as Ca
2+
 signalling
43
. A closer look can also show 
that the highest r (r=0.58) of PI(18:2/18:0) is with PC(18:2/18:2) and second highest (r=0.40) is 
with PC(18:2/18:0), most likely due to enzyme specificity to the FAC. These are just some 
examples of enhanced capacity for data interpretation by use of correlation networks when it comes 
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to rationalising findings from lipid profiling studies, as reference biochemical pathways can run 
short on providing adequate mapping of these metabolites. 
Correlation analyses have also assisted in validating the structural assignments of metabolites. One 
example is the connection of SM(d17:1/16:0) to PC(15:0/18:2) with high correlation value (r=0.63). 
SMs with 17:1 backbone are found in trace concentrations in humans. However, evidence provided 
by tandem MS supports this finding. The high r to a 15:0-acyl PC could signify the de novo 
synthesis of a 17:1 backbone SM from a 15:0 FAC and serine, to the corresponding ceramide. 
Ceramides are the direct precursors and SM. 
For the CCAD, the calcium score of all patients was available. In correlation analysis CS was 
included in an effort to evaluate the best biomarker to correlate with this information. However, CS 
was not highly correlated with any of the discriminating candidate markers, in an analysis including 
a total of 70 samples. The highest correlation values were found with SMs. Specifically, 
SM(d18:2/22:0) and SM(d18:2/24:0) with correlation values of r=-0.45 and -0.44, respectively. On 
one hand, it could be argued that the CS is an imperfect metric and the purpose of the current 
studies was to identify superior diagnostics for CCAD and CAVD. There is an unmet need to 
discover better diagnostic biomarker, which may contribute to a framework for stratification of 
patients in a concise and clinically meaningful way. 
5.5 Conclusions  
In the current study both similarities and differences in the metabolic profiles of the two calcific 
diseases (coronary artery and aortic valve) are demonstrated leading to the development of a 
hypothesis that the diseases are mechanistically different. To our knowledge, this has not been 
shown before at the level of the metabolic profile. Herein, a cross-platform metabonomic study was 
applied for the first time in cardiovascular calcific diseases. It is obvious that metabolic profiling 
approaches can deliver disease related biomarkers in blood serum from CCAD and CAVD patients, 
and combined with correlation and network analysis, can be useful in generating hypotheses 
relating to mechanisms of pathology. The lipid profiling, UPLC-MS method, provided more 
information in this case than the NMR analysis, which is unsurprising given that most of the disease 
signature manifested in the composition of serum lipids. The UPLC-MS data were highly 
reproducible, with all candidate markers, except one, having a coefficient of variation of < 9%. 
Thus, this will be the method of choice for future untargeted large population studies, which will 
follow to validate findings. 
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CCAD was characterized by lower serum levels of SMs, higher concentrations of TGs and a PC 
profile that was modulated differentially across the severe calcification versus control group. The 
trend in dysregulated PC profile in CCAD was noted in individuals with a mild to moderate disease 
stage and may have utility as an early indicator of disease. The metabolic signature of CAVD was 
dominated by changes in the PC profile and higher serum citrate levels. It appears that, while 
disease pathways are different between CCAD and CAVD, leading to a pathological process in 
which only the end-stage is osteoblastic/osteogenic phenotype and calcification, a number of 
processes co-exist. Dysregulation of specific and previously unreported FAC provides novel 
hypotheses that could shed light to the pathophysiology of vascular and valvural calcification. 
The results from this study beg further investigation into the fatty acid metabolism, the eicosanoid 
pathway, as well as other inflammation-related metabolites, such as docosanoids and inflammation-
related proteins. The specificity of the PLA2 enzyme towards the 20:4 and 22:6 FAC PCs also 
needs to be addressed. Another obvious lead is the suggestion of apoptotic pathways in CCAD 
emerging from findings related to the ceramide and mitochondrial Ca
2+
 overload signalling 
pathways. All of these along with established markers of osteoblastic/osteogenic phenotype will 
form the core of experimental design for future studies. 
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Table 5. 4: List of assigned significant metabolites obtained from analysis of serum samples, after comparison of calcific coronary artery disease class to the control group.  
Met Name 
Mol Formula 
[complex adduct] 
Ret 
Time 
(min) 
m/z 
(found) 
m/z 
(theor) 
Δppm 
p(corr
) 
p(1) 
p 
[t-test, 
NC Vs SC] 
Fold 
Change 
p 
[t-test, 
NC Vs MC] 
p 
[t-test, 
MC Vs SC] 
CV
% 
QCs 
(9) 
UPLC-MS 
Positive Mode 
 
           
Higher in SC 
            
PC(16:0/20:4) *,† C44H81NO8P+ 5.75 782.5704 782.5700 1 
       
 
C44H81NO8P+ 
(C13 Isotope) 
5.75 783.5745 783.5733 2 0.85 0.32 0.005036 1.29 0.023786 0.251396 7 
LysoPC(20:4) * 
C28H50NO7PNa+    
[C28H50NO7P+Na]+ 
1.00 566.3286 566.3223 11 0.70 0.02 0.011478 1.22 0.681547 0.017397 8 
TG(16:0/18:1/22:5)  
TG(18:1/18:1/20:4) 
C59H106NO6+    
[C59H102O6+NH4]+ 
15.36 924.7982 924.8020 -4 0.73 0.06 0.019369 1.29 0.461709 0.039684 8 
TG(16:0/18:1/18:1) 
C55H106NO6+    
[C55H102O6+NH4]+ 
15.68 876.8015 876.8020 -1 0.66 0.17 0.044971 1.40 0.743774 0.058982 5 
Lower in SC 
            
SM(d18:2/24:0) * C47H94N2O6P+ 12.81 813.6858 813.6850 1 -0.74 -0.09 0.000001 1.50 0.894457 0.000001 7 
SM(d18:2/22:0) C45H90N2O6P+ 9.77 785.6542 785.6537 1 -0.74 -0.10 0.000006 1.47 0.449461 0.000020 4 
SM(d18:2/24:1) C47H92N2O6P+ 9.71 811.6691 811.6693 0 -0.72 -0.12 0.000041 1.21 0.797471 0.000031 5 
SM(d18:1/23:0) C46H94N2O6P+ 13.03 801.6847 801.6850 0 -0.63 -0.07 0.000041 1.19 0.718762 0.000044 3 
SM(d18:2/16:0) C39H78N2O6P+ 4.30 701.5604 701.5598 1 -0.68 -0.07 0.000347 1.31 0.631770 0.000308 6 
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PC(18:2/18:0) *,† C44H85NO8P+ 7.87 786.6010 786.6013 0 
       
 
C44H85NO8P+ 
(C13 Isotope) 
7.87 787.6046 787.6047 0 -0.77 -0.31 0.001371 1.30 0.259191 0.005971 8 
PC(O-16:1/18:2) C42H81NO7P+ 6.73 742.5748 742.5751 0 -0.72 -0.08 0.001941 1.46 0.301605 0.032098 2 
SM(d17:1/16:0) C38H78N2O6P+ 4.70 689.5597 689.5598 0 -0.67 -0.05 0.002220 1.22 0.814786 0.010492 3 
PC(18:2/15:0) * C41H79NO8P+ 5.27 744.5545 744.5543 0 -0.78 -0.07 0.002464 1.36 0.612282 0.011036 3 
SM(d18:1/22:0) C45H92N2O6P+ 12.32 787.6696 787.6693 0 -0.65 -0.09 0.012648 1.19 0.502127 0.115613 3 
PC(18:2/18:2) * C44H81NO8P+ 4.96 782.5682 782.5700 -2 -0.75 -0.16 0.025146 1.47 0.357176 0.104597 6 
PC(16:0/18:3) C42H79NO8P+ 5.00 756.5546 756.5543 0 -0.68 -0.13 0.038234 1.55 0.056644 0.613973 3 
UPLC-MS 
Negative Mode             
Higher in SC 
            
PC(16:0/20:4) * 
C45H81NO10P-    
[C44H80NO8P+FA]- 
5.76 826.5625 826.5598 3 0.73 0.26 0.005061 1.18 0.087226 0.090059 4 
LysoPC(20:4) *,‡ C27H47NO7P- 1.00 528.2996 528.3090 -18 0.66 0.03 0.012770 1.41 0.243202 0.059168 5 
lower in SC 
            
SM(d18:2/24:0) * 
C48H94N2O8P-    
[C47H93N2O6P+FA]- 
12.82 857.6757 857.6748 1 -0.74 -0.10 0.000001 1.35 0.583687 0.035079 3 
PC(18:2/15:0) * 
C42H79NO10P-    
[C41H78NO8P+FA]- 
5.25 788.5475 788.5442 4 -0.84 -0.06 0.002136 1.37 0.158770 0.048678 5 
PC(18:2/18:0) * 
C45H85NO10P-    
[C44H84NO8P+FA]- 
7.90 830.5934 830.5911 3 -0.84 -0.30 0.002328 1.17 0.059537 0.070687 3 
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PC(18:2/18:2) * 
C45H81NO10P-    
[C44H80NO8P+FA]- 
4.99 826.5604 826.5598 1 -0.78 -0.13 0.003234 1.41 0.074336 0.126333 5 
PI(18:2/18:0) C45H82O13P- 6.01 861.5509 861.5493 2 -0.66 -0.13 0.013215 1.39 0.378844 0.068470 3 
SM(d18:1/16:0) 
C40H80N2O8P-    
[C39H79N2O6P+FA]- 
5.37 747.5662 747.5662 0 -0.69 -0.20 0.024765 1.10 0.903099 0.018255 5 
 
(*) Found with statistical significance in both polarities.  
(†) Metabolite removed due to detector saturation. Used only for assignment purposes. 
(‡) Metabolite detected as a fragment 
Coefficient of variation (CV%) is calculated based on nine injections of the same pooled sample, acquired through the run. 
P(corr) and p(1) refer to the correlation coefficient and covariance of the metabolites to disease classes, respectively. 
The position of double bonds cannot be determined. Position of fatty acyl chain cannot be determined; fatty acyl chains are presented from lowest to 
highest molecular weight (lower number of carbons to higher, and higher number of double bonds, to lower). 
Two-tailed t-tests were conducted, assuming unequal variance. 
NC: No calcification; MC: Mild calcification – calcific coronary artery disease; SC: Severe calcification – calcific coronary artery disease. 
PC: phosphatidylcholine; TG: triglyceride; SM: sphingomyelin; PI: phosphatidylinositol; FA: formate.  
 243 
 
Table 5. 5: List of assigned significant metabolites obtained from analysis of serum samples, after comparison of calcific aortic valve disease class to the control group.  
Met Name 
Mol Formula 
[non hydrogen adduct] 
Ret 
Time 
(min) m/z (found) 
m/z 
(theoretical) Δppm p(corr) p(1) 
p 
[t-test, 
NC vs 
CAVD] 
Fold 
Change 
CV% 
QCs (9) 
UPLC-MS  Positive Mode 
         Higher in CAVD 
          PC(16:0/22:6) C46H81NO8P+ 5.34 806.5699 806.5700 0 0.78 0.38 0.0089 1.23 8 
SM(d18:1/24:1) 
C47H93N2O6PNa+   
[C47H93N2O6P+Na]+ 12.16 835.6667 835.6669 0 0.62 0.08 0.0299 1.12 4 
Lower in CAVD 
          PC(18:0/20:3) C46H87NO8P+ 8.47 812.6178 812.6169 1 -0.70 -0.25 0.0079 1.30 6 
UPLC-MS; 
Negative Mode 
          Higher in CAVD 
          UKN  
 
0.66 307.0981 - - 0.79 0.43 0.0336 53.79 1 
Lower in CAVD 
          
SM(d18:1/22:0) 
C46H92N2O8P-    
[C45H91N2O6P+FA]- 12.42 831.6618 831.6591 3 -0.59 -0.10 0.0004 1.16 1 
PC(16:0/20:3) 
C45H83NO10P-    
[C44H82NO8P+FA]- 6.46 828.5782 828.5755 3 -0.52 -0.16 0.0045 1.20 2 
PC(18:2/18:0) 
C45H85NO10P-    
[C44H84NO8P+FA]- 7.90 830.5934 830.5911 3 -0.74 -0.29 0.0073 1.13 3 
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PC(18:2/18:2) 
C45H81NO10P-    
[C44H80NO8P+FA]- 4.99 826.5604 826.5598 1 -0.63 -0.11 0.0141 1.15 5 
1
H NMR 
          Higher in CAVD 
  
δ 1H (ppm) 
       
Citrate 
  
2.657 (d) ½ 
CH2,  
2.522 (d) ½ 
CH2 
  
0.6334 
(max) 0.0004 
0.004-
0.03 
1.30-
1.48 n/a 
 
Coefficient of variation (CV%) is calculated based on nine injections of the same pooled sample, acquired through the run.  
P(corr) and p(1) refer to the correlation coefficient and covariance of the metabolites to disease classes, respectively. 
The position of double bonds cannot be determined. Position of fatty acyl chain cannot be determined; fatty acyl chains are presented from lowest to 
highest molecular weight (lower number of carbons to higher, and higher number of double bonds, to lower). 
Two-tailed t-tests were conducted, assuming unequal variance. NC: No calcification; CAVD: Calcific aortic valve disease.  
PC: phosphatidylcholine; SM: sphingomyelin; UKN: unknown; FA: formate. 
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Table 5. 6: List of assigned significant metabolites obtained from analysis of serum samples, after comparison of calcific coronary artery disease to calcific aortic valve disease 
class.  
Met Name 
Mol Formula 
[non hydrogen adduct] 
Ret 
Time 
(min) 
m/z (found) 
m/z 
(theoretical) 
Δppm p(corr) p(1) 
p 
[t-test, 
SC Vs 
CAVD] 
Fold 
Change 
CV% 
QCs 
(9) 
UPLC-MS 
Positive Mode           
Lower in CCAD 
          
SM(d18:2/16:0) * C39H78N2O6P+ 4.30 701.5604 701.5598 1 0.68 0.08 0.0001 1.48 6 
SM(d18:2/24:1) * C47H92N2O6P+ 9.71 811.6691 811.6693 0 0.77 0.13 0.0003 1.34 5 
SM(d17:1/16:0) * C38H78N2O6P+ 4.70 689.5597 689.5598 0 0.67 0.05 0.0147 1.38 3 
PC(15:0/18:2) C41H79NO8P+ 5.27 744.5545 744.5543 0 0.72 0.06 0.0168 1.34 3 
PC(16:0/16:0) C40H81NO8P+ 7.15 734.5705 734.5700 1 0.59 0.08 0.0231 1.20 5 
PC(16:0/18:2) † C42H81NO8P+ 5.99 758.5724 758.5700 3 
     
 
C42H81NO8P+ 
(C13 Isotope) 
5.99 759.5754 759.5733 3 0.79 0.32 0.0258 1.20 8 
SM(d18:2/24:0)  C47H94N2O6P+ 12.81 813.6858 813.6850 1 0.61 0.06 0.0339 1.31 7 
UPLC-MS 
Negative Mode           
Lower in CCAD 
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SM(d18:2/16:0) * 
C40H78N2O8P-    
[C39H77N2O6P+FA]- 
4.32 745.5505 745.5496 1 0.71 0.11 0.0005 1.32 2 
PC(15:0/18:2) 
C42H79NO10P-    
[C41H78NO8P+FA]- 
5.25 788.5475 788.5442 4 0.57 0.04 0.0065 1.33 5 
SM(d18:2/24:1) * 
C48H92N2O8P-    
[C47H91N2O6P+FA]- 
9.73 855.6601 855.6591 1 0.50 0.09 0.0075 1.36 2 
SM(d17:1/16:0) * 
C39H78N2O8P-    
[C38H77N2O6P+FA]- 
4.72 733.5496 733.5496 0 0.72 0.07 0.0094 1.40 3 
SM(d18:1/22:1) 
SM(d16:1/24:1) 
C46H90N2O8P-    
[C45H89N2O6P+FA]- 
9.38 829.6466 829.6435 4 0.58 0.07 0.0395 1.06 19 
Higher in CCAD 
          
PC(16:0/20:4) 
C45H81NO10P-    
[C44H80NO8P+FA]- 
5.76 826.5625 826.5598 3 -0.69 -0.28 0.0051 1.25 4 
PC(18:0/22:4) 
C49H89NO10P-    
[C48H88NO8P+FA]- 
9.21 882.6222 882.6224 0 -0.65 -0.04 0.0133 1.59 7 
PC(18:0/20:4) 
C47H85NO10P-    
[C46H84NO8P+FA]- 
7.58 854.5922 854.5911 1 -0.60 -0.20 0.0141 1.26 2 
PI(18:0/20:4) C47H82O13P- 5.82 885.5476 885.5493 -2 -0.56 -0.21 0.0256 1.30 2 
(*) Found with statistical significance in both polarities. 
(†) Metabolite removed due to detector saturation. Used only for assignment purposes. 
 
Coefficient of variation (CV%) is calculated based on nine injections of the same pooled sample, acquired through the run.  
P(corr) and p(1) refer to the correlation coefficient and covariance of the metabolites to disease classes, respectively.  
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The position of double bonds cannot be determined.  Position of fatty acyl chain cannot be determined; fatty acyl chains are presented from lowest to 
highest molecular weight (lower number of carbons to higher, and higher number of double bonds, to lower).  
Two-tailed t-tests were conducted, assuming unequal variance.  
SC: Severe calcification – calcific coronary artery disease; CAVD: Calcific aortic valve disease.  
PC: phosphatidylcholine; SM: sphingomyelin; FA: formate. 
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Table 5. 7: List of assigned metabolites obtained from PLS-DA of analysed serum samples, after comparison of control, 
calcific coronary artery and calcific aortic valve disease groups.  
Metabolite Name 
Mol Formula [non 
hydrogen adduct] 
Ret 
Time 
(min) 
m/z 
(found) 
m/z 
(theoretical) Δppm 
UPLC-MS 
Positive Mode 
     lysoPC(16:0) C24H51NO7P+ 1.19 496.3459 496.3403 11 
PC(16:0/16:0) * C40H81NO8P+ 7.15 734.5705 734.5700 1 
PC(16:0/18:1) * C42H83NO8P+ 7.38 760.5877 760.5856 3 
PC(16:0/18:2) * C42H81NO8P+ 5.99 758.5724 758.5700 3 
PC(16:0/18:3) C42H79NO8P+ 5.00 756.5546 756.5543 0 
PC(16:0/20:3) * C44H83NO8P+ 6.40 784.5858 784.5856 0 
PC(16:0/20:4) * C44H81NO8P+ 5.75 782.5704 782.5700 1 
PC(16:0/20:5) C44H79NO8P+ 4.83 780.5550 780.5543 1 
PC(16:0/22:5) C46H83NO8P+ 5.82 808.5865 808.5856 1 
PC(16:0/22:6) * C46H81NO8P+ 5.34 806.5699 806.5700 0 
PC(18:0/20:3) * C46H87NO8P+ 8.47 812.6178 812.6169 1 
PC(18:0/20:4) * C46H85NO8P+ 7.55 810.6019 810.6013 1 
PC(18:0/22:6) C48H85NO8P+ 7.01 834.6015 834.6013 0 
PC(18:2/18:0) * C44H85NO8P+ 7.87 786.6010 786.6013 0 
PC(18:2/18:2) C44H81NO8P+ 4.96 782.5682 782.5700 -2 
PC(36:3) (†) C44H83NO8P+ 6.95 784.5856 784.5856 0 
SM(d18:1/16:0) * C39H80N2O6P+ 5.40 703.5761 703.5754 1 
SM(d18:1/24:0) C47H96N2O6P+ 13.32 815.7007 815.7006 0 
SM(d18:1/24:1) C47H94N2O6P+ 12.18 813.6863 813.6850 2 
SM(d18:2/16:0) * C39H78N2O6P+ 4.30 701.5604 701.5598 1 
SM(d18:2/22:0) * C45H90N2O6P+ 9.77 785.6542 785.6537 1 
SM(d18:2/24:0) * C47H94N2O6P+ 12.81 813.6858 813.6850 1 
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SM(d18:2/24:1) * C47H92N2O6P+ 9.71 811.6691 811.6693 0 
TG(16:0/16:1/18:1) 
C53H102NO6   
[C53H98O6+NH4]+ 15.43 848.7715 848.7707 1 
TG(16:0/18:1/18:1) 
C55H106NO6   
[C55H102O6+NH4]+ 15.68 876.8015 876.8020 -1 
TG(16:0/18:2/18:1) 
C55H104NO6   
[C55H100O6+NH4]+ 15.46 874.7870 874.7864 1 
      UPLC-MS 
Negative Mode 
     
PC(16:0/16:0) * 
C41H81NO10P-   
[C40H80NO8P+FA]- 7.16 778.5644 778.5598 6 
PC(16:0/18:1) * 
C43H83NO10P-  
[C42H82NO8P+FA]- 7.41 804.5785 804.5755 4 
PC(16:0/18:2) * 
C43H81NO10P-    
[C42H80NO8P+FA]- 6.00 802.5622 802.5598 3 
PC(16:0/20:3) * 
C45H83NO10P-  
[C44H82NO8P+FA]- 6.46 828.5782 828.5755 3 
PC(16:0/20:4) * 
C45H81NO10P-   
[C44H80NO8P+FA]- 5.76 826.5625 826.5598 3 
PC(16:0/22:6) * 
C47H81NO10P-   
[C46H80NO8P+FA]- 5.36 850.5614 850.5598 2 
PC(18:0/20:3) * 
C47H87NO10P-  
[C46H86NO8P+FA]- 8.50 856.6086 856.6068 2 
PC(18:0/20:4) * 
C47H85NO10P-  
[C46H84NO8P+FA]- 7.58 854.5922 854.5911 1 
PC(18:2/18:0) * 
C45H85NO10P-    
[C44H84NO8P+FA]- 7.90 830.5934 830.5911 3 
PE(16:0/22:6) C43H73NO8P- 5.76 762.5108 762.5074 4 
PE(18:0/22:6) C45H77NO8P- 7.57 790.5418 790.5387 4 
PI(18:0/20:4) C47H82O13P- 5.82 885.5476 885.5493 -2 
SM(d18:1/16:0) * 
C40H80N2O8P-    
[C39H79N2O6P+FA]- 5.37 747.5662 747.5662 0 
SM(d18:2/16:0) * 
C40H78N2O8P-    
[C39H77N2O6P+FA]- 4.32 745.5505 745.5496 1 
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SM(d18:2/22:0) * 
C46H90N2O8P-    
[C45H89N2O6P+FA]- 9.85 829.6462 829.6435 3 
SM(d18:2/24:0) * 
C48H94N2O8P-    
[C47H93N2O6P+FA]- 12.82 857.6757 857.6748 1 
SM(d18:2/24:1) * 
C48H92N2O8P-    
[C47H91N2O6P+FA]- 9.73 855.6601 855.6591 1 
UKN 
 
0.63 309.1149 
  UKN 
 
0.66 307.0981 
  (*) Found in both ionization modes. 
(†)Fatty acyl chains could not be determined. 
PC: phosphatidylcholine; TG: triglyceride; SM: sphingomyelin; PI: phosphatidylinositol; PE: 
phosphoethanolamine; UKN: unknown; FA: formate. 
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Chapter 6  General Discussion 
Cardiovascular disease (CVD) is one of the most studied clinical conditions. Most of the 
pathological events associated with CVD are directly or indirectly related to atherosclerosis
45
. In the 
context of novel technological advancements in instrumentation utilised in bioanalysis, 
atherosclerosis could still have ‗virgin‘ grounds for science to explore. The holistic approach taken 
with metabolic profiling facilitates a systems biology framework, delivering interacting metabolites 
and pathways. Since ‗omic‘ approaches generate vast quantities of data, especially when it comes to 
the field of metabolic profiling, CVD needs further investigation. Although numerous metabolic 
profiling studies have been conducted on biofluids, mostly focusing on diagnostic biomarker 
discovery, applications interrogating the pathophysiology of the disease using tissue samples are 
rare. In this chapter, combined analysis of both biofluids and plaque tissue to achieve a deep 
exploration of selected conditions associated with CVD, is presented. 
Apart from elucidation of the pathology of the disease, experiments in tissue may serve as 
biomarkers if they are appropriate for in vivo imaging. However, there are cases where tissue cannot 
be available to the researcher, either due to the format of the surgical procedure or due to the 
difficulty obtaining appropriate controls. In such cases interacting, or otherwise related biofluids, 
can serve as matrices to explore and assist towards making inferences of the manifestation of 
disease. Biofluids, such as blood or urine, can be obtained by minimally-invasive or non-invasive 
procedures, and would be the optimal biological matrix to provide biomarkers of disease. 
6.1 Overview of results 
In Chapter 3 an exploratory study was conducted in order to evaluate the performance of metabolic 
profiling methodologies on carotid plaque tissue, and the ability to discriminate between recently 
stroke-symptomatic patients (in high risk for a life-threatening stroke) and asymptomatic patients 
(low risk; control group). A range of metabolites were detected by using a combination of NMR 
and UPLC-MS platforms. Further assessment using multivariate data analysis (MVDA) and 
univariate statistics demonstrated that these two methodologies could discriminate the symptomatic 
from asymptomatic groups by using their metabolic profiles, and several compounds were 
characteristic with strong statistical significance for one of the groups. Although the sample number 
was low (n=10) some pathways could be cautiously inferred in the dysregulation associated with 
symptomatic stroke. Intensities of precursor metabolites (arachidonic acid and PC(16:0/20:4)) of the 
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eicosanoid pathway, were detected in higher concentrations in tissue samples from symptomatic 
patients (Figure 6. 1). Three acyl-carnitines (AcC), intermediates of β-oxidation, were detected in 
higher intensities in the stroke symptomatic group. This finding is also very important, depicting 
involvement of mitochondrial dysregulation. Lastly, but with less statistical significance, inosine 
and uridine were detected higher, again directly correlating with the symptomatic group.  
In Chapter 4 the metabolic basis of atherogenesis, and specifically plaque formation were sought. 
This was achieved by comparison of atherosclerotic plaques to intimal thickening tissue. Intima 
thickening tissue can be considered the immediate pre-plaque stage. It is therefore the optimal 
matrix to be used as control, when studying plaque formation and it is more easily acquired than 
normal tissue. Results from this study both validate well-established risk factors and literature 
findings, but also provide novel insights into plaque formation. Higher concentrations of cholesterol 
and oxidised cholesterol esters in plaque tissue, the involvement of purines and pyrimides, and 
implication of the ceramide (Cer) pathway, are know and well-established findings
148, 152-154, 159
.  
Novel findings included: 
1. The suggested truncation of β-oxidation (with decrease in short-chain AcCs, such as 
butyrylcarnitine), along with a reduction of polyunsaturated lipids. Although it is well-known 
that mitochondria manifest metabolic abnormalities in atherosclerosis 
190
, there is only one 
report of acyl-carnitine dysregulation
191
. 
2. The detection of a previously unassociated to atherogenesis lipid, namely 
phosphoethanolamine-ceramide (PE-Cer), with higher levels in plaques, as compared to intimal 
thickening tissue, and with strong statistical significance. PE-Cers, a subgroup of sphingolipids 
and member of the Cer pathway, were detected as two moieties, PE-Cer(d18:1/16:0) and PE-
Cer(d18:1/24:1). They generated t-test p-values as low as 9.8x10
-12
. Most importantly they 
presented a high inverse Spearman correlation (r) to cholesterol, higher in absolute value than 
any other member of the Cer pathway. This infers that PE-Cers may be the link between the Cer 
pathway and cholesterol, that the scientific community has been trying to pinpoint
169, 170
. This 
finding could be of interest not only to explain the manifestation of disease, and provide a novel 
pharmaceutical target, but also to potentially explain ineffectiveness of current cholesterol 
lowering treatment. 
Chapter 5 describes a metabolic profiling study of cardiovascular calcification (CVC). Serum 
samples from patients with calcific coronary artery (CCAD) and calcific aortic valve disease 
(CAVD) were compared to patients with no traces of calcification in the heart. The two diseases 
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manifested distinct profiles with similarities limited to only two 18-carbon phosphatidylcholines 
(PC) and a sphingomyelin (SM) (Figure 6. 1). One highlighted difference was the global 
dysregulation of SMs in CCAD disease not observed in CAVD, and not detected in mildly calcified 
patients with CCAD, either. PCs did not appear to follow the same trend across the two diseases. 
Their trends were more associated to the fatty acyl-chains incorporated in each PC. Hypotheses 
were generated stating the possible biochemical mechanism of metabolic dysregulation of PCs for 
CCAD and CAVD manifestation. Several FACs found to be dysregulated in this study have not 
been previously implicated in CVC and require further validation. 
All novel and significant findings uncovered in these studies should be further validated in 
independent sample groups, via metabolite, or enzyme activity assays. Additionally, bottom-up 
approaches are required to verify key interactions detected between metabolites. 
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Figure 6. 1: Venn diagram demonstrating all the metabolites detected dysregulated in this thesis, for the studied diseases. Metabolites were coloured according to the manifested 
trends as presented in disease (red: metabolites detected with higher intensities in disease, blue: metabolites detected with lower intensities in disease).
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6.2 Pathway mapping of cardiovascular disease 
The major causes of CVD are related to atherosclerosis
45
. This may mislead one to believe that 
metabolic profiles of CVD would be identical or, to an extent, similar. If the totality of metabolites 
found to be discriminatory for the aspects of CVD studied in this thesis is combined, similarities 
between the three studies, i.e. i) symptomatic versus asymptomatic, ii) plaque formation 
(atherosclerosis), iii) CCAD and CAVD; metabolites demonstrating analogous dysregulated pattern 
are limited. This can be observed from the Venn diagram (Figure 6. 1) demonstrating the common 
irregularities between the diseases studied. This comparison should be cautiously interpreted due to 
the different matrices the studies are conducted on (tissue and serum), and the number of samples in 
each study.  
The most obvious similarity, but only between plaque formation and CCAD, is the lower intensities 
of SMs in the disease groups. Low intensities of SMs are connected to Cer reduction and activation 
of the sphingomyelinase enzyme. The Cer pathway is connected to apoptosis
160
. However, how 
different FACs and Cer backbone lengths affect the biological activity of SMs should be addressed 
in future studies. 
Two PCs, namely PC(16:0/20:4) and PC(16:0/22:6), were found to follow the same trend in 
Symptomatic and CCAD, and Atherosclerosis and CAVD groups, respectively. PCs incorporating 
the 20:4 and 22:6 FACs have been associated to the downstream pathways of eicosanoids and 
docosanoids, respectively. These PCs can function as donors of the immediate precursor molecules 
of these pathways, arachidonic acid and docosahexanoic acid. Phospholipase A(2) (PLA2) is the 
enzyme hydrolysing the sn-2 ester bond releasing the free fatty acid. PLA2 has become a recognised 
biomarker in CVD risk assessment, in the form of lipoprotein-associated PLA2
192
. 
Inosine and uridine, two members of the purine and pyrimidine pathways, and (iso-)butyrylcarnitine 
a downstream product of β-oxidation were found to be dysregulated in both the atherosclerosis and 
symptomatic study. However, this dysregulation manifested opposite trends for the two conditions 
and is another indication of the distinct biological procedures occurring even in the direct 
progression and advancement of atherosclerosis, and, therefore, should be perceived as such. 
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6.3 Metabolic profiling techniques and methodologies in 
cardiovascular disease 
During the course of this thesis, constant optimisation was conducted to applied methodologies, 
introduced by experimental development or from literature and/or collaborators. Significant 
improvements were made, especially in chromatographic separation, when comparing the HILIC 
methods and lipid profiling reversed-phase methods. Nonetheless, it became apparent, especially 
with the number of compounds detected in all three results chapters (Chapters 3-5), but 
predominately in chapter 4, that the right choice of UPLC-MS methodologies can maximise the 
amount and range of physicochemical properties of the compounds detected, but also minimise 
analysis time needed to obtain such a wealth of information. The number of compounds detected in 
a UPLC-MS assay can be expected to increase with the technological advancements focusing a lot 
on increasing sensitivity and dynamic range of concentration. 
Current data and statistical analysis tools for untargeted UPLC-MS experiments provide the 
automation needed to process such data. Thus, disease profiles and candidate biomarkers can 
efficiently filtered and forwarded for further validation. 
6.4 Closing remarks 
From the whole of the experimental results presented in this thesis, it becomes apparent that 
metabolic profiling not only can identify disease profiles and interactions, but it can also contribute 
to uncovering novel candidate biomarkers. This has been achieved even in a well studied disease 
such as cardiovascular disease. Finally, metabolic profiling in combination with pathway mapping 
can fulfil its potential as a hypothesis generating discipline. Present findings are more of an end to a 
beginning, rather than a beginning of an end, in the quest for elucidating the pathology of 
cardiovascular disease and discovery of novel biomarkers. 
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Appendix 1: Supplementary methodologies 
 
Chapter 3: Command lines used for data processing of LC-MS data, using the 
XCMS package112. 
 
library(xcms) 
library(snow) 
source("http://bioconductor.org/biocLite.R") 
biocLite("multtest") 
% Data must be in NetCDF format 
 
Lipid profiling positive mode 
dir ="directory where data are " 
setwd(dir) 
% peak width at 5% approx. 3-12s be used 
pw1=3 
pw2=12 
 
ppm=30 
sn=20 
 
pp <- xcmsSet(method="centWave", peakwidth=c(pw1,pw2), lock=TRUE, ppm=ppm, snthresh=sn, 
nSlaves=4) 
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gpp <- group(pp, method="density", bw=15, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
gpp 
% using missing=13 to account for blanks etc that don‘t have peaks in all samples 
cgpp <- retcor(gpp,  family="s", plottype="m", missing=13) 
 
gcgpp <- group(pp, method="density", bw=15, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
fgcgpp <- fillPeaks(gcgpp) 
 
report <- 
diffreport(fgcgpp,class1="sympt",class2="asympt",filebase="20130226_results_liprof_pos", 1000, 
metlin = 0.02) 
 
Lipid profiling positive mode 
dir ="directory where data are " 
setwd(dir) 
 
pw1=3 
pw2=12 
 
ppm=30 
sn=20 
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pp <- xcmsSet(method="centWave", peakwidth=c(pw1,pw2), lock=TRUE, ppm=ppm, snthresh=sn, 
nSlaves=4) 
 
gpp <- group(pp, method="density", bw=15, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
% using missing=13 to account for blanks etc that don‘t have peaks in all samples 
cgpp <- retcor(gpp, method="linear", family="s", plottype="m", missing=13) 
 
gcgpp <- group(pp, method="density", bw=15, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
fgcgpp <- fillPeaks(gcgpp) 
 
report <- 
diffreport(fgcgpp,class1="sympt",class2="asympt",filebase="20130227_results_liprof_neg", 1000, 
metlin = 0.02) 
peak width at 5% approx. 0.10-0.20min 
 
6-20s 
 
HILIC UPLC-MS of aqueous extracts – Positive mode 
dir ="directory where data are " 
setwd(dir) 
 
% peak width at 5% approx. 0.10-0.20min (6-20ss will be used) 
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pw1=6 
pw2=20 
 
ppm=30 
sn=20 
 
pp <- xcmsSet(method="centWave", peakwidth=c(pw1,pw2), lock=TRUE, ppm=ppm, snthresh=sn, 
nSlaves=4) 
 
gpp <- group(pp, method="density", bw=30, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
cgpp <- retcor(gpp,  method="linear", family="s", plottype="m") 
 
 
gcgpp <- group(pp, method="density", bw=30, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
fgcgpp <- fillPeaks(gcgpp) 
 
report <- diffreport(fgcgpp,class1="sympt",class2="asympt",filebase="results", 1000, metlin = 
0.02) 
HILIC UPLC-MS of aqueous extracts – Negative mode 
dir ="directory where data are " 
setwd(dir) 
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pw1=6 
pw2=20 
  
ppm=30 
sn=20 
 
pp <- xcmsSet(method="centWave", peakwidth=c(pw1,pw2), lock=TRUE, ppm=ppm, snthresh=sn, 
nSlaves=4) 
 
gpp <- group(pp, method="density", bw=30, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
cgpp <- retcor(gpp,  method="linear", family="s", plottype="m") 
 
gcgpp <- group(pp, method="density", bw=30, mzwid=0.07, minfrac=0.5, minsamp=1, sleep=.001) 
 
 
fgcgpp <- fillPeaks(gcgpp) 
 
report <- diffreport(fgcgpp,class1="sympt",class2="asympt",filebase="results", 1000, metlin = 
0.02)
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